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General introduction and Aim of the study
Microarray gene expression analysis to evaluate cell type 
specific expression of targets relevant for immunotherapy 
of hematological malignancies
LB-ARHGDIB-1R as novel minor histocompatibility antigen 
for therapeutic application
Minor histocompatibility antigen LB-TTK-1D is encoded 
by an alternative transcript that is degraded by nonsense 
mediated decay
Integrated whole genome and transcriptome analysis 
identified a therapeutic minor histocompatibility antigen in 
a splice variant of ITGB2
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General introduction
Allogeneic hematopoietic stem cell transplantation
Patients with hematological malignancies can be successfully treated with 
allogeneic hematopoietic stem cell transplantation (alloSCT). In alloSCT, 
patient hematopoiesis is destroyed and replaced by a new hematopoietic 
system from a healthy donor. The alloSCT treatment protocol includes pre-
transplantation conditioning of the patient with chemotherapy, irradiation 
and/or immunosuppressive agents. The aim of the conditioning regimen is 
to eradicate the malignant cells and to suppress the patient immune system 
to prevent rejection of the donor stem cell engraftment. The donor-derived 
hematopoietic stem cell graft contains hematopoietic stem and progenitor cells 
as well as immune cells, including mature B, T and NK cells, and can fully replace 
the patient lympho-hematopoietic system. Although pre-transplant conditioning 
regimens aim to reduce tumor burden, outgrowth of residual malignant cells 
can lead to relapse of the disease. Successful treatment by alloSCT relies on 
complete eradication of residual malignant cells by donor immune cells as 
present in the allograft, known as the Graft-versus-Leukemia/Lymphoma (GvL) 
effect1-3. 
Initial indirect evidence that donor immune cells in the allograft mediate the 
GvL effect came from studies in which patients with Graft-versus-Host Disease 
(GvHD) were shown to have a low risk for relapse of their malignancy after 
alloSCT4,5. GvHD is a complication that is characterized by attack of tissues of 
the patient by donor immune cells in the stem cell graft6,7. Large retrospective 
analysis confirmed a decrease in relapse rate in patients suffering from GvHD 
after alloSCT as compared to patients without clinically evident GvHD8. The 
beneficial effect on relapse rate was abrogated when T cells were depleted from 
the allograft to prevent GvHD. In addition, relapse rates are higher in recipients 
of autologous and syngeneic twin transplants than in patients transplanted with 
stem cell grafts from other sibling or unrelated donors, demonstrating that GvL 
and GvHD after alloSCT are caused by alloreactive donor T cells with specific 
reactivity against patient cells8-10. 
In the early post-transplant period, tissue damage and secretion of inflammatory 
cytokines caused by the pre-transplant conditioning activate host antigen 
presenting cells (APC) presenting patient antigens to the donor-derived immune 
system. In these inflammatory conditions host APCs can efficiently activate 
donor T cells and the lymphopenic state of the patient stimulates homeostatic 
proliferation of T cells, thereby often inducing a strong alloreactive immune 
response that leads to severe GvHD7,11,12. To reduce the risk and severity of 
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GvHD, immunosuppressive drugs such as cyclosporin A, methotrexate and 
prednisolone can be administered after alloSCT. These immunosuppressive 
drugs reduce the risk of GvHD, but simultaneously increase the risk of relapse of 
the malignancy as well as infectious complications. Another approach that has 
been successfully applied to reduce GvHD is (partial) depletion of T cells from 
the donor stem cell graft13-15. However, also this strategy results in an increased 
risk of relapse and opportunistic infections.
To re-introduce GvL reactivity and restore anti-viral immunity, donor T cells can 
be administered after T-cell depleted alloSCT by donor lymphocyte infusions 
(DLI)16. Administration of DLI from 6 months after alloSCT is relatively safe and 
can be given prophylactically17 or pre-emptively18,19. Late administration of DLI 
lowers the risk for GvHD, since tissue damage has been restored and APCs 
of patient origin have been gradually replaced by donor APCs, thus limiting 
presentation of patient antigens. However, even after delayed administration, 
DLI can still cause severe side effects in the form of GvHD20. Thus, the main 
challenge for treatment of leukemia with alloSCT and DLI is to evoke an effective 
GvL response that prevents relapse, while keeping the risk of severe GvHD 
limited. Relapse risk can be an important factor to determine the treatment 
protocol of alloSCT and DLI. For example, despite an increased risk of GvHD, 
DLI is preferably administered early after alloSCT to patients with aggressive 
malignancies to have a better chance of inducing a strong GvL response that 
reduces the risk of relapse21,22.
Minor histocompatibility antigens
To minimize GvHD, patients are preferably transplanted with HLA-matched 
donors. Selection of the donor is based on genetic identity with the patient for the 
locus that encodes human leukocyte antigens (HLA) or major histocompatibility 
antigens (MHC) class I and II. HLA class I is expressed on all nucleated cells 
and presents peptides derived from intracellular proteins on the cell surface 
to CD8 T cells. Antigen presenting cells can process and present peptides 
derived from both endogenous and extracellular proteins in HLA class II to CD4 
T cells. Genetic disparity between patient and donor outside the MHC locus 
results in amino acid differences in peptides that are presented by HLA. These 
polymorphic peptides can be recognized on patient cells by donor T-cells23,24 and 
are called minor histocompatibility antigens (MiHA). Most MiHA are encoded 
by non-synonymous single nucleotide polymorphisms (SNP) and two unrelated 
individuals differ from each other for ~10,000 non-synonymous SNPs25,26, giving 
rise to a large pool of polymorphic peptides that are different between patient 
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Recognition of MiHA by alloreactive donor T cells can lead to GvL and/or GvHD 
depending on the tissue distribution of the peptides. Donor T cells recognizing 
peptides that are expressed on the malignant cells of the patient can lead to 
GvL. When these peptides are broadly expressed on hematopoietic and non-
hematopoietic tissues, donor T cells mediate not only GvL, but also GvHD. After 
alloSCT, patient hematopoiesis is replaced by a new hematopoietic system from 
a healthy donor and therefore, donor T cells recognizing MiHA with restricted 
expression on cells of the hematopoietic system eliminate the malignant cells 
of the patient, while sparing healthy hematopoietic cells of donor origin. It has 
previously been proposed that the broad alloreactive response in GvHD might 
be essential in driving development of GvL reactivity27. Marijt et al.28, however, 
showed a direct association between emergence of T cells for hematopoiesis-
restricted MiHA (HA-1 and HA-2), and disappearance of malignant cells. In one 
of the patients in this study, induction of high numbers of HA-1 and HA-2 specific 
T cells coincided with strong GvL, while GvHD was limited (grade I). These studies 
illustrate that although MiHA-specific T-cell responses often elicit GvHD as well 
as GvL, these clinical responses can be separated, indicating that MiHA can be 
exploited to selectively induce GvL after alloSCT without GvHD. 
Discovery of MiHA
Over the years, many different methods have been exploited to identify novel 
MiHA29,30. In so-called forward immunology approaches, in vivo activated T cells 
are isolated followed by identification of their specific antigens. For forward 
approaches aimed at MiHA identification, patients with effective anti-tumor 
immune responses after alloSCT with an HLA-matched donor are selected 
for isolation of in vivo activated alloreactive T cells. After isolation and in vitro 
culture, the specificity of these T cells and their potential role in GvL and GvHD 
can be investigated. The intrinsic property of forward approaches is that T cells 
with undefined specificities are isolated. These strategies can be laborious 
and large numbers of T-cell clones need to be cultured and screened in order 
to identify MiHA with hematopoiesis-restricted expression. To increase the 
efficiency for identification of hematopoiesis-restricted MiHA using forward 
approaches, T cells can be in vitro stimulated with patient leukemic or healthy 
hematopoietic cells and specifically isolated based on up-regulation of activation 
marker CD137. Subsequently, in the first round of screening, reactivity against 
patient fibroblasts can be included to distinguish T-cell clones for broadly-
reactive MiHA from T-cell clones recognizing potential hematopoiesis-restricted 
MiHA. As an alternative strategy that is more focused on direct identification 
of hematopoiesis-restricted MiHA, reverse immunology approaches emerged in 
which data from various bio-informatics sources, such as gene expression and 
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HLA-peptide binding prediction, are combined to select peptide candidates31-36. 
These peptide candidates are then used to search for specific T cells in in vivo 
immune responses after alloSCT or in the naïve T-cell repertoire of healthy 
individuals. This method allows more direct searching for T cells for a priori 
selected antigens, but thus far resulted in identification of only a limited number 
of MiHA.
Initially, MiHA identification in forward approaches was performed by laborious 
techniques, such as biochemical identification of peptides eluted from HLA-
molecules, which has been used to characterize several MiHA, including HA-1 
and HA-237,38. cDNA library screening is another method that can be used to 
identify a MiHA-encoding gene and has also successfully been applied to identify 
HLA class II-restricted MiHA39,40. With the development of whole genome 
association scanning (WGAs), discovery of MiHA has become more efficient41-42. 
Van Bergen et al.43 reported the identification of 10 new HLA-class I restricted 
MiHA using a panel of EBV-LCLs that were SNP-genotyped for 1.1 million SNPs. 
In WGAs, T-cell recognition of a panel of EBV-LCLs is investigated for association 
with each individual SNP-genotype. WGAs can be used to identify both HLA-
class I and II restricted MiHA44,45. Associating SNPs as identified by WGAs may 
directly produce the MiHA or identify a small genomic region that encodes the 
MiHA. 
For associating SNPs identified by WGAs, the presence of SNP disparity is 
confirmed by sequencing the gene region of interest for both patient and donor. 
When SNP disparity has been confirmed, the consequence of the SNP on protein 
translation is evaluated. Non-synonymous SNPs can directly encode MiHA in the 
normal open reading frame of the primary gene transcript, while synonymous 
SNPs encode amino acid differences when the transcript is translated in an 
alternative reading frame. Therefore, the gene region that encompasses 
the associating SNP is translated in all three possible forward reading frames 
and searched for peptides of 9-11 amino acids with predicted binding to the 
respective HLA-restriction molecule using the algorithm of NetMHC server 
3.446,47. According to the algorithm, peptides with predicted binding affinity 
<500nM and <50nM are classified as weak and strong binders, respectively. 
Patient (and donor) peptides with predicted HLA binding are then selected, 
synthesized and tested for T-cell recognition. If the patient variant is recognized 
by the MiHA-specific T cells, the associating SNP has been confirmed to encode 
a new MiHA. Associating SNPs can also function as genetic markers for antigen-
encoding SNPs that are in linkage disequilibrium with associating SNPs, which 
have not been captured by the array. For these MiHA, the entire primary gene 
transcript is sequenced for SNP disparities between patient and donor that can 
then be evaluated for peptides with predicted HLA binding and T-cell recognition 
1
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as described above. Due to genetic linkage in haplotypes, MiHA discovery by 
WGAs extends far beyond the ~1 million SNPs that are measured by SNP arrays. 
Molecular mechanisms of MiHA
Different mechanisms can result in the generation of polymorphic peptides. 
Most of the HLA-class I-restricted MiHA that are identified to date are encoded 
by non-synonymous SNPs in coding exons that lead to single amino acid changes 
translated from primary gene transcripts in the normal reading frame. However, 
the potential for polymorphic peptides extends far beyond these epitopes to 
peptides translated in alternative reading frames and peptides encoded by 
alternative transcripts, thereby greatly increasing the repertoire of different 
MiHA that can be generated by SNP differences between patient and donor. 
HA-1 and HA-2 are examples of MiHA encoded by non-synonymous SNPs in 
the normal reading frame of the primary gene transcript37,38. LB-ECGF-1H48 and 
LB-ADIR-1F49 were the first MiHA that were shown to be translated from the 
primary gene transcript in an alternative reading frame and also SNPs located 
in the 5’ or 3’ untranslated region (UTR) can encode MiHA, as reported for LB-
TRIP-10-1EPC50. LRH-1 is a MiHA that is translated in an alternative reading 
frame as a result of an insertion/deletion of a nucleotide (INDEL-variant) and the 
recognized peptide is encoded by a gene region located downstream from this 
polymorphism51. Another group of MiHA are encoded on the Y-chromosome, 
the so-called H-Y antigens. H-Y antigens often include multiple amino acid 
differences from their X-chromosome allelic variants, but they behave in the 
same way as MiHA encoded by non-synonymous SNPs.
Next to polymorphisms in primary gene transcripts, MiHA can be produced by 
SNPs that are present in or create alternative transcripts. ACC-6 and ZAPHIR are 
MiHA that result from alternative splicing52,53, while PANE1 is generated by a SNP 
that disrupts a stop codon in an alternative transcript54. Even a complete gene 
can be deleted, rendering the protein as encoded by this gene in the patient 
entirely polymorphic for the transplanted immune system of the donor. This has 
been described for UGT2B17, a gene that encodes multiple MiHA restricted to 
HLA-A2, -A29 and -B4441,55. An overview of the different molecular mechanisms 
through which genetic variation can create immune targets is shown in 
Figure 1. Although examples of MiHA generated by polymorphisms other 
than non-synonymous SNPs have been described, their frequency is probably 
underestimated, since MiHA encoded by non-synonymous SNPs are easier to 
discover by current techniques. 
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Discovery of MiHA encoded by alternative transcripts may give relevant insight 
into mechanisms that regulate transcription and translation as well as antigen 
processing and presentation. Antigenic peptides can be derived from different 
sources and protein turnover and aberrant translation are relevant factors in 
processing and presentation of these peptides56. Aberrant proteins derived from 
alternative transcripts or alternative reading frames are examples of defective 
ribosomal products (DRiPs), which are thought to be a main source of antigenic 
peptides for T-cell immunosurveillance57,58. MiHA derived from alternative 
transcripts and their specific T cells may therefore function as model antigens 
to study regulation of transcription, translation and antigen processing and 
presentation.
Tissue distribution
The tissue distribution of MiHA can be determined to evaluate their role in 
GvL and GvHD. Ideally, the tissue distribution of MiHA should be analyzed by 
measuring T-cell recognition of a large variety of (malignant) hematopoietic as 
well as non-hematopoietic cell types cultured from tissues that are targeted in 
GvHD. However, primary cells from non-hematopoietic tissues are often difficult 
to culture and not available in quantities that allow in depth T-cell analysis, which 
requires expression of the relevant HLA-restriction allele and MiHA-encoding 
SNP. Therefore, as an efficient and feasible alternative strategy, gene expression 
can be measured to investigate the tissue distribution of MiHA and estimate 
their value for therapy. 
Thus far, only a limited number of MiHA are encoded by genes with restricted 
or predominant expression in (malignant) hematopoietic cells, i.e. HB-1H/Y 
(HMHB1)34,59, HA-2 (MYO1G)37,60, HA-1 (HMHA1)38,61, ACC-1Y/C (BCL2A1)62, 
LRH-1 (P2X5)51, PANE1 (CENPM)54, ACC-6 (HMSD)53 and UTA2-1 (KIAA1551)63. 
With the current repertoire of hematopoiesis-restricted MiHA, only 25% and 
40% of recipients of sibling and unrelated donors, respectively, are eligible for 
T-cell therapies in which one of the therapeutically relevant MiHA is targeted24. 
Therefore, to increase applicability, efficacy and safety of alloSCT, more 
therapeutic MiHA with favorable population frequencies in common HLA class I 
alleles are needed. 
MiHA as tools to measure GvL and GvHD
Many different alloSCT (and DLI) treatment strategies are currently exploited 
in various centers leading to significant differences in the occurrence of GvL 
and GvHD. In many centers patients are transplanted preferably in complete 
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Figure 1: Molecular mechanisms by which genetic variants create MiHA. 
Normal DNA, RNA and protein sequences are indicated in gray, whereas alternative sequences are shown in 
black. Patient and donor sequences are shown in red and green (if allelic variants exist), respectively. Whether 
the allelic variants are actually presented on the cell surface is also dependent on intracellular processing and 
presentation mechanisms, which are not taken into consideration in this figure. This figure originates from a 
review by Griffioen et al.25.
remission. While long-lasting remissions after alloSCT are indicative of GvL, lack 
of biomarkers and absence of detectable tumor cells do not allow for evaluation 
of GvL. Thus, occurrence of GvL responses in the absence of GvHD, which is the 
most favorable outcome of alloSCT, cannot be monitored and are likely missed 
when evaluating the efficacy of alloSCT. With the identification of large numbers 
of MiHA, a toolbox can be generated to screen for immune responses using 
peptide-MHC (pMHC)-multimers. Screening for MiHA-specific T-cell responses 
1
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will reveal specific characteristics of immune responses in GvL and GvHD with 
respect to specificity, diversity, frequency, and dynamics and thus provide more 
insight in the biology of GvL and GvHD. Large-scale screening for MiHA-specific T 
cells may therefore facilitate comparison of in vivo immune responses between 
patients and allow evaluation of different alloSCT treatment strategies. 
Studies investigating whether individual MiHA mismatches associate with 
clinical outcome are hampered by HLA restriction and MiHA allele frequency. 
Moreover, GvL and GvHD are often mediated by polyclonal immune responses in 
which multiple MiHA are targeted. In particular the polyclonality of the immune 
response significantly disturbs analysis of single MiHA, which could explain 
controversial findings on clinical outcome as for example reported for HA-127,64-
66. In contrast, screening for T cells using a large toolbox of MiHA may allow 
for grouping of patients based on the total number of MiHA that are targeted 
and the number of MiHA with hematopoiesis-restricted expression versus MiHA 
that are broadly expressed to study their effect on clinical outcome. However, 
this analysis requires discovery of a large proportion of the entire repertoire of 
MiHA that are recognized in common HLA alleles. Studies in which female-to-
male transplants are screened for T cells recognizing HY antigens67,68 and their 
association with clinical outcome may provide a proof of principle. Grouping of 
patients based on total number of MiHA T-cell responses or number of targeted 
MiHA with specific tissue distribution patterns can provide the statistical power 
to assess whether certain types of MiHA mismatches are predictive for clinical 
outcome. Based on those studies an algorithm may be developed to include or 
exclude certain MiHA mismatches as a factor in donor selection.  
Therapeutic value of MiHA
MiHA are also therapeutically relevant for treatment strategies aimed at 
augmenting GvL without GvHD. Donor T cells targeting MiHA that are broadly 
presented on (non-)hematopoietic tissues can be depleted from the stem 
cell graft or DLI to prevent GvHD, while donor T cells recognizing MiHA with 
restricted or predominant expression on (malignant) hematopoietic cells can be 
enriched to selectively induce GvL. Depletion of the majority of T cells targeting 
broadly expressed MiHA is the rationale behind studies that deplete CD8 T 
cells from the DLI69-72, although this also abrogates selective GvL responses 
induced by hematopoiesis-restricted CD8 T cells. More selective approaches 
to treat patients with relapsed leukemia after alloSCT are adoptive transfer of 
in vitro induced leukemia-reactive T-cell lines73, administration of T-cell clones 
recognizing MiHA on patient hematopoietic cells but not on dermal fibroblasts74 
and cellular therapy with T cells for HA-175. Although these studies support the 
potential of MiHA-specific T cells to induce GvL upon adoptive transfer, the 
1
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results by Warren et al.74 also indicate that selection of T-cell clones based on 
lack of in vitro reactivity against patient skin fibroblasts is not sufficient to avoid 
GvHD, since severe toxicity developed as a result of on-target recognition of 
MiHA in the lung. Thus, in-depth analysis of the tissue distribution is required 
to accurately estimate the therapeutic potential of MiHA as well as their risk 
for toxicity. MiHA with therapeutic potential show restricted or predominant 
expression in cells of the hematopoietic system, since T cells for these MiHA 
will eliminate the malignant cells of the patient while sparing healthy tissues. A 
major drawback of in vitro generation of MiHA-specific T cells is that long-term 
in vitro culture under stringent GMP conditions is required to obtain sufficient 
cell numbers for infusion, while this may limit their in vivo expansion capacity. 
Another approach by which long-term in vitro culture can be bypassed is adoptive 
transfer of T cells for hematopoiesis-restricted MiHA directly after isolation from 
the DLI by pMHC-multimers. Furthermore, T cells can be genetically engineered 
by T-cell receptor (TCR) gene transfer for hematopoiesis-restricted MiHA to 
obtain high frequencies of MiHA-specific T-cells76. Alternatives to adoptive 
T-cell transfer include vaccination strategies with donor or patient APC loaded 
with MiHA peptides, mRNA or DNA77-79. In the above-described clinical trials, 
hematopoiesis-restricted or “therapeutic” MiHA, including newly identified 
MiHA can be easily employed to selectively induce GvL and reduce GvHD after 
alloSCT. However, to broaden applicability of MiHA as therapeutic targets to 
augment GvL after alloSCT without GvHD, more MiHA in different HLA restriction 
alleles need to be identified.
1
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Aim of the study
To increase effectiveness and safety of alloSCT as treatment modality for 
hematological malignancies, more MiHA need to be identified for different HLA-
restriction alleles. Although MiHA discovery has become more efficient with the 
implementation of WGAs, MiHA discovery still fails for 20-30% of T-cell clones 
for which associating SNPs can be successfully identified, but no SNP disparity 
is present in the primary gene transcript. These MiHA are probably encoded 
by alternative transcripts and their characterization requires more advanced 
technologies than WGAs with our standard panel of EBV-LCLs that have been 
genotyped for 1.1M SNPs. MiHA encoded by alternative transcripts are probably 
underrepresented in the current collection of known MiHA and discovery of 
these MiHA is relevant to establish a toolbox to measure T-cell responses in GvL 
and GvHD after alloSCT and to broaden the repertoire of MiHA that can be used 
therapeutically. 
With the development of WGAs as high-throughput method for MiHA 
discovery, the need for strategies that allow efficient analysis of the tissue 
distribution of MiHA increased. The tissue distribution of MiHA is relevant to 
estimate their role in GvL and GvHD and to separate hematopoiesis-restricted 
MiHA with potential therapeutic relevance from MiHA that are more broadly 
expressed on non-hematopoietic tissues. The tissue distribution of MiHA can 
be determined by measuring T-cell recognition of cell types of different origins, 
but this analysis is laborious and access to specific tissues is often limited. 
Therefore, in chapter 2, we set out to compose a microarray gene expression 
database for cell types that are commonly targeted in GvL and GvHD to provide 
a platform to efficiently establish gene expression patterns. For this purpose, 
we collected hematological malignancies of different origins as well as healthy 
(non-) hematopoietic cell samples, validated their cell-type origin and excluded 
samples that are contaminated with peripheral blood cells. In addition, various 
non-hematopoietic cells have been cultured in the presence of IFN-γ to allow 
gene expression analysis under inflammatory conditions and gene expression 
profiles for various known hematopoiesis-restricted MiHA and B-cell surface 
antigens have been generated to investigate the value of the microarray gene 
expression database for evaluation of potential efficacy and toxicity of these 
antigens as targets for immunotherapy of hematological malignancies. 
Using the microarray gene expression database as described in chapter 2, we 
identified LB-ARHGDIB-1R as promising MiHA and therefore aim to characterize 
this MiHA in detail for its therapeutic relevance in chapter 3. We investigated 
whether LB-ARHGDIB-1R is hematopoiesis-restricted and whether LB-ARHGDIB-
1R-specific T cells can recognize and lyse primary leukemic cells, while sparing 
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skin-derived fibroblasts. In addition, we investigated potential toxicity of LB-
ARHGDIB-1R-specific T cells against endothelial cells, in which the ARHGDIB 
gene is expressed at low levels, and studied the in vivo immunogenicity of LB-
ARHGDIB-1R in MiHA-disparate HLA-B*07:02-positive patient-donor pairs. 
To enable discovery of MiHA that are encoded by alternative transcripts, we 
developed new methods using publicly available whole genome and whole 
transcriptome data. In chapter 4, we aim to identify a MiHA for which multiple 
associating SNPs were identified in intron regions of the TTK gene, but no SNP 
disparity was found in the primary gene transcript. Using an ‘inferred correlation’ 
analysis with publicly available SNP data from the 1000 Genomes Project, we 
identified LB-TTK-1D and further characterized this MiHA for immunogenicity 
and tissue distribution by T-cell experiments and quantitative RT-PCR. 
In chapter 5, we isolated a MiHA-specific T-cell clone from a patient with 
strong anti-tumor immunity after alloSCT. Similar as in chapter 4, the T cells 
recognized a MiHA for which an associating SNP in an intronic region of the gene 
was identified, while no SNP disparity was present in the normal ITGB2 gene 
transcript. To investigate whether the MiHA could be encoded by an alternative 
transcript, we searched for alternative ITGB2 transcripts in publicly available 
whole transcriptome data and identified LB-ITGB2-1 as novel MiHA that is 
encoded by an alternative transcript. The tissue distribution of the alternative 
transcript has been studied by T-cell recognition and quantitative RT-PCR and the 
cytolytic potential of LB-ITGB2-1-specific T cells has been studied in chromium-
release and clonogenic progenitor assays.
In chapter 6, we summarize the results on the new MiHA and their gene 
expression patterns as described in chapters 2-5, as well as the identification 
methods used. We discuss the role of MiHA in GvL and GvHD and the criteria 
that should be met by MiHA in order to be therapeutically relevant. Furthermore, 
the added value of whole transcriptome analysis for discovery of these MiHA are 
discussed as well as the immunological knowledge acquired by studying MiHA 
as identified by forward strategies. 
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Cellular immunotherapy has proven to be effective in the treatment of hematological cancers by donor lymphocyte 
infusion after allogeneic hematopoietic stem cell transplantation 
and more recently by targeted therapy with chimeric antigen 
or T-cell receptor-engineered T cells. However, dependent on 
the tissue distribution of the antigens that are targeted, anti-
tumor responses can be accompanied by undesired side effects. 
Therefore, detailed tissue distribution analysis is essential to 
estimate potential efficacy and toxicity of candidate targets for 
immunotherapy of hematological malignancies. 
We performed microarray gene expression analysis of 
hematological malignancies of different origins, healthy 
hematopoietic cells and various non-hematopoietic cell types 
from organs that are often targeted in detrimental immune 
responses after allogeneic stem cell transplantation leading to 
Graft-versus-Host disease. Non-hematopoietic cells were also 
cultured in the presence of IFN-γ to analyze gene expression 
under inflammatory circumstances. Gene expression was 
investigated by Illumina HT12.0 microarrays and quality control 
analysis was performed to confirm the cell-type origin and 
exclude contamination of non-hematopoietic cell samples 
with peripheral blood cells. Microarray data were validated 
by quantitative RT-PCR showing strong correlations between 
both platforms. Detailed gene expression profiles were 
generated for various minor histocompatibility antigens and 
B-cell surface antigens to illustrate the value of the microarray 
dataset to estimate efficacy and toxicity of candidate targets 
for immunotherapy. 
In conclusion, our microarray database provides a relevant 
platform to analyze and select candidate antigens with 
hematopoietic (lineage)-restricted expression as potential 
targets for immunotherapy of hematological cancers.
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Cellular immunotherapy of hematological cancers has proven very effective. 
After allogeneic hematopoietic stem cell transplantation (alloSCT), anti-tumor 
immunity is mediated by donor T cells recognizing the malignant cells of the 
patient1. Another effective approach is targeted therapy by chimeric antigen 
receptor (CAR) or T-cell receptor (TCR) gene transfer. CAR T-cell therapy specific 
for CD19 has successfully been used to treat patients with B-cell malignancies2. 
In addition to strong anti-tumor immunity, immunotherapy can cause life-
threatening toxicity, i.e. liver or neurological damage as reported after CAR or 
TCR gene therapy3,4 or Graft-versus-Host disease (GvHD) after alloSCT5, due to 
on-target recognition of healthy organs by the adoptively transferred T cells. 
Both the efficacy and potential toxicity of immunotherapy is strongly dependent 
on the tissue distribution of the antigens that are targeted. Thus, gene expression 
profiles of candidate targets for immunotherapy of hematological cancers need 
to be carefully examined.
Immunotherapy can be directed against extracellular or intracellular antigens. 
Specific antibodies or CARs can recognize extracellular antigens that are 
expressed on the cell surface of malignant cells. These antigens need to be 
selectively expressed on the tumor or on the lineage from which the tumor 
originates to limit the risk of toxicity2,6. Intracellular antigens can be targeted by 
specific TCRs when peptides from these proteins are presented by HLA on the 
cell surface. As such, the repertoire of candidate antigens that can be targeted 
by TCR-based immunotherapy extends beyond extracellular antigens, but the 
necessity for tumor- or lineage-restricted expression remains. In the setting 
of alloSCT, polymorphic antigens with hematopoietic-restricted expression 
are relevant targets for immunotherapy, since donor T cells recognizing these 
antigens eliminate the malignant cells of the patient, while sparing healthy 
hematopoietic cells of donor origin. Polymorphic peptides that are targeted 
by donor T cells after HLA-matched alloSCT, so-called minor histocompatibility 
antigens, can be efficiently discovered by whole genome association scanning 
and minor histocompatibility antigens with hematopoiesis-restricted expression 
are selected as targets with potential therapeutic relevance7-11. Ideally, the 
tissue distribution of minor histocompatibility antigens is analyzed by measuring 
T-cell recognition of a large variety of (malignant) hematopoietic and non-
hematopoietic cell types cultured from tissues that are targeted in GvHD. 
However, non-hematopoietic cells are often difficult to culture and not available 
in quantities that allow in depth T-cell analysis. Therefore, as an alternative, the 
tissue distribution can be estimated by determining gene expression. 
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Whole transcriptome analysis can be performed by microarray gene expression 
or RNA-sequence analysis. Microarray data have become increasingly available 
over the years in platforms such as Gene Expression Omnibus12,13. However, 
integration of datasets is challenging due to differences in sample handling 
and technologies. Various integrated and normalized datasets are offered now 
and allow online analysis of tissue expression. Oncomine is a large platform 
providing cancer microarray data14, while BioGPS, among others, allows easy 
access to Gene Atlas datasets15. GeneSapiens16 provides a bioinformatic 
analysis of ~10,000 samples including normal human tissues, different cancer 
types and cell lines. Many samples in these databases represent whole tissues, 
which are composed of a mix of non-hematopoietic cell types that are often 
contaminated with peripheral blood cells. Gene expression profiles from these 
samples are heterogeneous in nature and do not allow accurate identification 
of hematopoiesis (lineage)-restricted genes. The value of existing datasets with 
whole tissue samples for estimating the therapeutic relevance and potential 
toxicity of candidate targets for immunotherapy of hematological malignancies 
thus remains limited. 
AlloSCT and CAR/TCR gene transfer are treatments that can induce inflammation 
in patients in particular upon development of an effective anti-tumor 
response17-19. Therefore, to estimate potential toxicity, expression of the antigen 
targeted by immunotherapy needs to be investigated under inflammatory 
conditions. However, whole tissues or non-hematopoietic cells are generally 
collected for transcriptome analysis under non-inflammatory conditions and 
on line databases are therefore of limited use to estimate potential toxicity of 
immunotherapeutic targets. 
In this study, we performed microarray gene expression analysis on hematological 
malignancies of different origins isolated from bone marrow or peripheral blood 
based on expression of specific surface markers. We also collected healthy 
hematopoietic cells and non-hematopoietic cells from organs that are often 
targeted in GvHD. Non-hematopoietic cells were cultured from tissue specimen 
or biopsies and various non-hematopoietic cell types were cultured in the 
presence of IFN-γ to mimic inflammation. Gene expression was investigated by 
Illumina HT12.0 microarray and quality control analysis confirmed the cell-type 
origin of the samples and excluded contamination of non-hematopoietic cell 
samples with peripheral blood cells. We validated gene expression as measured 
by microarray gene expression analysis by quantitative RT-PCR and investigated 
gene expression in non-hematopoietic cells under conditions of inflammation. 
Finally, we illustrated the value of our dataset to estimate efficacy and toxicity of 
potential targets for immunotherapy of hematological malignancies.
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Collection of human samples
Malignant and normal hematopoietic cells were isolated from peripheral blood 
or bone marrow samples and non-hematopoietic cell types were obtained 
from tissue biopsies or surgically removed specimen obtained from patients or 
healthy individuals after approval by the Medical Research Ethics Committee 
and Institutional Review Board of the Leiden University Medical Center (LUMC) 
and informed consent according to the Declaration of Helsinki. The majority of 
samples were collected after 2002 and written informed consent was obtained 
for these samples. Only for leukemic samples collected before 2002, oral 
informed consent was documented in the patient files by the patient’s physician 
as the only procedure approved by the ethical board.
Isolation and culture of healthy hematopoietic cells
Detailed isolation and culture methods are described in the Supplementary 
Methods section. Briefly, bone marrow and peripheral blood mononuclear 
cells (BMMC and PBMC) were isolated by Ficoll-Isopaque separation and 
cryopreserved. B cells, T cells, monocytes and hematopoietic stem cells were 
purified by fluorescence-activated cell sorting. Immature DC (imDC) were 
generated from isolated monocytes and further differentiated into mature 
DC (matDC). Isolated monocytes were also used to generate M1 and M2 
macrophages (MФ). EBV-transformed B-cell lines (EBV-LCL) and PHA-stimulated 
T-cell lines (PHA-T) were generated from PBMC as previously described20,21. 
Isolation and characterization of malignant hematopoietic cells
Detailed isolation methods are described in the Supplementary Methods 
section. In short, flow cytometric analyses were performed on malignant 
cells, followed by cell sorting based on surface expression of specific markers. 
Malignant hematopoietic cells included are acute B-lymphoblastic leukemia 
(ALL) cells, chronic lymphocytic leukemia (CLL) cells, CD34-positive chronic 
myeloid leukemia (CML) cells, multiple myeloma (MM) cells and acute myeloid 
leukemia (AML) cells. AML samples were sorted as single cell populations using 
antibodies for CD33 or as two separate cell populations expressing CD33 in 
the absence or presence of CD14 to distinguish cells differentiated into the 
monocytic pathway (CD14pos) from more immature cells (CD14neg). To classify 
the different malignant samples according to WHO 2008 standards22, FISH and 
karyotyping was performed on freshly isolated or cryopreserved cells. For AML 
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samples, additional analyses were performed to determine NPM1 mutations 
and FLT3 gene internal tandem duplication (FLT3-ITD) on genomic DNA and 
CEPBA mutation23 and EVI1 overexpression24,25 on cDNA. 
Culture of malignant human cell lines
The human erythroleukemia cell line K562, T-B lymphoblastoid cell line T2, acute 
myeloid leukemia cell lines AML-193 and THP-1, Burkitt’s lymphoma cell line 
Daudi, acute T cell leukemia cell line Jurkat and the human cervix carcinoma cell 
line HeLa were obtained from the ATCC. Burkitt’s lymphoma cell line Raji was 
kindly provided by M. Ressing (Dept. of Molecular Cell Biology, LUMC). All cell 
lines were cultured in IMDM with 10% FCS.
Isolation and culture of non-hematopoietic cells
Fibroblasts, keratinocytes, proximal tubular epithelial cells (PTEC), melanocytes, 
primary bronchial epithelial cells (PBEC) and human umbilical vein endothelial 
cells (HUVEC) were derived from tissue biopsies or surgically removed specimen 
from patients or healthy individuals at the LUMC. Cornea epithelial (Cornea) 
and stroma cells were harvested from human cadaveric eyes obtained from 
the EuroCorneabank, (Beverwijk, the Netherlands). Hepatocytes were obtained 
from Beckton Dickinson (New Jersey, USA) and colon and small intestinal 
epithelial cells were obtained from epithelial organoid cultures from the 
Hubrecht Institute for Developmental Biology and Stem Cell Research (University 
Medical Centre Utrecht, Utrecht, The Netherlands). Bile duct epithelial cells 
were purchased from ScienCell (Carlsbad, CA, USA). Fibroblasts, keratinocytes, 
PTEC, melanocytes and HUVEC were also cultured in the presence of IFN-γ (100 
IU/ml) for 4 days to mimic inflammation. In addition, two fibroblast samples 
were cultured with T-cell culture supernatant for 4 days. Isolation and culture of 
primary cell types from non-hematopoietic tissues was performed as described 
in the Supplementary Methods section.
Total RNA isolation 
Total RNA was isolated with normal and micro scale RNAqueous isolation kits 
(Ambion, Thermo Fisher Scientific, Waltham, MA, USA) and treated with DNAse 
I for 30 min at 37°C. RNA clean-up was performed using RNeasy mini kit (Qiagen, 
Valencia, CA, USA) and the quality of isolated RNA was checked using Agilent 
RNA 6000 Nano and Pico chips and Agilent Bioanalyzer (Santa Clara, CA, USA). 
Total RNA was stored at -80°C for gene expression analysis by human HT-12.0 
microarrays or quantitative RT-PCR. 
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Total RNA as stored at -80°C was thawed to amplify and biotinylate cRNA using 
the TotalPrep RNA amplification kit (Ambion) and T7 Oligo(dT) primer for First 
Strand cDNA synthesis. After preparation, cRNA samples were hybridized onto 
Human HT-12.0 Version 3 or Version 4 Expression BeadChips (Illumina, San 
Diego, CA, USA). Hybridization was performed in the hybridization oven for 17 
hours at 58°C. Chips were stained with streptavidin-Cy3 and scanned using a 
Bead Array 500 GX scanner. Raw data were imported into Genome Studio 
(all Illumina) for gene expression quantification. Microarray gene expression 
data were analyzed with R 2.1526. For this analysis, all samples as measured 
on Illumina HT-12 chips versions 3 and 4 were combined and merged in one 
dataset containing all probes as included on both chip versions (n=39,425), of 
which 28,280 probes (71.7%) are for designated NM transcripts as annotated 
by RefSeq. Normalization was done in the lumi R package using the variance 
stabilizing transformation and quantile normalization27,28. The data discussed in 
this publication have been deposited in NCBI’s Gene Expression Omnibus12 and 
are accessible through GEO Series accession number GSE76340 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76340). Probe fluorescence is 
determined as log-transformed value or as 2 to the power of the log-transformed 
value. In comparisons of gene expression profiles between two sample groups, 
the average log-transformed values for both groups were subtracted and the 
fold increase in probe fluorescence was calculated as 2 to the power of this 
difference (2avg1-avg2). Expression profiles could not be determined for all genes 
that have been described as (non-)hematopoietic lineage specific markers due 
to probe absence on the Illumina HT12.0 array or inclusion of probes showing 
overall non-significant fluorescence.
Quantitative RT-PCR
Total RNA as stored at -80°C was thawed to generate cDNA using M-MLV Reverse 
Transcriptase and Oligo(dT) primer. Quantitative RT-PCR (q-PCR) was performed 
using predesigned Taqman Gene Expression assays (Table S2) and Universal 
Master Mix II, no UNG (all Thermo Fisher Scientific, Waltham, MA, USA) and 
amplification was measured in real-time using LightCycler 480 (Roche, Basel, 
Switzerland). Data were analyzed using LightCycler 480 software and fit points 
analyses. Data was normalized using three reference genes: HMBS (alias: PBGD), 
GAPDH and ACTB (alias: β-actin). Amplifications started with 10 minutes at 
95°C, followed by 45 cycles of 30 seconds for denaturing at 95°C, 30 seconds 
of annealing at 60°C, and 30 seconds extension at again 60°C. In the regression 





The predictability of array expression measurements based on RT-PCR 
measurements was investigated. A quadratic prediction model was built for a 
set of 24 genes. Measurements of reference genes HMBS, ACTB and GAPDH 
were available. Missing data was imputed. Data was measured in two batches 
and genes are corrected against reference genes measured in the same batch. 
For unsupervised clustering analysis, we estimated the sample relation with 









Validation of the cell type origin of hematopoietic and non-
hematopoietic samples
Various hematological malignancies of different origins and their healthy non-
malignant counterparts as well as various cell types isolated or cultured from 
non-hematopoietic tissues were collected for gene expression profiling by 
Illumina HT12.0 microarrays to enable high-throughput analysis and selection 
of targets with relevant expression profiles for immunotherapy of hematological 
malignancies. The majority of hematopoietic cell types have been included 
directly after isolation by flow cytometry based on expression of specific surface 
markers. The genes for isolation markers CD19, CD3, CD14 and CD34 showed 
restricted expression to B cells, T cells, monocytes and HSC, respectively, 
thereby confirming the origin of hematopoietic cell samples (data not shown). 
All cell types from healthy non-hematopoietic tissues were included after short-
term incubation or culture under specific conditions to eliminate contaminating 
peripheral blood cells. These cell types were checked and negative for expression 
of hematopoietic marker genes, indicating that contamination with peripheral 
blood cells was below the detection limit (data not shown). In addition, we 
generated expression profiles for various known cell type-associated genes 
to confirm the origin of non-hematopoietic cell samples in our dataset. In 
Figure 1A, expression of cell type-specific or -associated genes are shown for 
hepatocytes, melanocytes, fibroblasts and keratinocytes. Expression profiles 
for cell type-associated genes for PTEC, HUVEC and PBEC (lung) are depicted in 
Figure S1. In addition, profiles for genes that are expressed in the gut are shown 
as well as profiles for genes with more specific expression in the small intestine. 
For bile duct epithelial cells, cell type-associated genes with significant probe 
fluorescence could not be identified and cornea epithelial and cornea stroma 
cells were shown to share significant gene expression with keratinocytes and 
fibroblasts, respectively (Figure 1).
For in vitro modified hematopoietic cells, we checked whether the induced cell 
types properly differentiated from their original cell type based on expression of 
a number of pre-defined genes. DC cultured from monocytes with GM-CSF and 
IL-4 were checked for down-regulation of the monocyte-specific CD14 gene and 
up-regulation of DC-specific genes (Figure 1B, left panel). Full DC maturation 
was confirmed by induced gene expression of known maturation markers and 
down-regulated expression of markers for immature DC (Figure 1B, right panel). 
The combination of these markers allows for quality control and two DC samples 
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Figure 1: Validation of the cell type origin of (non-)hematopoietic samples
Probe fluorescence as measured by microarray gene expression analysis is depicted on the x-axis in logarithmic 
scale. (A) Gene expression for various cell type-associated genes as determined by microarray gene expression 
analysis is shown. Hepatocyte-specific expression is shown for APOA2, ORM1, FGA and ALB and melanocyte-
specific expression is shown for MLANA, SILV, TYRP1 and TYR. Fibroblasts-associated expression as defined by 
detectable expression in fibroblasts as well as a limited number of other non-hematopoietic cell types is shown 
for FBLN2, CD248, ITGA11 and THY1 and keratinocyte-associated expression is demonstrated for KRT14, LAMA3, 
KLK5 and DSG3. Fibroblasts, FB; keratinocytes, KC. (B) Gene expression for monocytes and dendritic cells (DC) 
is shown (left graph) as well as for immature and mature DC (right graph). Down-regulation of CD14 and up-
regulation of CD86, CD209 and CCL22 is shown for DC (filled bars) cultured from monocytes (open bars) with 
GM-CSF and IL-4 (left graph). To validate maturation of DC, down-regulation of markers for immature DC (CCL13 
and CD36) and up-regulation of markers for mature DC (LAMP3, HLA-DOB, FLT3, CD80, CD83 and HLA-DQA1) was 










Macrophages (MΦ) were generated from isolated monocytes by culturing with 
GM-CSF (type I MΦ) or M-CSF (type II MΦ). Differentiation to macrophages 
was confirmed by induced expression of MMP929 and SPP130 and expression of 
CCL231 and CD16332 was stronger in type II than in type I MΦ (data not shown). 
To evaluate the role of inflammation on gene expression in non-hematopoietic 
cells, we cultured various non-hematopoietic cell types (fibroblasts, 
keratinocytes, PTEC, melanocytes and HUVEC) in the presence of IFN-γ. The 
effect of IFN-γ was checked by measuring expression of interferon-inducible 
genes as well as genes involved in HLA-class I and II processing and presentation 
(Figure 1C). All samples showed strong up-regulation of these genes after IFN-γ 
treatment, except for one HUVEC sample (HUVEC #3), which was excluded from 
the dataset.
As additional unbiased method for cell type validation, we performed hierarchical 
clustering for the complete panel of healthy (non-)hematopoietic samples based 
on expression profiling of all genes (Figure S2). In this analysis, hematopoietic cell 
types were distinguished from non-hematopoietic cell types and samples with 
the same cell type origin clustered based on shared gene expression profiles. This 
further validated the cell type origin of the (non-)hematopoietic cell samples in 
the microarray dataset and confirmed lack of detectable contamination of non-
hematopoietic cell samples with peripheral blood cells. 
Inclusion of hematological malignancies of different origins
All malignant hematopoietic cell types were categorized according to the 
WHO classification standards and analyzed for cytogenetic abnormalities and, 
if applicable, for morphology and immune phenotype (Table 1 and complex 
karyotypes in Table S1). A wide variety of samples were included to obtain a 
broad repertoire of hematological malignancies. Malignant cell populations 
were isolated by flow cytometry based on expression of specific surface markers. 
Gene expression for these surface markers is depicted in Figure S3. In addition 
to primary hematological malignancies, we included tumor cell lines K562, T2, 
AML-193, THP-1, Daudi, Raji, Jurkat and HeLa.
circles. Red symbols indicate samples which have been excluded from the dataset for incomplete maturation. 
(C) Various non-hematopoietic cell types (fibroblasts, keratinocytes, PTEC, melanocytes and HUVEC) were 
cultured in the presence of IFN-γ (100 IU/ml) for 4 days to mimic inflammation. Expression of various genes 
that are known to be induced by IFN-γ is shown (GBP2, IFITM1), including genes that are involved in HLA 
processing and presentation (TAP1, CD74, PSMB9 and HLA-DRA). Circles represent samples cultured without 
IFN-γ, while squares indicate samples after IFN-γ treatment. Red symbols indicate samples which have been 
excluded from the dataset for incomplete maturation.
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Table 1: Characteristics of leukemic cells selected for microarray gene 
expression analysis
a Markers for flow cytometric isolation of malignant cells are indicated between brackets. AML cells have 
been isolated by expression of CD33 (CD33) or a combination of CD33 and CD14 (CD33/CD14) in which 
CD33 expressing AML cells positive or negative for monocyte lineage differentiation marker CD14 have been 
selected as two separate cell populations. CLL cells have been selected for co-expression of CD19 and CD5. 
ALL, CML and MM cells have been isolated by expression of CD19, CD34 and CD38, respectively.
b Origin of sample either peripheral blood (PB) or bone marrow (BM) mononuclear cells. 
c WHO classification as described by Swerdlow et al, 2008. 
d Other abnormalities include numerical abnormalities, CEBPA mutations, FLT3-ITD, or EVI1 overexpression. 
e Partial del(6q?) in fraction of the cells 
f Complex karyotypes are depicted in Supplementary Table 1. 
g CML in blast crisis. 
h CML in chronic phase. 
i Genetic abnormalities as detected by FISH for CLL or MM. 
j del/del; homozygous deletion.
Samplea Originb WHO classificationc Other genetic abnormalitiesd
AML 2467 (CD33/CD14) PB Acute myeloid leukemia with inv(16)
(p13.1q22); CBFB-MYH11
trisomy 8, trisomy 14, 
trisomy 21
AML 1310 (CD33/CD14) PB Acute myeloid leukemia with inv(16)
(p13.1q22); CBFB-MYH11
-




AML 2179 (CD33) PB Acute promyelocytic leukemia with t(15;17)
(q22;q12); PML-RARA
-
AML 1591 (CD33) PB Acute promyelocytic leukemia with t(15;17)
(q22;q12); PML-RARA
FLT3-ITD positive
AML 1466 (CD33/CD14) BM Acute myeloid leukemia with t(9;11) 
(p22q23); MLLT3-MLL
-
AML 4781 (CD33/CD14) PB Acute myeloid leukemia with inv(3)
(q21q26.2); RPN1-EVI1
EVI1 overexpression, 
monosomy 7, del (7) 
(q21); complexf
AML 587 (CD33) BM Acute myeloid leukemia with mutated NPM1 FLT3-ITD positive
AML 2536 (CD33) BM Acute myeloid leukemia with mutated NPM1 -
AML 4443 (CD33) PB Acute myeloid leukemia with mutated NPM1 FLT3-ITD positive
AML 6395 (CD33) PB Acute myeloid leukemia with mutated NPM1 -
AML 3370 (CD33) PB Acute myeloid leukemia with mutated NPM1 -
AML 5205 (CD33/CD14) PB Acute myeloid leukemia with mutated NPM1 FLT3-ITD positive
AML 3590 (CD33) PB t-AML -
AML 3714 (CD33) BM AML-NOS, with minimal differentiation complexf
AML 5596 (CD33) BM AML-NOS, without maturation -
AML 3778 (CD33) PB AML-NOS, without maturation complexf
AML 3870 (CD33) BM AML-NOS, with maturation trisomy 8
AML 6283 (CD33) BM AML-NOS, with maturation FLT3-ITD positive
AML 1143 (CD33) PB AML-NOS, acute monoblastic leukemia -
AML 3009 (CD33) BM AML-NOS, acute monoblastic leukemia FLT3-ITD positive
AML 5074 (CD33/CD14) PB AML-NOS, acute monoblastic leukemia complexf
Sample Origin WHO classification Other genetic abnormalities
ALL 2391 (CD19) BM B Lymphoblastic leukemia NOS trisomy 5
ALL 2872 (CD19) BM B Lymphoblastic leukemia NOS -
ALL 1299 (CD19) BM B Lymphoblastic leukemia NOS del(6) (q21q23), 
del(Y)
ALL 3281 (CD19) PB B Lymphoblastic leukemia NOS -
ALL 5903 (CD19) BM B Lymphoblastic leukemia with t(9;22)
(q34;q11.2); BCR-ABL1 p190
complexf
ALL 3639 (CD19) BM B Lymphoblastic leukemia with t(9;22)
(q34;q11.2); BCR-ABL1 p190
trisomy 5, trisomy 8
ALL 2375 (CD19) BM B Lymphoblastic leukemia with t(4;11) 
(q21;q23); MLL rearranged
-
ALL 1833 (CD19) PB B Lymphoblastic leukemia with t(11;19) 
(q23;p13.3); MLL rearranged
-
ALL 3655 (CD19) BM B Lymphoblastic leukemia with hyperdiploidy complexf
Sample Origin WHO classification Other genetic abnormalities
CML 3471 (CD34)g BM Chronic myelogenous leukemia, BCR-ABL1 
positive
del (9q);  complexf




CML 3087 (CD34)h BM Chronic myelogenous leukemia, BCR-ABL1 
positive
del (Xp), del (17q);  
complexf
CML 4779 (CD34)h BM Chronic myelogenous leukemia, BCR-ABL1 
positive
-









Table 1: Characteristics of leukemic cells selected for microarray gene 
expression analysis
a Markers for flow cytometric isolation of malignant cells are indicated between brackets. AML cells have 
been isolated by expression of CD33 (CD33) or a combination of CD33 and CD14 (CD33/CD14) in which 
CD33 expressing AML cells positive or negative for monocyte lineage differentiation marker CD14 have been 
selected as two separate cell populations. CLL cells have been selected for co-expression of CD19 and CD5. 
ALL, CML and MM cells have been isolated by expression of CD19, CD34 and CD38, respectively.
b Origin of sample either peripheral blood (PB) or bone marrow (BM) mononuclear cells. 
c WHO classification as described by Swerdlow et al, 2008. 
d Other abnormalities include numerical abnormalities, CEBPA mutations, FLT3-ITD, or EVI1 overexpression. 
e Partial del(6q?) in fraction of the cells 
f Complex karyotypes are depicted in Supplementary Table 1. 
g CML in blast crisis. 
h CML in chronic phase. 
i Genetic abnormalities as detected by FISH for CLL or MM. 
j del/del; homozygous deletion.
Table 1: continued
Sample Origin WHO classification
Genetic abnormalitiesi
Trisomy 12 13q14.3 ATM p53
CLL 1695  
(CD19/CD5)
BM Chronic lymphocytic 
leukemia
absent del/delj del normal
CLL 4725  
(CD19/CD5)f
BM Chronic lymphocytic 
leukemia
absent del normal del
CLL 5535  
(CD19/CD5)
PB Chronic lymphocytic 
leukemia
absent del normal normal
CLL 6242  
(CD19/CD5)
PB Chronic lymphocytic 
leukemia
absent normal normal del
CLL 2159  
(CD19/CD5)
PB Chronic lymphocytic 
leukemia
absent del/delj normal normal
















+9, +15 +1q del normal  t(4;14)(p16;q32) absent
MM 5744 
(CD38)f
BM Plasma cell 
myeloma
diploid absent +1q del normal  t(4;14)(p16;q32) absent
MM 6622 
(CD38)
BM Plasma cell 
myeloma
diploid absent normal normal normal normal absent
MM 4298 
(CD38)
BM Plasma cell 
myeloma
diploid -15 normal del del t(4;14)(p16;q32) absent
MM 5019 
(CD38)f
BM Plasma cell 
myeloma











Figure 2: Effect of IFN-γ on gene expression in non-hematopoietic cell types
Microarray gene expression analysis was performed on fibroblasts, keratinocytes, PTEC, melanocytes and 
HUVEC cultured in the presence of IFN-γ and probe fluorescence was compared with the same cell samples 
cultured in the absence of IFN-γ. All probes that were >10-fold up-regulated after IFN-γ treatment in one or 
more cell types are depicted. Probe fluorescence is shown on the y-axis in logarithmic scale. Circles show gene 
expression in the absence of IFN-γ, while squares indicate expression in the presence of IFN-γ. For each cell 
type, the number of probes that are >10-fold up-regulated by IFN-γ is shown. 
Validation of microarray gene expression analysis by quantitative RT-
PCR
For all 39,426 probes as included in HT12.0 microarray versions 3 and 4, we 
determined the maximum probe fluorescence as measured in any of the 166 
(non-)hematopoietic cell samples in the dataset. Maximum probe fluorescence 
showed great variability, ranging from log 5.6 to log 15.2. No or low fluorescence 
can be the consequence of poor probe quality or absence or low expression of 
the gene transcript in the dataset, while high probe fluorescence indicates that 
the gene transcript is strongly expressed. To investigate whether gene expression 
patterns can be accurately and reliably established with our microarray dataset, 
we validated microarray gene expression data by q-PCR for 24 genes that were 
selected for different maximum probe fluorescence values.
For 53 samples, which were selected based on wide variability in gene expression 
throughout the 24 genes, cDNA was generated from the same mRNA source as 
used for microarray gene expression analysis and gene expression was measured 
by q-PCR. The complete set of samples, genes, probes and Taqman assays are 
depicted in Tables S2 and S3. Using a quadratic prediction model, the correlation 
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between microarray and q-PCR expression data was determined by calculating 
the coefficient of determination (R2). The average correlation for the entire set 
of 24 genes was strong (corrected R2 = 0.868). Correlation plots for separate 
genes are depicted in Figure S4. In Table 2, individual R2 values are depicted 
as well as the maximum probe fluorescence as measured by microarray gene 
expression analysis in the sample set for q-PCR validation. Table 2 shows that R2 
> 0.67, which indicates that the variability in gene expression in more than two 
third of the samples fits between microarray and q-PCR analysis, was measured 
for all 11 genes (100%) with a maximum probe fluorescence > log 11, whereas 
for the remaining 13 genes with maximum probe fluorescence < log 11, only 3 
genes (23%) showed R2 > 0.67.
In conclusion, our data show that gene expression patterns can be accurately 
established with our microarray dataset for transcripts with a maximum probe 
fluorescence > log 11, while q-PCR analysis is recommended if the transcript 
of interest has a maximum probe fluorescence < log 11. If maximum probe 
fluorescence is < log 11, less detailed qualitative analysis can still be performed, 
but quantitative analysis by microarray gene expression is not possible. 
The effect of inflammation on gene expression in non-hematopoietic 
cell types
To evaluate gene expression in non-hematopoietic cell types under inflammatory 
conditions, we performed microarray gene expression analysis on fibroblasts, 
keratinocytes, PTEC, melanocytes and HUVEC cultured in the presence of 
IFN-γ and compared probe fluorescence with the same samples that were 
cultured in the absence of cytokines. In total, 9 probes were >10-fold induced 
by IFN-γ in all 5 non-hematopoietic cell types. These probes were specific for 
interferon-inducible genes (GBP2) as well as genes involved in HLA-class II 
processing and presentation (CD74, HLA-DMA, HLA-DPA1, HLA-DRA, HLA-DRB4 
and LOC649143). In addition, 106 probes were > 10-fold up-regulated in at least 
one non-hematopoietic cell type (Figure 2 and Table S4). Up-regulated gene 
expression by IFN-γ was detected for 32, 83, 35, 11 and 40 probes in fibroblasts, 
keratinocytes, PTEC, melanocytes and HUVEC, respectively, while expression 
levels in the absence of IFN-γ were similar between these non-hematopoietic 
cell types.
To determine whether gene expression patterns are different between cell types 
cultured with a cocktail of inflammatory cytokines as compared to IFN-γ alone, 
we performed microarray gene expression analysis on fibroblast samples that 
we cultured in the presence of culture supernatant from an activated CD4 T-cell 
clone in which high levels of IFN-γ, IL-13, TNF-α and IL-2 were detected. Table 
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HLA-DRA ILMN_1689655 ILMN_2157441 15.03 14.61 14.82 0.925f
TAP1 ILMN_1751079  14.78 0.759
COL1A1 ILMN_1701308  14.75 0.948
CD14 ILMN_1740015 ILMN_2396444 13.20 14.80 14.00 0.732
ELANE ILMN_1706635  13.87 0.783
CD34 ILMN_1732799 ILMN_2341229 13.59 13.54 13.57 0.944
CD19 ILMN_1782704  13.49 0.985
PRTN3 ILMN_1753584  13.16 0.867
CD33 ILMN_1747622  11.66 0.834
KRT8 ILMN_1753584  11.55 0.974
P2RX5 ILMN_1677793  11.09 0.679
MOB3A ILMN_1721344  10.88 0.326
POLE ILMN_1728199  10.76 0.409
C19orf48 ILMN_1759184 ILMN_2383484 11.34 10.11 10.73 0.266
HMHA1 ILMN_1811392  10.11 0.779
CLYBL ILMN_1663538  9.30 0.487
ROR1 ILMN_1655904  9.20 0.938
COIL ILMN_1688034  8.65 -0.001
MS4A1g ILMN_1776939  8.62 0.320
PFAS ILMN_1755862  8.61 0.216
PTPRCh ILMN_2340217 ILMN_1653652 8.07 8.78 8.43 0.347
APOBEC3B ILMN_2219466  8.23 0.652
TTK ILMN_1788166  8.09 0.545
WT1 ILMN_1802174  8.00 0.856
a R2 values for individual genes were calculated from the regression model. b Official gene symbols are depicted 
for genes as included in the q-PCR validation set. c Illumina probe IDs as measured in the microarray  database. 
d Maximum probe fluorescence as measured by microarray gene expression analysis in the sample set for 
q-PCR validation. e Average of maximum probe fluorescence is given for genes with more than 1 probe. f R2 
>0.667 are bold. g MS4A1 is also known as CD20. h PTPRC is also known as CD45.
3 shows all separate probes (n=47) for genes that are >10-fold up-regulated by 
IFN-γ or T-cell supernatant. The data show that 46 out of 47 probes were at least 
5-fold up-regulated under both conditions, indicating that IFN-γ can be used as 
single agent to induce an inflammatory gene expression signature.
Gene expression profiles of immunotherapeutic targets for 
hematological malignancies
Minor histocompatibility antigens with hematopoiesis-restricted expression are 
relevant targets to selectively induce anti-tumor reactivity after alloSCT. Only 
a limited number of minor histocompatibility antigens have been reported 








to be hematopoiesis-restricted. To evaluate expression of these antigens in 
our microarray dataset of malignant and healthy hematopoietic and non-
hematopoietic cell types, we generated gene expression profiles for the known 
therapeutic minor histocompatibility antigens HA-1 (HMHA1)33,34, LB-ARHGDIB-
1R (ARHGDIB)35,36 and LB-ITGB2-1 (ITGB2)37. Figure 3A shows that maximum 
probe fluorescence was < log 11 for HMHA1, while values > log 11 were 
measured for ARHGDIB and ITGB2. Despite low probe fluorescence, HMHA1 
was accurately measured by microarray gene expression analysis as illustrated 
by strong association with q-PCR data (Table 2; R2 = 0.779). The data also show 
that expression of HMHA1 and ARHGDIB was restricted or predominant in all or 
the majority of hematopoietic cells, while expression of ITGB2 was specific for 
certain hematopoietic lineages. No expression of HMHA1 could be measured in 
any of the non-hematopoietic cell types even when cultured with IFN-γ, while 
ARHGDIB and ITGB2 showed intermediate and low expression in HUVEC and 
fibroblasts, respectively. In conclusion, microarray analysis confirmed restricted 
or predominant gene expression in hematopoietic cells for therapeutic minor 
histocompatibility antigens. 
In addition to minor histocompatibility antigens, surface antigens with restricted 
expression on hematopoietic lineages or malignancies are relevant targets 
for therapeutic antibodies or CAR T-cell therapy. We therefore explored our 
microarray dataset to evaluate gene expression for surface antigens with known 
expression on B cells (CD19 and CD79B) or B-cell malignancies (ROR1). Figure 
3B shows that maximum probe fluorescence was > log 11 for CD19 and CD79B, 
while values < log 11 were observed for ROR1. Despite low probe fluorescence, 
ROR1 microarray data were reliable as confirmed by q-PCR data (R2 = 0.938, 
Table 2). Furthermore, the data show that CD19 was highly expressed in healthy 
B cells, ALL and CLL, while no expression was detected in any other (non-)
hematopoietic cell type. ROR1 demonstrated overexpression in CLL, while 
expression of this gene was not detectable in healthy B cells. However, ROR1 
expression was also found in biliary epithelial cells and to variable extents in 
skin fibroblasts. Finally, expression of CD79B was most pronounced in the B-cell 
lineage, but expression was also found in a variety of other (non-)hematopoietic 
cell types. Thus, restricted or predominant expression in (malignant) B cells 
could be confirmed by microarray gene expression analysis for surface antigens 
with known B-cell specific expression.
In conclusion, the data show that our microarray gene expression dataset as 
collected for (malignant) hematopoietic cell samples and non-hematopoietic 
cell types cultured under steady state and inflammatory conditions provides 
a high-throughput platform for detailed analysis and selection of candidate 





Fibroblasts Fibroblasts + IFN-γ Fold 
IncreasedAVGc SDc AVG SD
ILMN_1705247 ACSL5 71,48 18,18 915,69 4,61 12,81
ILMN_1756862 APOL3 127,45 50,12 1744,54 88,76 13,69
ILMN_1720048 CCL2 405,52 320,65 566,98 379,69 1,40
ILMN_2098126 CCL5 56,56 5,03 87,02 7,13 1,54
ILMN_1773352 CCL5 55,04 4,49 70,60 14,72 1,28
ILMN_1772964 CCL8 79,79 26,74 654,98 396,22 8,21
ILMN_1736567 CD74 105,73 53,25 4540,97 791,32 42,95
ILMN_2379644 CD74 77,73 31,38 1627,96 282,95 20,94
ILMN_1761464 CD74 51,45 1,29 730,79 41,60 14,20
ILMN_2047511 CENTA1 187,61 62,18 1916,52 1491,98 10,22
ILMN_1791759 CXCL10 51,04 4,63 178,24 64,32 3,49
ILMN_1745356 CXCL9 48,55 4,44 303,32 131,99 6,25
ILMN_2388547 EPSTI1 124,13 41,46 1691,41 606,22 13,63
ILMN_1701114 GBP1 183,62 52,59 2569,15 182,46 13,99
ILMN_2148785 GBP1 143,83 37,33 1191,59 6,56 8,28
ILMN_1774077 GBP2 745,66 345,68 17626,86 2385,66 23,64
ILMN_1771385 GBP4 48,49 2,67 903,78 21,36 18,64
ILMN_2114568 GBP5 56,21 4,33 1124,80 148,70 20,01
ILMN_1803945 HCP5 91,78 15,97 892,47 51,92 9,72
ILMN_1778401 HLA-B 1305,90 484,58 9930,80 649,29 7,60
ILMN_1695311 HLA-DMA 542,10 87,50 7641,55 2580,39 14,10
ILMN_1761733 HLA-DMB 89,92 32,72 2127,14 1065,96 23,66
ILMN_1659075 HLA-DOA 51,01 4,51 897,08 186,07 17,59
ILMN_1772218 HLA-DPA1 160,29 7,45 3916,33 585,53 24,43
ILMN_1808405 HLA-DQA1 59,19 9,86 887,82 661,25 15,00
ILMN_1689655 HLA-DRA 176,76 126,36 12566,25 3920,68 71,09
ILMN_2157441 HLA-DRA 138,34 86,70 5530,45 687,54 39,98
ILMN_1715169 HLA-DRB1 49,64 3,33 302,36 253,61 6,09
ILMN_1752592 HLA-DRB4 97,08 25,57 3135,67 1486,29 32,30
ILMN_1697499 HLA-DRB5 73,82 26,82 826,23 777,15 11,19
ILMN_2066060 HLA-DRB6 56,77 0,82 317,56 109,15 5,59
ILMN_2066066 HLA-DRB6 52,33 1,69 192,74 48,32 3,68
ILMN_1723912 IFI44L 63,42 5,51 1192,97 174,91 18,81
ILMN_2347798 IFI6 212,00 45,36 2234,49 782,87 10,54
ILMN_1739428 IFIT2 148,34 6,69 2190,73 666,22 14,77
ILMN_1701789 IFIT3 309,27 24,42 5293,10 106,34 17,11









Fibroblasts Fibroblasts + T-supe Fold 
IncreasedAVGc SDc AVG SD
ILMN_1705247 ACSL5 57,07 5,64 410,79 21,92 7,20
ILMN_1756862 APOL3 126,02 3,27 1215,58 198,99 9,65
ILMN_1720048 CCL2 146,88 58,76 3739,10 578,67 25,46
ILMN_2098126 CCL5 80,04 4,21 1448,07 17,78 18,09
ILMN_1773352 CCL5 52,54 0,90 564,89 13,32 10,75
ILMN_1772964 CCL8 76,86 23,08 1092,76 27,37 14,22
ILMN_1736567 CD74 59,62 4,58 6697,04 438,61 112,33
ILMN_2379644 CD74 46,04 4,27 3008,86 137,93 65,35
ILMN_1761464 CD74 45,18 2,03 518,30 79,50 11,47
ILMN_2047511 CENTA1 94,46 27,37 664,84 489,58 7,04
ILMN_1791759 CXCL10 54,72 1,54 1600,24 844,80 29,24
ILMN_1745356 CXCL9 41,91 1,69 5149,88 3359,40 122,89
ILMN_2388547 EPSTI1 165,03 48,22 2084,78 643,31 12,63
ILMN_1701114 GBP1 182,31 43,53 3793,63 414,77 20,81
ILMN_2148785 GBP1 274,42 56,92 5802,20 1534,56 21,14
ILMN_1774077 GBP2 582,62 90,58 7100,17 300,24 12,19
ILMN_1771385 GBP4 57,47 0,85 1439,61 406,66 25,05
ILMN_2114568 GBP5 48,52 1,19 1189,30 25,32 24,51
ILMN_1803945 HCP5 71,62 1,81 936,66 97,71 13,08
ILMN_1778401 HLA-B 1354,92 495,95 15916,89 2069,86 11,75
ILMN_1695311 HLA-DMA 355,31 31,05 3309,74 1393,47 9,32
ILMN_1761733 HLA-DMB 66,70 10,93 930,50 471,41 13,95
ILMN_1659075 HLA-DOA 51,14 1,29 312,10 118,38 6,10
ILMN_1772218 HLA-DPA1 119,74 3,57 2708,72 724,98 22,62
ILMN_1808405 HLA-DQA1 41,27 0,96 870,79 606,77 21,10
ILMN_1689655 HLA-DRA 93,09 0,69 4449,93 1823,37 47,80
ILMN_2157441 HLA-DRA 62,36 1,05 5817,44 2067,78 93,29
ILMN_1715169 HLA-DRB1 51,16 0,40 880,52 833,29 17,21
ILMN_1752592 HLA-DRB4 59,02 1,21 2467,91 384,34 41,81
ILMN_1697499 HLA-DRB5 48,12 0,54 1122,44 1073,92 23,32
ILMN_2066060 HLA-DRB6 60,67 1,64 812,22 438,83 13,39
ILMN_2066066 HLA-DRB6 48,40 2,49 988,46 215,83 20,42
ILMN_1723912 IFI44L 64,62 10,67 1230,95 168,61 19,05
ILMN_2347798 IFI6 664,54 215,55 12733,61 8737,71 19,16
ILMN_1739428 IFIT2 333,39 47,93 2205,74 1097,87 6,62





Fibroblasts Fibroblasts + IFN-γ Fold 
IncreasedAVGc SDc AVG SD
ILMN_1664543 IFIT3 61,94 6,84 500,90 52,90 8,09
ILMN_2334296 IL18BP 124,90 13,66 3132,98 608,04 25,08
ILMN_2368530 IL32 54,42 6,19 149,61 4,61 2,75
ILMN_1656310 INDO 48,99 9,14 523,11 154,06 10,68
ILMN_1708375 IRF1 498,42 212,95 2664,97 295,19 5,35
ILMN_1662358 MX1 198,75 6,86 10822,34 4316,73 54,45
ILMN_1701613 RARRES3 291,17 134,16 9431,88 2494,20 32,39
ILMN_1751079 TAP1 1184,40 16,21 13220,08 1203,62 11,16
ILMN_1678841 UBD 49,97 2,18 76,70 15,87 1,53
ILMN_1727271 WARS 1219,84 167,93 18566,63 8233,61 15,22









Fibroblasts Fibroblasts + T-supe Fold 
IncreasedAVGc SDc AVG SD
ILMN_1664543 IFIT3 111,53 4,69 1162,56 556,31 10,42
ILMN_2334296 IL18BP 68,50 2,03 2266,51 1379,17 33,09
ILMN_2368530 IL32 109,67 4,68 1873,74 978,51 17,09
ILMN_1656310 INDO 45,64 0,65 5685,52 4062,65 124,58
ILMN_1708375 IRF1 277,69 29,54 4185,18 822,05 15,07
ILMN_1662358 MX1 671,64 353,82 6055,89 2475,95 9,02
ILMN_1701613 RARRES3 190,98 15,69 4008,61 1773,14 20,99
ILMN_1751079 TAP1 824,61 168,64 6181,11 527,53 7,50
ILMN_1678841 UBD 52,95 1,42 1077,09 664,73 20,34
ILMN_1727271 WARS 364,88 11,13 7669,97 593,84 21,02
ILMN_2337655 WARS 508,79 30,61 11333,68 2227,47 22,28
a Illumina probe IDs as included in the microarray database. 
b Official gene symbols are depicted for genes that are >10-fold up-regulated by IFN-γ, T-cell supernatant or 
both. 
c AVG and SD are the average and standard deviation of probe fluorescence as measured in different fibroblast 
samples, respectively. 
d Fold increase was calculated from the average probe fluorescence as measured in fibroblasts after pre-
treatment with IFN-γ or T-cell supernatant divided by the average probe fluorescence in the corresponding 
fibroblast samples cultured without cytokines. Values in bold indicate >10-fold upregulated gene expression 
by IFN-γ, T-cell supernatant or both. 





Figure 3: Gene expression profiles for potential targets for immunotherapy of hematological malignancies.  
Gene expression profiles were generated for hematopoiesis-restricted minor histocompatibility antigens and B-cell 
specific surface antigens as potential targets for immunotherapy of hematological malignancies. (A) Gene expression 
profiles for minor histocompatibility antigens HA-1 (HMHA1), LB-ARGHDIB-1R (ARHGDIB) and LB-ITGB2-1 (ITGB2). 
(B) Gene expression profiles for B-cell specific antigens CD19, CD79B and ROR1. Probe fluorescence intensity is shown 
on the x-axis in logarithmic scale. On the y-axis malignant and healthy (non-)hematopoietic cell types as included in the 
microarray dataset are shown. Each dot represents a different sample and the mean and standard deviation of gene 
expression is shown for each cell type.
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In this study, we performed microarray gene expression analysis on malignant 
and healthy hematopoietic cells and various non-hematopoietic cell types 
cultured under steady state and inflammatory conditions. Quality control was 
performed to confirm cell-type origin of the samples and to exclude peripheral 
blood contamination of non-hematopoietic samples. Validation of gene 
expression was performed by quantitative RT-PCR and an inflammatory gene 
signature was established by comparing gene expression between different 
non-hematopoietic cells after pre-treatment with IFN-γ. Furthermore, we 
demonstrated the value of the microarray dataset to generate gene expression 
profiles for potential targets for immunotherapy of hematological malignancies. 
Validation of the Illumina HT12 microarray gene expression dataset by q-PCR 
analysis demonstrated a strong correlation between both platforms with 
an overall corrected R2 of 0.868. However, maximum probe fluorescence 
as measured in any cell type of the dataset varied significantly. No or low 
fluorescence can be the consequence of poor probe quality or absence or low 
expression of the gene transcript in the dataset, while high probe fluorescence 
indicates that the gene transcript is strongly expressed. Strong correlation 
between q-PCR and microarray data with R2 > 0.667 was obtained for all probes 
with maximum fluorescence > log 11. Of the 28,280 probes (20,215 when 
selecting probes for unique genes) for designated NM transcripts on Illumina 
HT12 chips, fluorescence > log 11 was measured for 4301 probes (15%), 3787 
(19%) after selection of probes for unique genes. Provided that ~50% of all 
genes as present in the human genome are expressed in differentiated cell 
types38, expression profiles can be determined with high accuracy for ~40% of 
genes. For probes with maximum fluorescence < log 11, qualitative analysis can 
still be performed, but q-PCR studies are recommended for quantitative gene 
expression analysis. 
To evaluate up-regulated gene expression under inflammatory conditions, we 
cultured various non-hematopoietic cell types in the presence of IFN-γ and 
compared gene expression to the same cells cultured in the absence of cytokines. 
In total 106 probes were >10-fold up-regulated in at least one non-hematopoietic 
cell type with melanocytes being less sensitive to IFN-γ pre-treatment (n=11 
probes) than keratinocytes (n=83 probes). To determine whether IFN-γ can be 
used as single agent to mimic inflammation, we also cultured fibroblasts in the 
presence of T-cell culture supernatant containing high levels of inflammatory 
cytokines (IFN-γ, IL-13, TNF-α and IL-2). There was great overlap between genes 
up-regulated by IFN-γ and T-cell culture supernatant, illustrating that IFN-γ as 
single compound can create an inflammatory gene signature. As such, gene 
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expression analysis of samples cultured with IFN-γ can be used to estimate 
toxicity of immunotherapeutic targets against non-hematopoietic cells under 
inflammatory conditions. 
In our microarray dataset, contamination of non-hematopoietic cells with 
peripheral blood cells was excluded to allow identification and selection of 
genes with hematopoietic (lineage)-restricted expression, which may encode 
relevant targets for immunotherapy of hematological malignancies. To evaluate 
the value of our microarray dataset to analyze and select potential targets for 
immunotherapy of hematological malignancies, we generated gene expression 
profiles for hematopoiesis-restricted minor histocompatibility antigens that are 
recognized by specific T cells in the context of HLA. Microarray analysis confirmed 
restricted or predominant expression of these antigens in hematopoietic cells, 
but ARHGDIB and ITGB2 also showed intermediate and low expression in 
endothelial cells and fibroblasts, respectively. Since actual antigen presentation 
by HLA is not measured by microarray gene expression analysis, additional 
experiments are required to further evaluate potential toxicity against non-
hematopoietic cell types with detectable expression of the gene of interest. For 
ARHGDIB and ITGB2, we measured T-cell reactivity against endothelial cells and 
fibroblasts, but did not find any evidence for toxicity35,37. In addition to minor 
histocompatibility antigens, we generated gene expression profiles for surface 
antigens with known B-cell specific expression that can be targeted independent 
of HLA by CAR-based immunotherapy. Microarray analysis confirmed restricted 
or predominant expression of these antigens in (malignant) B cells. However, 
CD79B was also expressed in a variety of other (non-)hematopoietic cell types, 
which was supported by Jahn et al.39, who demonstrated that intracellular 
CD79B peptides are presented by HLA and recognized by specific T cells on 
other cell types than B cells. Since actual surface expression is not measured 
by microarray gene expression analysis, additional experiments are required to 
evaluate whether CD79B is an appropriate target for CAR-based therapy. For 
ROR1, microarray data confirmed overexpression in CLL as compared to healthy 
B cells, supporting its relevance as therapeutic target. ROR1 expression was also 
found in biliary epithelial cells and to variable extents in skin fibroblasts, but 
no evidence has been found that gene expression in these cell types leads to 
detectable surface expression as illustrated by the safety of CAR-based therapy 
targeting ROR1 in nonhuman primates40,41. 
In summary, we performed microarray gene expression analysis on hematological 
malignancies of different origins, healthy hematopoietic cells and various (IFN-γ 
pre-treated) non-hematopoietic cell types and demonstrate that our microarray 
gene expression database allows detailed analysis and selection of candidate 
targets with hematopoietic (lineage-)restricted expression for immunotherapy 
2
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of hematological cancers. 
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Isolation and culture of healthy hematopoietic cells
Bone marrow and peripheral blood mononuclear cells (BMMC and PBMC) were 
isolated by Ficoll-Isopaque separation and cryopreserved. B cells, T cells and 
monocytes were purified from PBMC by fluorescence-activated cell sorting 
on a FACS-ARIAIII (BD Biosciences) after staining with monoclonal antibodies 
(BD Biosciences) for CD19, CD3 and CD14, respectively. Hematopoietic stem 
cells (HSC) were isolated from G-CSF mobilized peripheral blood by flow 
cytometric sorting for CD34 surface expression. Immature DC (imDC) were 
generated by culturing isolated monocytes in medium with 10% human serum 
(HS) supplemented with 100 ng/mL GM-CSF (Novartis) and 500 IU/mL IL-4 
(Schering-Plough) for 5 days. Mature DC (matDC) were generated by culturing 
imDC for 2 days with 100 ng/mL GM-CSF, 10 ng/mL TNF-α (Cellgenix), 10 ng/mL 
IL-1β (Cellgenix), 10 ng/mL IL-6 (Cellgenix), 1 μg/mL prostaglandin E2 (Sigma-
Aldrich) and 500 IU/mL IFN-γ (Boehringer Ingelheim). Isolated monocytes were 
also incubated for 7 days in medium with 10% HS supplemented with 5 ng/ml 
GM-CSF or 5 ng/ml M-CSF (Chiron) to culture M1 and M2 macrophages (MФ), 
respectively. EBV-transformed B-cell lines (EBV-LCL) and PHA-stimulated T-cell 
lines (PHA-T) were generated from PBMC as previously described1,2.
Isolation and culture of malignant hematopoietic cells
Flow cytometric analyses for malignant cells were performed on a FACS-Calibur 
and cell sorting on a FACS-AriaIII after staining with monoclonal antibodies 
(all BD Biosciences). Acute lymphoblastic leukemia (ALL) cells were isolated 
from samples with >85% leukemic blasts (range 85-98%) using antibodies for 
CD19. Chronic lymphoblastic leukemia (CLL) cells were purified from samples 
with >90% malignant cells using antibodies for CD19 and CD5. Chronic myeloid 
leukemia (CML) cells were isolated using antibodies for CD34 from samples with 
>5% CD34-positive cells. Multiple myeloma cells were sorted from samples with 
>30% plasma cells (range 30-95%) using antibodies for CD38. Acute myeloid 
leukemia (AML) cells were sorted from samples with >20% leukemic blasts 
(range 22%-95%) as single cell populations or as two separate cell populations 
expressing CD33 in the absence or presence of CD14 (CD14neg or CD14pos, 
respectively). 
Isolation and culture of non-hematopoietic cells
Fibroblasts and keratinocytes were cultured from skin-biopsies as previously 
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described1. PTEC were provided by C. van Kooten (Dept. of Nephrology, LUMC) 
after isolation from pre-transplant biopsies or from kidneys not suitable for 
transplantation and culturing in serum-free DMEM/HAM-F12 (Bio-Whittaker, 
Walkersville, MD) supplemented with antibiotics and insulin, transferrin, 
selenium, triiodothyronine, epidermal growth factor and hydrocortisone 
as described earlier3. Skin melanocytes were provided by C. Out (Dept. of 
Dermatology, LUMC) and cultured in F10 supplemented medium (Invitrogen) 
from surgically removed nevi obtained after informed consent from patients with 
the atypical nevus syndrome or healthy individuals4. PBEC were provided by P.S. 
Hiemstra (Dept. of Pulmonology, LUMC) and were isolated from macroscopically 
normal, resected lung tissue from anonymized patients undergoing surgery for 
lung cancer. Cells were expanded by culture under submerged conditions, and 
mucociliary differentiation was achieved by culture at the air-liquid interface5. 
HUVEC were provided by H.C. de Boer (Dept. of Nephrology, LUMC) and were 
isolated from umbilical cords according to Jaffe et al.6 using a cannula sized to fit 
the vein. HUVEC were cultured in EGM-2 medium supplemented with the EGM-
2 bullet kit (Lonza BioWhittaker, Basel, Switzerland) and refreshed every 3 days.
Cornea stroma and epithelial cells were provided by M.J. Jager (Dept. of 
Ophthalmology, LUMC) and cultured as previously described7. In short, corneal 
epithelial cells were harvested by cutting the cornea into four equal quadrants, 
washing the corneal pieces three times in PBS, and incubating the tissue 
overnight at 4°C in dispase II (Roche Applied Science, Mannheim, Germany). 
The corneal epithelium was manually separated as a sheet from the underlying 
tissue, centrifuged, and incubated in trypsin (TrypLE Select, Life Technologies 
Europe BV, Bleiswijk, the Netherlands) for 10-15 minutes. Single cell suspensions 
were cultured in CnT-20 medium (Bio-connect BV, Huissen, the Netherlands) 
with 1% penicillin/streptomycin. The cornea was cut into small parts of about 
1 x 1 mm to isolate cornea stromal cells. The corneal parts were placed in a 
0.1% collagenase type II solution (Life Technologies Europe BV) and incubated 
overnight at 37°C. The obtained cell solution was cultured in DMEM/HAM F12 
medium with stable glutamin (Biochrom AG, Berlin, Germany), supplemented 
with 5% fetal calf serum and 1% penicillin/streptomycin.
Hepatocytes were provided by E. Schmelzer (McGowan Institute for Regenerative 
Medicine, University of Pittsburgh, USA). Hepatocytes were plated on collagen 
I-coated culture plates in William’s Medium E with glutamax, antibiotics, insulin, 
transferrin, selenium and hydrocortisone. Medium was renewed daily and 
hepatocytes were collected at day 2 after two washes with PBS. Colon and small 
intestinal epithelial cells were provided by R.G. Vries and H. Clevers (Hubrecht 
Institute for Developmental Biology and Stem Cell Research, University Medical 
Centre Utrecht, Utrecht, The Netherlands) and cultured as described previously8. 
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Bile duct epithelial cells (SC-5100, passage 4) were purchased from ScienCell 
(Carlsbad, CA, USA) and cultured according to manufacturer’s instructions. 
Fibroblasts, keratinocytes, PTEC, melanocytes and HUVEC were also cultured 
in the presence of IFN-γ (100 IU/ml) for 4 days to mimic an inflammatory 
environment. Additionally, two fibroblast samples were cultured with a T-cell 
culture supernatant for 4 days. This supernatant was collected from a CD4 T-cell 
clone that was stimulated with leukemic-antigen presenting cells9 and contained 
high levels of IFN-γ (3100 pg/ml), IL-13 (500 pg/ml), TNF-α (700 pg/ml) and IL-2 
(600 pg/ml) as measured by multi-cytokine ELISA.
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Figure S2: Clustering analysis of hematopoietic and non-hematopoietic cell types
Hierarchical clustering analysis was performed on all healthy hematopoietic and non-hematopoietic cell types 
as included in the dataset based on microarray expression profiling of all genes. Hematopoietic cell types were 
accurately distinguished from non-hematopoietic cell types.
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Figure S3: Gene expression for differentiation markers on cell populations isolated from malignant 
hematopoietic samples
Gene expression for differentiation markers on cell populations isolated from AML, CML, ALL, CLL and MM 
samples is shown. Black symbols indicate gene expression for surface markers that were used for isolation of 
malignant cell populations, while gray symbols indicate gene expression for other differentiation markers on 
isolated cell populations. From AML samples, cell populations were isolated by surface expression of CD33 
only (filled circles) or by CD33 in combination with CD14 (open triangles and open squares represent CD33 
positive cell populations that are positive or negative for CD14, respectively). Probe fluorescence is indicated 





























































































































































































































































































































































































































































































































































































































































































































































































































































0.925 0.759 0.948 0.732
0.783 0.944 0.985 0.867
0.834 0.974 0.679 0.326
0.409 0.266 0.779 0.487
0.938 -0.001 0.320 0.216
0.347 0.652 0.545 0.856
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Table S1: Complex karyotypes of leukemic cells selected for 
microarray gene expression analysis
Figure S4: Correlation plots for q-PCR and microarray data
Plots depicting regression models are given for each gene separately. q-PCR values are given on the x-axis 
and microarray probe fluorescence on the y-axis. For the purpose of graphical representation Cp values were 
normalized according to reference genes prior to fitting the regression model. Individual R2 values derived 
from the model are depicted in the left upper corner of each plot. Genes are shown in order of maximum 
probe fluorescence as measured in any cell type of the dataset as selected for q-PCR validation starting with 
genes with highest maximum probe fluorescence. Each dot represents the mean corrected q-PCR value of 
duplicate measurements and the probe fluorescence intensity as measured by microarray gene expression 
analysis. Q-PCR measurements were corrected for expression of reference genes (HMBS, ACTB and GAPDH) 









45-46, XX, ?inv (3) (p?q?), -4, add (5) (q1?2), der (9) t(4;9) (q21;q34), ?dic 
(11;?) (p1?2;?), add (12) (p13), der (12) add (12) (p?) del (12) (q22), add 
(14) (q13), -17, del (17) (q21), +1-2mar [19] / 46, XX [1]
AML 3778 
(CD33)
47, XX, +8, del (12) (p13) [5] / 47, idem, i (17) (q10) [7] / 47, XX, +add (8) 
(q24), del (12) (p13), i (17) (q10) [2]  
AML 5074 
(CD33/CD14) 47, XY, +3 [3] / 48, idem, +20 [2]  / 46, XY, t(10;16) (q21;p13) [3]
ALL 5903  
(CD19) 
46, XX, t(9;22) (q34;q11) [6] / 45, XX, -7, t(9;22) (q34;q11), add (14) (p11) 
[2] / 46, XX [7]
ALL 3655  
(CD19) 
 85-88, XX, +1, -3, -4, -5, -6, -7, -7, -8, -9, -9, -10, +11, +12, -13, -14, -15, -15, -16, 
-17, -17, -18. +6-14mar, inc [cp16] / 46, XX [1]
CML 3471 (CD34) 46, XY, t(9;22) (q34;q11) .ish der(9) t(9;22) del(9) (q34q34) (ABL-, WCP22+), der(22) t(9;22) (BCR+, ABL+, WCP22+) [19] /46, XY [1]
CML 3087 (CD34)
46, XX, t(9;22) (q34;q11) [10]/46, X, del(X) (p11.?4), t(9;22) (q34;q11) 
[13]/46, X, del(X) (p11.?4), t(9;22) (q34;q11), del(17) (q11.2q21) [5]/46, XX 
[1]
CLL 4725  
(CD19/CD5) 
45, XY, -10, ?der (17;22) (q10;q10), +mar [5] / 45, XY, -10, ?der (17;18) 
(q10;q10), +mar [cp3]  / 46, XY [2] / 44-46, XY, +1-2 mar [cp5] 
MM 5987  
(CD38)
 46-47, X, -Y, del(1) (p13), +6, del(6) (q1?6), del(8) (p1?2), -11, -12, -12, -13, 
add(14) (p11),  +2-4mar [cp2]
MM 5744  
(CD38)  43, X -X, der(2) t(1;2) (q11;q37), -10, -13, -14, +mar [2] / 46,XX [7] 
MM 5019  
(CD38)
40-43, XY, del (1)  (p13), add (6) (q21), add (8) (q24), add (9) (q34), add 
(12) (p11), -13, der (14) t(11;14) (q13;q32), -16, add (18) (q23), der (19) del 
(19) (p13) del (19) (q13), -21, -22 [cp16]  / 46, XY [4]
a Markers for flow cytometric isolation of malignant cells are indicated between brackets. AML cells have 
been isolated by expression of CD33 (CD33) or a combination of CD33 and CD14 (CD33/CD14) in which 
CD33 expressing AML cells positive or negative for monocyte lineage differentiation marker CD14 have been 
selected as two separate cell populations. CLL cells have been selected for co-expression of CD19 and CD5. 
ALL, CML and MM cells have been isolated by expression of CD19, CD34 and CD38, respectively. b Complex 
karyotypes are depicted for unstimulated and/or stimulated cells.
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Table S2: Assays and probe IDs for genes included for validation by q-PCR
a Set indicates in which q-PCR validation sample set the gene was included. b Official gene symbols are depicted 
for genes included in the q-PCR validation set. c Predesigned Taqman gene expression assays were obtained 
from Thermo Fisher Scientific. d Illumina probe IDs as included in the microarray database. e Ref indicates 
genes that are used as reference genes for q-PCR.
Seta Genesb Taqman assayc Probe 1d Probe 2 Probe 3
1 PRTN3 Hs01597752_m1 ILMN_1753584   
1 ELANE Hs00975994_g1 ILMN_1706635   
1 CD33 Hs01076281_m1 ILMN_1747622   
1 CD34 Hs00990732_m1 ILMN_1732799 ILMN_2341229  
1 TAP1 Hs00388675_m1 ILMN_1751079   
1 CD14 Hs02621496_s1 ILMN_1740015 ILMN_2396444  
1 HLA-DRA Hs00219575_m1 ILMN_1689655 ILMN_2157441  
1 PTPRC Hs04189704_m1 ILMN_2340217 ILMN_1653652  
1 HMHA1 Hs00943375_m1 ILMN_1811392   
1 COL1A1 Hs00164004_m1 ILMN_1701308   
1 CD19 Hs01047410_g1 ILMN_1782704   
1 KRT8 Hs02339474_g1 ILMN_1753584   
2 APOBEC3B Hs00358981_m1 ILMN_2219466   
2 C19orf48 Hs01066105_m1 ILMN_1759184 ILMN_2383484  
2 CLYBL Hs00370518_m1 ILMN_1663538   
2 COIL Hs00982300_m1 ILMN_1688034   
2 MOB3A Hs00926925_m1 ILMN_1721344   
2 MS4A1 Hs00544819_m1 ILMN_1776939   
2 P2RX5 Hs01112471_m1 ILMN_1677793   
2 PFAS Hs00389822_m1 ILMN_1755862   
2 POLE Hs00173030_m1 ILMN_1728199   
2 ROR1 Hs00938677_m1 ILMN_1655904   
2 TTK Hs01009870_m1 ILMN_1788166   
2 WT1 Hs01103751_m1 ILMN_1802174   
refe HMBS Hs00609293_g1 ILMN_1685954 ILMN_1726306  
refe ACTB Hs99999903_m1 ILMN_1777296 ILMN_2038777 ILMN_2152131
refe GAPDH Hs99999905_m1 ILMN_1343295 ILMN_1802252 ILMN_2038778
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Table S3: RNA samples used for validation by q-PCR
a RNA samples for q-PCR were the same as used for microarray gene expression analysis and were 
stored at -80°C. b Used in set indicates in which q-PCR validation set the samples were included.
Number RNA samplesa Used in setb
1 ALL 2375 (CD19) 1 & 2
2 ALL 2391 (CD19) 1
3 ALL 1833 (CD19) 1 & 2
4 ALL 1299 (CD19) 2
5 ALL 3281 (CD19) 2
6 AML 3714 (CD33) 1 & 2
7 AML 2467 (CD33/CD14pos) 1
8 AML 1310 (CD33/CD14pos) 1
9 AML 1310 (CD33/CD14neg) 1 & 2
10 CML 2195 (CD34) 1
11 CML 5036 (CD34) 1
12 CLL 4725 (CD19/CD5) 2
13 CLL 2159 (CD19/CD5) 2
14 MM 5987 (CD38) 2
15 MM 5744 (CD38) 2
16 PBMC 5957 1
17 PBMC 4762 1
18 B-cells 5957 (CD19) 1 & 2
19 B-cells 4762 (CD19) 1 & 2
20 T-cells 3087 (CD3) 1
21 HSC 5381 (CD34) 1 & 2
22 HSC 5321 (CD34) 1 & 2
23 Mono 5957 (CD14) 1 & 2
24 Mono 4762 (CD14) 1
25 Mono 3087 (CD14) 2
26 matDC 5957 1 & 2
27 matDC 4762 1
28 matDC 3087 2
29 Cornea Stroma 02 1
30 Cornea Stroma 03 1
31 BEC 01 1
32 BEC 02 1
33 FB 5852A 1 & 2
34 FB 7645 1
35 FB 3087B 2
36 FB 5852A + IFN-γ 1 & 2
37 FB 7645 + IFN-γ 1
38 FB 3087B + IFN-γ 2
39 KC 6317 1 & 2
40 KC 6342 1 & 2
41 KC 6317 + IFN-γ 1
42 KC 6342 + IFN-γ 1
43 EBV-B 3089A 2
44 EBV-B 3089C 2
45 EBV-B 2876 2
46 EBV-B 5852 2
47 EBV-B 3087A 2
48 Colon 02 2
49 Colon 03 2
50 BEC 01 2
51 BEC 02 2
52 Hepatocytes 01 2
53 Hepatocytes 02 2
2
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S4 Table: Gene expression as induced in different non-hematopoietic cells by IFN-γ 
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_2329927 ABCG1 48.84 0.1 49.90 5.8 81.75 21.1 1035.69 252.9 50.06 1.6 54.51 6.9 44.59 2.0 48.09 4.9 150.05 21.7 98.93 16.9 
ILMN_1763666 ALDH3B2 49.61 0.1 46.71 2.6 189.23 44.3 5453.54 1219.8 46.83 3.6 50.84 4.3 43.76 4.3 48.32 4.6 38.85 0.2 41.77 0.5 
ILMN_2363880 ALDH3B2 54.16 0.2 52.95 2.7 72.33 11.1 962.44 427.3 54.65 2.4 55.87 2.2 56.12 5.5 58.23 4.1 45.37 4.2 41.72 3.1 
ILMN_1692332 ALOX12B 51.75 0.1 51.18 3.6 54.84 5.8 933.92 134.3 52.97 2.3 51.53 4.0 48.58 2.3 48.44 0.9 45.34 1.1 40.87 4.1 
ILMN_1756862 APOL3 159.03 0.6 1947.70 459.5 49.63 6.4 640.93 208.9 75.73 10.1 404.24 81.3 45.81 1.2 59.00 14.6 194.68 160.5 1638.69 590.1 
ILMN_1762284 ASPRV1 58.08 0.0 57.51 5.0 53.05 2.2 1152.97 459.9 55.18 4.3 60.09 5.6 72.56 7.9 68.28 5.4 49.69 1.0 49.94 1.1 
ILMN_1723480 BST2 115.21 1.0 602.93 306.3 67.15 14.4 898.60 138.7 702.79 229.8 1569.08 273.2 227.37 96.1 384.41 129.3 511.90 506.5 1248.34 1181.2 
ILMN_1677198 C1R 1852.86 1.2 4264.54 2880.8 156.71 67.2 1299.28 248.7 264.47 256.3 1632.03 596.7 56.32 12.4 101.82 30.5 52.36 5.5 987.57 259.9 
ILMN_1764109 C1R 1709.28 1.4 4510.50 3015.5 111.55 66.5 1211.92 247.7 232.46 200.7 1218.73 332.8 62.81 6.4 101.00 32.1 58.07 1.2 733.80 113.5 
ILMN_1781626 C1S 2733.16 0.6 10171.05 3994.1 113.80 22.5 846.83 313.2 225.07 179.0 2447.75 1696.2 54.04 4.2 86.21 17.2 63.89 3.8 1524.57 649.4 
ILMN_1773352 CCL5 54.39 0.2 73.26 20.2 54.55 1.3 2737.69 1472.4 60.95 11.7 182.60 56.6 91.06 16.9 106.04 69.7 60.86 0.4 58.66 2.9 
ILMN_2098126 CCL5 57.79 0.2 72.36 18.0 61.30 8.7 1980.55 706.8 73.48 26.5 263.78 109.3 114.04 35.4 150.66 83.7 88.92 3.4 82.33 5.3 
ILMN_1736567 CD74 77.09 0.8 3767.31 1778.8 68.31 25.1 7122.15 3193.4 301.65 91.9 15682.34 3869.4 58.57 2.8 1633.06 845.3 50.41 3.5 6673.13 1222.4 
ILMN_2379644 CD74 61.66 0.6 1642.13 898.2 53.63 3.4 2318.52 842.6 133.58 56.4 4314.29 716.8 44.68 5.7 560.01 220.9 44.12 1.2 2848.28 1142.9 
ILMN_1761464 CD74 47.12 0.2 985.43 776.3 49.35 6.0 2704.66 1553.0 69.99 14.4 1939.27 899.9 44.81 7.4 249.88 77.0 40.52 2.3 309.32 151.4 
ILMN_1712522 CEACAM6 45.48 0.1 43.42 4.6 48.79 7.1 985.71 977.1 67.23 29.2 70.09 36.1 41.14 3.3 43.02 4.0 46.19 1.3 44.51 2.8 
ILMN_1774287 CFB 304.78 0.9 1014.58 450.3 128.66 14.3 5047.12 1322.1 189.58 66.8 1658.66 530.1 54.19 4.3 61.49 7.3 83.75 22.2 353.69 164.0 
ILMN_1803838 CNFN 93.28 0.3 75.92 21.3 196.52 45.6 8871.86 1546.6 81.94 2.7 66.44 2.5 109.86 12.3 92.76 20.6 72.91 13.3 64.48 14.4 
ILMN_1803452 CRCT1 61.52 0.2 55.13 2.0 119.52 57.9 4816.55 2047.1 47.39 0.7 51.37 2.4 50.83 6.0 50.52 6.5 55.02 0.4 54.00 4.0 
ILMN_1697733 CST6 103.71 1.2 53.76 10.2 99.92 46.5 2001.80 1302.7 143.03 58.2 174.10 100.7 49.59 2.9 48.88 4.0 55.37 2.6 55.20 6.3 
ILMN_1698666 CST6 79.79 0.8 50.15 3.7 127.88 74.4 1807.84 1407.5 138.67 40.1 202.76 100.5 45.67 1.9 44.24 4.7 44.30 0.3 45.73 1.2 
ILMN_1654072 CX3CL1 49.39 0.1 56.89 4.3 134.20 47.6 2110.01 827.4 403.92 166.7 2121.91 962.7 51.93 3.4 50.39 1.7 133.02 43.4 649.37 600.8 
ILMN_1791759 CXCL10 50.13 0.1 187.09 128.1 136.35 96.2 17124.49 8744.2 54.74 10.1 2037.19 1558.5 53.98 10.1 87.52 21.7 69.02 0.6 15285.57 16284.2 
ILMN_1745356 CXCL9 54.28 0.2 214.43 158.3 41.93 6.0 4979.47 4668.8 48.87 4.8 507.69 571.4 50.43 2.1 89.30 29.9 44.66 1.0 14988.97 19786.6 
ILMN_1686573 DEFB1 51.22 0.1 52.32 5.9 633.89 236.4 10526.60 6622.4 1816.05 1946.7 883.34 565.2 45.94 8.1 45.16 5.3 47.79 2.7 53.22 1.9 
ILMN_1684308 DEFB103B 55.06 0.2 53.17 4.1 63.96 13.8 7264.68 7549.3 49.21 2.3 54.45 4.7 52.69 4.5 49.26 2.8 58.58 0.7 52.89 1.0 
ILMN_1714587 DEFB103B 50.71 0.1 49.86 2.7 53.23 4.7 2182.45 1939.4 46.29 2.5 50.05 2.4 45.53 1.2 46.63 2.2 46.71 2.9 47.94 3.2 
ILMN_1733998 DHRS9 52.63 0.1 53.11 9.8 79.20 10.4 2211.26 2488.2 78.67 25.3 54.43 7.6 49.61 2.9 50.49 2.9 64.24 1.4 74.75 2.5 
ILMN_1769201 ELF3 47.54 0.1 49.41 4.0 63.21 9.5 739.08 506.2 867.37 122.3 1078.05 154.1 56.94 6.1 56.35 0.9 56.94 2.6 61.41 1.1 
ILMN_1671600 EPS8L1 49.09 0.2 46.40 4.6 83.61 24.7 879.20 406.4 95.58 29.4 82.11 24.3 114.34 29.4 88.67 16.7 104.74 63.1 93.78 52.4 
ILMN_2388547 EPSTI1 113.74 0.7 1647.95 506.8 317.50 175.0 2245.49 275.1 350.78 64.1 3297.06 297.7 366.54 214.8 498.67 112.1 85.62 20.6 993.58 415.0 
ILMN_1701114 GBP1 173.11 0.4 2023.51 706.8 150.79 84.2 1135.13 297.1 200.54 44.8 2493.85 1102.2 128.84 95.6 827.20 273.8 134.26 62.1 3115.13 2505.9 
ILMN_2148785 GBP1 125.72 0.4 1239.64 132.5 116.18 39.8 497.33 118.5 109.20 44.3 1258.73 406.2 78.70 31.8 538.87 248.4 150.13 42.2 3480.33 2692.5 
ILMN_1774077 GBP2 603.04 0.8 12958.95 5995.9 89.61 17.4 3991.82 1595.7 1435.90 760.5 16358.86 7106.1 135.98 28.5 1920.36 953.9 518.73 260.1 9395.13 5650.8 
ILMN_1771385 GBP4 48.66 0.2 725.83 211.4 51.44 4.5 902.42 195.9 71.79 15.3 2237.92 305.7 50.86 5.2 124.59 67.2 72.91 11.6 2401.53 308.5 
ILMN_2114568 GBP5 55.38 0.1 892.66 507.3 60.87 24.8 1138.56 226.2 46.33 3.7 5276.27 789.8 44.24 1.1 50.40 6.7 44.09 2.1 2017.36 1414.2 
ILMN_2188862 GDF15 1059.99 0.4 1072.21 600.2 198.91 159.0 3104.88 2204.0 2550.20 2171.0 5469.76 2321.4 726.40 235.3 2450.76 2072.3 4771.94 1280.1 3503.67 216.0 
ILMN_1803945 HCP5 77.79 0.4 958.35 460.8 656.35 301.3 3072.55 1779.9 254.44 65.1 2029.85 535.5 449.64 451.6 1056.99 905.8 48.92 0.9 569.00 235.4 
ILMN_1758623 HIST1H2BD 210.09 0.3 334.05 105.0 295.16 103.9 4056.45 2697.8 94.68 15.9 109.31 33.9 649.55 153.6 617.30 34.9 61.36 1.3 62.48 9.3 
ILMN_1651496 HIST1H2BD 287.15 0.3 420.55 176.9 409.24 193.7 5452.04 3516.2 103.39 4.6 132.37 46.8 1063.49 169.2 1013.49 66.1 68.91 5.1 70.99 16.6 
ILMN_1778401 HLA-B 907.11 0.9 9361.50 1594.6 1635.81 252.0 17150.88 6003.9 2165.09 1430.9 14946.59 964.3 2928.13 2434.1 11274.35 2700.4 305.69 119.6 8580.11 3072.6 
ILMN_1695311 HLA-DMA 396.45 0.8 6931.34 2366.2 236.17 111.9 4290.23 960.5 296.47 53.2 4341.77 2171.5 268.77 72.6 4124.57 415.3 118.99 46.0 2158.77 2130.0 
ILMN_1761733 HLA-DMB 65.93 0.7 1780.86 967.1 56.33 12.8 2044.10 785.5 1072.82 206.4 3251.26 1203.6 62.33 20.3 737.00 40.8 63.16 5.6 1047.80 845.0 
ILMN_1659075 HLA-DOA 50.75 0.1 1231.98 741.6 44.49 8.9 247.60 138.4 46.69 1.5 852.73 754.7 46.01 2.5 251.80 72.0 51.47 6.1 376.36 230.0 
ILMN_1772218 HLA-DPA1 116.29 0.8 5347.41 3408.7 45.00 1.4 5898.30 3368.2 67.18 6.3 3476.02 2001.4 226.50 192.2 2819.46 1753.3 55.11 6.1 1527.72 1152.5 
ILMN_1808405 HLA-DQA1 55.12 0.2 1200.68 1121.2 43.22 2.7 1594.54 1138.9 44.10 1.9 1238.75 960.5 43.13 6.5 309.54 147.8 41.21 1.4 455.84 448.5 
ILMN_2157441 HLA-DRA 96.33 1.0 5896.75 2407.4 50.73 2.2 8090.95 751.2 64.95 14.3 7896.86 3547.8 59.93 10.1 3979.94 923.2 54.50 1.6 4817.07 2652.6 
ILMN_1689655 HLA-DRA 120.13 1.2 13994.52 4867.1 51.71 3.1 16149.33 6775.5 69.65 14.1 8802.78 5386.2 55.33 8.7 4770.78 1192.5 72.54 6.4 3582.60 2716.6 
ILMN_1715169 HLA-DRB1 52.87 0.3 272.20 263.5 45.56 5.0 316.79 227.4 53.89 3.2 638.04 41.7 47.29 5.5 297.85 212.7 54.96 0.2 57.51 1.1 
Table S4: Effect of IFN-γ on gene expression in non-hematop ietic 
cell types
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_1752592 HLA-DRB4 80.20 0.5 4722.43 3240.0 63.89 14.3 9081.97 10653.3 61.87 5.8 2789.86 483.3 59.24 1.3 3116.55 2734.7 62.92 4.3 2740.59 2753.1 
ILMN_1697499 HLA-DRB5 61.78 0.5 439.61 775.9 48.06 3.4 1972.46 2024.2 47.41 3.7 2414.16 1278.0 45.96 6.1 1061.59 908.5 46.57 2.8 48.44 4.4 
ILMN_2066066 HLA-DRB6 52.99 0.1 231.58 66.0 56.97 10.1 396.13 36.8 56.42 1.2 371.08 101.0 55.20 7.1 264.19 36.0 49.87 5.4 702.18 568.2 
ILMN_2186806 HLA-F 216.76 0.6 815.38 143.3 364.69 75.9 2206.76 533.1 371.17 245.1 2035.55 946.4 519.52 295.8 1016.74 572.3 194.52 72.4 1946.75 103.7 
ILMN_2130441 HLA-H 1416.17 0.6 9505.64 1554.9 2118.79 133.5 11458.84 1271.5 2174.33 1698.4 13557.52 3087.1 4030.01 3242.4 10037.66 5575.5 651.59 351.7 9103.70 171.5 
ILMN_2316236 HOPX 45.94 0.1 42.92 5.1 138.08 76.0 2507.79 432.2 58.52 3.8 41.71 1.0 48.73 4.7 44.02 3.5 147.44 91.6 226.15 173.8 
ILMN_2058782 IFI27 632.45 0.9 8740.06 8071.3 14560.92 9119.4 25672.22 808.3 229.73 293.4 2802.31 1266.4 8251.50 9949.4 8078.30 4960.9 5575.76 389.9 7839.86 5570.8 
ILMN_1723912 IFI44L 88.38 0.7 1204.84 453.2 420.66 327.9 1397.99 544.1 254.71 135.9 3737.78 296.1 2091.36 981.5 3245.26 692.0 131.47 37.5 1500.45 753.1 
ILMN_1739428 IFIT2 164.99 0.2 2214.68 576.0 212.66 88.9 2151.56 1623.0 224.64 112.9 2156.26 265.6 1110.65 480.2 2026.69 486.0 61.63 0.6 176.29 27.0 
ILMN_1701789 IFIT3 277.23 0.5 5719.26 1860.9 600.17 448.6 5257.17 2311.6 339.85 126.6 4337.01 354.1 3155.73 1894.5 6597.25 2651.4 60.53 6.3 732.62 220.4 
ILMN_1801246 IFITM1 1117.55 1.2 9494.69 3342.8 3503.69 1844.2 17076.49 837.7 4407.33 2726.6 23031.44 893.8 3985.89 3134.6 14673.66 5747.0 155.79 87.8 1637.90 1283.6 
ILMN_2334296 IL18BP 121.12 0.1 4541.91 2733.1 73.80 19.9 1258.71 223.4 145.65 38.5 8542.26 2796.2 85.65 4.7 541.61 280.5 272.38 157.1 3289.94 212.3 
ILMN_1804901 IL1F5 49.36 0.2 52.07 7.8 72.91 6.4 888.23 86.5 49.05 2.4 54.00 2.2 52.98 4.0 55.31 3.1 42.38 3.4 41.52 2.2 
ILMN_2368530 IL32 57.32 0.2 210.39 74.3 74.24 6.8 1227.70 225.6 608.33 531.3 1470.46 1547.2 51.85 6.1 52.15 10.6 1922.19 1012.3 2679.37 1611.7 
ILMN_1778010 IL32 78.33 0.2 356.41 214.5 79.44 17.2 1033.18 452.3 454.47 337.1 815.64 698.4 53.89 3.4 51.30 0.8 526.22 456.5 686.87 601.3 
ILMN_1656310 INDO 45.82 0.3 525.29 132.5 59.43 15.1 340.77 266.9 59.23 14.7 1360.05 819.0 49.24 4.0 86.92 18.1 44.89 0.2 2549.94 1035.2 
ILMN_1708375 IRF1 378.04 0.8 2621.77 246.6 196.84 19.1 4635.05 2186.4 1053.01 505.7 5612.52 2483.5 221.94 84.3 1715.14 649.4 214.73 193.6 2441.88 179.7 
ILMN_1695924 KLK11 53.19 0.2 50.59 4.5 802.88 179.3 10005.51 2019.0 47.30 4.5 50.59 3.4 49.22 4.6 47.91 4.3 55.29 5.9 50.29 3.1 
ILMN_1745570 KLK7 55.77 0.2 64.67 8.1 1300.40 728.1 15106.71 6679.6 84.20 49.4 68.63 11.9 56.67 3.9 56.57 9.1 48.37 2.7 47.63 1.7 
ILMN_1791545 KRT23 74.38 0.1 70.16 13.3 124.39 42.6 2088.33 1200.5 85.89 26.6 64.48 6.9 104.50 12.7 88.69 16.1 47.56 1.6 47.43 4.3 
ILMN_1705814 KRT80 77.66 0.5 48.93 5.6 87.15 29.0 7107.21 2982.1 551.53 267.0 197.97 88.2 50.82 3.3 48.89 2.5 303.35 22.4 223.93 1.7 
ILMN_2170814 LAMP3 55.19 0.4 119.83 127.9 76.10 21.9 1048.95 275.9 53.25 9.0 549.14 145.3 48.29 4.8 64.23 12.4 323.06 26.2 419.63 22.6 
ILMN_1808220 LCE3E 66.39 0.3 64.63 14.8 56.19 7.2 802.66 396.4 53.53 9.7 65.71 12.2 60.13 6.0 58.36 3.6 51.24 2.6 51.57 4.3 
ILMN_1659688 LGALS3BP 544.76 0.8 1396.51 911.7 644.97 299.3 1007.35 384.4 1181.26 513.3 2832.00 660.7 3228.87 1842.7 4620.85 2686.5 45.16 1.2 480.59 92.3 
ILMN_2412214 LGALS9 67.59 0.4 314.35 196.5 56.63 5.6 56.83 5.9 67.32 6.6 198.68 59.5 87.12 27.7 92.45 39.4 94.55 34.4 975.77 235.6 
ILMN_2332964 LGMN 627.24 0.5 560.58 70.3 424.37 80.7 5382.45 2008.1 505.11 46.6 1106.87 235.8 319.24 47.5 419.66 67.4 470.90 38.3 681.96 106.8 
ILMN_1815895 LOC649143 48.16 0.1 496.09 411.0 46.77 4.4 995.65 242.8 46.62 3.8 714.91 792.5 47.59 1.4 604.77 769.9 58.81 2.1 880.51 810.9 
ILMN_1722670 LYNX1 48.19 0.2 46.55 5.1 54.21 8.6 842.70 443.5 46.51 6.0 49.77 9.9 48.51 2.7 50.88 6.9 46.05 2.2 47.37 0.7 
ILMN_1718033 LYPD5 44.27 0.1 61.20 16.9 106.35 13.0 1951.04 1216.2 55.10 3.4 89.77 13.3 52.32 5.2 66.97 15.7 56.74 7.3 70.75 3.8 
ILMN_2388484 MAP2 59.78 0.3 82.31 24.2 98.60 18.6 1171.85 722.7 58.57 6.7 79.79 3.2 47.16 1.8 53.15 3.2 113.04 27.6 107.14 8.1 
ILMN_1801610 METRNL 536.69 0.3 591.33 251.6 63.46 4.9 694.96 345.5 62.40 7.5 74.02 12.3 117.07 24.8 138.34 14.0 131.82 14.2 115.86 13.4 
ILMN_2371911 MUC1 143.36 0.6 202.42 53.2 74.92 21.0 1000.48 263.6 1568.28 1073.0 2580.89 1351.5 73.54 7.5 77.76 8.5 49.12 2.2 60.31 16.0 
ILMN_1662358 MX1 718.26 1.9 10730.74 7371.9 5578.05 4398.0 17909.55 2646.0 2081.13 1510.0 13433.93 4637.0 20289.26 6972.0 19984.79 6859.6 309.04 70.4 2534.77 893.0 
ILMN_1713397 NCCRP1 50.95 0.2 53.63 2.8 105.54 46.3 2133.37 612.5 100.53 41.2 61.27 4.9 447.73 398.4 163.58 124.6 44.15 0.6 46.92 0.4 
ILMN_1674063 OAS2 253.92 0.6 4329.48 1836.7 3083.40 1274.9 7362.87 2188.3 117.20 106.3 1897.39 368.1 3043.40 1688.0 3615.51 1555.6 202.56 89.1 1208.07 194.9 
ILMN_1693192 PI3 48.98 0.1 44.36 1.9 965.35 557.7 11419.86 2677.6 283.62 195.0 65.43 10.3 50.67 3.8 48.72 2.4 43.94 2.9 42.29 0.7 
ILMN_1815023 PIM1 1176.16 1.1 901.48 359.0 354.74 45.6 4939.44 2578.8 747.24 343.8 943.70 416.6 102.64 21.6 96.69 19.9 87.08 32.5 96.57 23.4 
ILMN_2376108 PSMB9 187.57 0.7 2542.10 516.9 243.36 9.9 1042.49 419.2 288.94 29.2 2723.48 655.0 403.61 274.2 1086.98 313.4 78.08 47.5 1358.51 1202.1 
ILMN_1800091 RARRES1 52.02 0.2 118.93 82.1 48.70 2.1 1661.48 1005.2 89.68 18.2 193.27 89.9 55.11 6.2 58.95 2.3 62.65 6.4 69.09 10.6 
ILMN_1701613 RARRES3 286.89 0.7 12942.20 5804.9 128.36 21.7 8772.33 2324.2 2348.77 337.8 28950.28 602.9 171.05 44.9 383.49 106.1 62.17 22.9 1809.49 1367.0 
ILMN_1683179 RRAD 86.19 0.6 63.27 2.1 69.76 9.0 1201.41 880.7 1611.67 1019.4 1444.14 481.5 45.99 4.5 47.28 3.5 56.15 1.7 53.73 0.5 
ILMN_1801216 S100P 51.84 0.3 104.19 117.8 58.75 11.5 12726.25 1851.0 85.61 34.5 72.25 29.3 49.15 4.8 43.18 1.8 42.09 2.0 41.94 1.5 
ILMN_1712759 SBSN 244.46 1.0 182.80 167.6 300.96 100.3 14248.09 3514.4 51.16 3.9 47.55 3.8 53.46 2.9 51.97 3.7 42.26 0.9 44.32 2.9 
ILMN_1740917 SCNN1B 52.96 0.1 55.99 6.6 62.13 5.3 696.83 247.9 48.70 3.7 55.12 5.0 54.35 1.6 52.32 2.7 50.34 3.9 51.08 1.6 
ILMN_2114720 SLPI 51.63 0.2 50.64 4.5 597.01 197.4 6506.51 739.5 2139.08 1426.8 2184.73 951.3 49.57 2.3 44.48 1.3 42.82 3.4 43.37 0.4 
ILMN_1716591 SPRR1A 38.85 0.2 42.92 9.3 266.78 200.3 6084.44 5091.9 54.15 20.9 44.65 8.6 48.47 6.0 45.33 11.2 97.59 11.8 93.50 15.3 
ILMN_2191967 SPRR2D 44.58 0.2 44.37 2.3 420.01 416.6 13954.08 12217.5 44.87 3.5 46.25 4.0 44.24 4.0 44.30 1.6 57.09 1.7 52.51 3.3 
ILMN_1810835 SPRR3 50.74 0.1 50.81 2.4 85.75 37.2 5981.57 7827.6 49.48 1.7 52.13 5.5 52.04 5.8 55.10 2.4 46.01 2.2 42.43 0.2 
ILMN_1727589 SULT2B1 51.65 0.0 51.75 5.2 85.03 13.7 1457.46 235.2 53.49 7.5 52.54 3.6 69.51 16.2 68.01 8.1 44.97 3.0 48.06 4.8 
ILMN_1751079 TAP1 1236.54 0.5 13773.11 3210.4 1972.73 192.8 25648.96 2364.5 1434.62 544.7 15504.01 1948.7 3833.53 1618.3 14098.87 1982.3 654.16 334.6 10409.28 5849.2 
ILMN_1770922 TMEM45A 758.53 0.2 813.31 134.5 269.60 62.2 2767.81 917.2 73.13 27.7 53.04 3.3 139.19 49.0 122.61 33.8 137.64 90.3 126.11 71.7 
ILMN_1758418 TNFSF13B 74.69 0.4 697.88 321.1 57.43 1.9 180.66 74.8 65.40 12.7 819.94 7.5 75.92 16.8 226.77 79.1 60.31 3.9 260.83 9.5 
ILMN_1678841 UBD 49.53 0.1 68.58 16.1 50.81 13.0 1960.63 804.8 150.86 117.1 5551.24 826.5 47.89 2.2 100.32 33.1 73.61 16.0 1967.35 291.8 
ILMN_1727271 WARS 1514.53 0.5 20408.54 7452.5 689.49 104.2 30022.06 501.3 913.46 79.7 18692.93 2211.8 6765.34 1591.4 27572.74 1562.6 914.36 61.8 14680.06 11560.4 
2
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S4 Table: Gene expression as induced in different non-hematopoietic cells by IFN-γ 
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_2329927 ABCG1 48.84 0.1 49.90 5.8 81.75 21.1 1035.69 252.9 50.06 1.6 54.51 6.9 44.59 2.0 48.09 4.9 150.05 21.7 98.93 16.9 
ILMN_1763666 ALDH3B2 49.61 0.1 46.71 2.6 189.23 44.3 5453.54 1219.8 46.83 3.6 50.84 4.3 43.76 4.3 48.32 4.6 38.85 0.2 41.77 0.5 
ILMN_2363880 ALDH3B2 54.16 0.2 52.95 2.7 72.33 11.1 962.44 427.3 54.65 2.4 55.87 2.2 56.12 5.5 58.23 4.1 45.37 4.2 41.72 3.1 
ILMN_1692332 ALOX12B 51.75 0.1 51.18 3.6 54.84 5.8 933.92 134.3 52.97 2.3 51.53 4.0 48.58 2.3 48.44 0.9 45.34 1.1 40.87 4.1 
ILMN_1756862 APOL3 159.03 0.6 1947.70 459.5 49.63 6.4 640.93 208.9 75.73 10.1 404.24 81.3 45.81 1.2 59.00 14.6 194.68 160.5 1638.69 590.1 
ILMN_1762284 ASPRV1 58.08 0.0 57.51 5.0 53.05 2.2 1152.97 459.9 55.18 4.3 60.09 5.6 72.56 7.9 68.28 5.4 49.69 1.0 49.94 1.1 
ILMN_1723480 BST2 115.21 1.0 602.93 306.3 67.15 14.4 898.60 138.7 702.79 229.8 1569.08 273.2 227.37 96.1 384.41 129.3 511.90 506.5 1248.34 1181.2 
ILMN_1677198 C1R 1852.86 1.2 4264.54 2880.8 156.71 67.2 1299.28 248.7 264.47 256.3 1632.03 596.7 56.32 12.4 101.82 30.5 52.36 5.5 987.57 259.9 
ILMN_1764109 C1R 1709.28 1.4 4510.50 3015.5 111.55 66.5 1211.92 247.7 232.46 200.7 1218.73 332.8 62.81 6.4 101.00 32.1 58.07 1.2 733.80 113.5 
ILMN_1781626 C1S 2733.16 0.6 10171.05 3994.1 113.80 22.5 846.83 313.2 225.07 179.0 2447.75 1696.2 54.04 4.2 86.21 17.2 63.89 3.8 1524.57 649.4 
ILMN_1773352 CCL5 54.39 0.2 73.26 20.2 54.55 1.3 2737.69 1472.4 60.95 11.7 182.60 56.6 91.06 16.9 106.04 69.7 60.86 0.4 58.66 2.9 
ILMN_2098126 CCL5 57.79 0.2 72.36 18.0 61.30 8.7 1980.55 706.8 73.48 26.5 263.78 109.3 114.04 35.4 150.66 83.7 88.92 3.4 82.33 5.3 
ILMN_1736567 CD74 77.09 0.8 3767.31 1778.8 68.31 25.1 7122.15 3193.4 301.65 91.9 15682.34 3869.4 58.57 2.8 1633.06 845.3 50.41 3.5 6673.13 1222.4 
ILMN_2379644 CD74 61.66 0.6 1642.13 898.2 53.63 3.4 2318.52 842.6 133.58 56.4 4314.29 716.8 44.68 5.7 560.01 220.9 44.12 1.2 2848.28 1142.9 
ILMN_1761464 CD74 47.12 0.2 985.43 776.3 49.35 6.0 2704.66 1553.0 69.99 14.4 1939.27 899.9 44.81 7.4 249.88 77.0 40.52 2.3 309.32 151.4 
ILMN_1712522 CEACAM6 45.48 0.1 43.42 4.6 48.79 7.1 985.71 977.1 67.23 29.2 70.09 36.1 41.14 3.3 43.02 4.0 46.19 1.3 44.51 2.8 
ILMN_1774287 CFB 304.78 0.9 1014.58 450.3 128.66 14.3 5047.12 1322.1 189.58 66.8 1658.66 530.1 54.19 4.3 61.49 7.3 83.75 22.2 353.69 164.0 
ILMN_1803838 CNFN 93.28 0.3 75.92 21.3 196.52 45.6 8871.86 1546.6 81.94 2.7 66.44 2.5 109.86 12.3 92.76 20.6 72.91 13.3 64.48 14.4 
ILMN_1803452 CRCT1 61.52 0.2 55.13 2.0 119.52 57.9 4816.55 2047.1 47.39 0.7 51.37 2.4 50.83 6.0 50.52 6.5 55.02 0.4 54.00 4.0 
ILMN_1697733 CST6 103.71 1.2 53.76 10.2 99.92 46.5 2001.80 1302.7 143.03 58.2 174.10 100.7 49.59 2.9 48.88 4.0 55.37 2.6 55.20 6.3 
ILMN_1698666 CST6 79.79 0.8 50.15 3.7 127.88 74.4 1807.84 1407.5 138.67 40.1 202.76 100.5 45.67 1.9 44.24 4.7 44.30 0.3 45.73 1.2 
ILMN_1654072 CX3CL1 49.39 0.1 56.89 4.3 134.20 47.6 2110.01 827.4 403.92 166.7 2121.91 962.7 51.93 3.4 50.39 1.7 133.02 43.4 649.37 600.8 
ILMN_1791759 CXCL10 50.13 0.1 187.09 128.1 136.35 96.2 17124.49 8744.2 54.74 10.1 2037.19 1558.5 53.98 10.1 87.52 21.7 69.02 0.6 15285.57 16284.2 
ILMN_1745356 CXCL9 54.28 0.2 214.43 158.3 41.93 6.0 4979.47 4668.8 48.87 4.8 507.69 571.4 50.43 2.1 89.30 29.9 44.66 1.0 14988.97 19786.6 
ILMN_1686573 DEFB1 51.22 0.1 52.32 5.9 633.89 236.4 10526.60 6622.4 1816.05 1946.7 883.34 565.2 45.94 8.1 45.16 5.3 47.79 2.7 53.22 1.9 
ILMN_1684308 DEFB103B 55.06 0.2 53.17 4.1 63.96 13.8 7264.68 7549.3 49.21 2.3 54.45 4.7 52.69 4.5 49.26 2.8 58.58 0.7 52.89 1.0 
ILMN_1714587 DEFB103B 50.71 0.1 49.86 2.7 53.23 4.7 2182.45 1939.4 46.29 2.5 50.05 2.4 45.53 1.2 46.63 2.2 46.71 2.9 47.94 3.2 
ILMN_1733998 DHRS9 52.63 0.1 53.11 9.8 79.20 10.4 2211.26 2488.2 78.67 25.3 54.43 7.6 49.61 2.9 50.49 2.9 64.24 1.4 74.75 2.5 
ILMN_1769201 ELF3 47.54 0.1 49.41 4.0 63.21 9.5 739.08 506.2 867.37 122.3 1078.05 154.1 56.94 6.1 56.35 0.9 56.94 2.6 61.41 1.1 
ILMN_1671600 EPS8L1 49.09 0.2 46.40 4.6 83.61 24.7 879.20 406.4 95.58 29.4 82.11 24.3 114.34 29.4 88.67 16.7 104.74 63.1 93.78 52.4 
ILMN_2388547 EPSTI1 113.74 0.7 1647.95 506.8 317.50 175.0 2245.49 275.1 350.78 64.1 3297.06 297.7 366.54 214.8 498.67 112.1 85.62 20.6 993.58 415.0 
ILMN_1701114 GBP1 173.11 0.4 2023.51 706.8 150.79 84.2 1135.13 297.1 200.54 44.8 2493.85 1102.2 128.84 95.6 827.20 273.8 134.26 62.1 3115.13 2505.9 
ILMN_2148785 GBP1 125.72 0.4 1239.64 132.5 116.18 39.8 497.33 118.5 109.20 44.3 1258.73 406.2 78.70 31.8 538.87 248.4 150.13 42.2 3480.33 2692.5 
ILMN_1774077 GBP2 603.04 0.8 12958.95 5995.9 89.61 17.4 3991.82 1595.7 1435.90 760.5 16358.86 7106.1 135.98 28.5 1920.36 953.9 518.73 260.1 9395.13 5650.8 
ILMN_1771385 GBP4 48.66 0.2 725.83 211.4 51.44 4.5 902.42 195.9 71.79 15.3 2237.92 305.7 50.86 5.2 124.59 67.2 72.91 11.6 2401.53 308.5 
ILMN_2114568 GBP5 55.38 0.1 892.66 507.3 60.87 24.8 1138.56 226.2 46.33 3.7 5276.27 789.8 44.24 1.1 50.40 6.7 44.09 2.1 2017.36 1414.2 
ILMN_2188862 GDF15 1059.99 0.4 1072.21 600.2 198.91 159.0 3104.88 2204.0 2550.20 2171.0 5469.76 2321.4 726.40 235.3 2450.76 2072.3 4771.94 1280.1 3503.67 216.0 
ILMN_1803945 HCP5 77.79 0.4 958.35 460.8 656.35 301.3 3072.55 1779.9 254.44 65.1 2029.85 535.5 449.64 451.6 1056.99 905.8 48.92 0.9 569.00 235.4 
ILMN_1758623 HIST1H2BD 210.09 0.3 334.05 105.0 295.16 103.9 4056.45 2697.8 94.68 15.9 109.31 33.9 649.55 153.6 617.30 34.9 61.36 1.3 62.48 9.3 
ILMN_1651496 HIST1H2BD 287.15 0.3 420.55 176.9 409.24 193.7 5452.04 3516.2 103.39 4.6 132.37 46.8 1063.49 169.2 1013.49 66.1 68.91 5.1 70.99 16.6 
ILMN_1778401 HLA-B 907.11 0.9 9361.50 1594.6 1635.81 252.0 17150.88 6003.9 2165.09 1430.9 14946.59 964.3 2928.13 2434.1 11274.35 2700.4 305.69 119.6 8580.11 3072.6 
ILMN_1695311 HLA-DMA 396.45 0.8 6931.34 2366.2 236.17 111.9 4290.23 960.5 296.47 53.2 4341.77 2171.5 268.77 72.6 4124.57 415.3 118.99 46.0 2158.77 2130.0 
ILMN_1761733 HLA-DMB 65.93 0.7 1780.86 967.1 56.33 12.8 2044.10 785.5 1072.82 206.4 3251.26 1203.6 62.33 20.3 737.00 40.8 63.16 5.6 1047.80 845.0 
ILMN_1659075 HLA-DOA 50.75 0.1 1231.98 741.6 44.49 8.9 247.60 138.4 46.69 1.5 852.73 754.7 46.01 2.5 251.80 72.0 51.47 6.1 376.36 230.0 
ILMN_1772218 HLA-DPA1 116.29 0.8 5347.41 3408.7 45.00 1.4 5898.30 3368.2 67.18 6.3 3476.02 2001.4 226.50 192.2 2819.46 1753.3 55.11 6.1 1527.72 1152.5 
ILMN_1808405 HLA-DQA1 55.12 0.2 1200.68 1121.2 43.22 2.7 1594.54 1138.9 44.10 1.9 1238.75 960.5 43.13 6.5 309.54 147.8 41.21 1.4 455.84 448.5 
ILMN_2157441 HLA-DRA 96.33 1.0 5896.75 2407.4 50.73 2.2 8090.95 751.2 64.95 14.3 7896.86 3547.8 59.93 10.1 3979.94 923.2 54.50 1.6 4817.07 2652.6 
ILMN_1689655 HLA-DRA 120.13 1.2 13994.52 4867.1 51.71 3.1 16149.33 6775.5 69.65 14.1 8802.78 5386.2 55.33 8.7 4770.78 1192.5 72.54 6.4 3582.60 2716.6 
ILMN_1715169 HLA-DRB1 52.87 0.3 272.20 263.5 45.56 5.0 316.79 227.4 53.89 3.2 638.04 41.7 47.29 5.5 297.85 212.7 54.96 0.2 57.51 1.1 
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_1752592 HLA-DRB4 80.20 0.5 4722.43 3240.0 63.89 14.3 9081.97 10653.3 61.87 5.8 2789.86 483.3 59.24 1.3 3116.55 2734.7 62.92 4.3 2740.59 2753.1 
ILMN_1697499 HLA-DRB5 61.78 0.5 439.61 775.9 48.06 3.4 1972.46 2024.2 47.41 3.7 2414.16 1278.0 45.96 6.1 1061.59 908.5 46.57 2.8 48.44 4.4 
ILMN_2066066 HLA-DRB6 52.99 0.1 231.58 66.0 56.97 10.1 396.13 36.8 56.42 1.2 371.08 101.0 55.20 7.1 264.19 36.0 49.87 5.4 702.18 568.2 
ILMN_2186806 HLA-F 216.76 0.6 815.38 143.3 364.69 75.9 2206.76 533.1 371.17 245.1 2035.55 946.4 519.52 295.8 1016.74 572.3 194.52 72.4 1946.75 103.7 
ILMN_2130441 HLA-H 1416.17 0.6 9505.64 1554.9 2118.79 133.5 11458.84 1271.5 2174.33 1698.4 13557.52 3087.1 4030.01 3242.4 10037.66 5575.5 651.59 351.7 9103.70 171.5 
ILMN_2316236 HOPX 45.94 0.1 42.92 5.1 138.08 76.0 2507.79 432.2 58.52 3.8 41.71 1.0 48.73 4.7 44.02 3.5 147.44 91.6 226.15 173.8 
ILMN_2058782 IFI27 632.45 0.9 8740.06 8071.3 14560.92 9119.4 25672.22 808.3 229.73 293.4 2802.31 1266.4 8251.50 9949.4 8078.30 4960.9 5575.76 389.9 7839.86 5570.8 
ILMN_1723912 IFI44L 88.38 0.7 1204.84 453.2 420.66 327.9 1397.99 544.1 254.71 135.9 3737.78 296.1 2091.36 981.5 3245.26 692.0 131.47 37.5 1500.45 753.1 
ILMN_1739428 IFIT2 164.99 0.2 2214.68 576.0 212.66 88.9 2151.56 1623.0 224.64 112.9 2156.26 265.6 1110.65 480.2 2026.69 486.0 61.63 0.6 176.29 27.0 
ILMN_1701789 IFIT3 277.23 0.5 5719.26 1860.9 600.17 448.6 5257.17 2311.6 339.85 126.6 4337.01 354.1 3155.73 1894.5 6597.25 2651.4 60.53 6.3 732.62 220.4 
ILMN_1801246 IFITM1 1117.55 1.2 9494.69 3342.8 3503.69 1844.2 17076.49 837.7 4407.33 2726.6 23031.44 893.8 3985.89 3134.6 14673.66 5747.0 155.79 87.8 1637.90 1283.6 
ILMN_2334296 IL18BP 121.12 0.1 4541.91 2733.1 73.80 19.9 1258.71 223.4 145.65 38.5 8542.26 2796.2 85.65 4.7 541.61 280.5 272.38 157.1 3289.94 212.3 
ILMN_1804901 IL1F5 49.36 0.2 52.07 7.8 72.91 6.4 888.23 86.5 49.05 2.4 54.00 2.2 52.98 4.0 55.31 3.1 42.38 3.4 41.52 2.2 
ILMN_2368530 IL32 57.32 0.2 210.39 74.3 74.24 6.8 1227.70 225.6 608.33 531.3 1470.46 1547.2 51.85 6.1 52.15 10.6 1922.19 1012.3 2679.37 1611.7 
ILMN_1778010 IL32 78.33 0.2 356.41 214.5 79.44 17.2 1033.18 452.3 454.47 337.1 815.64 698.4 53.89 3.4 51.30 0.8 526.22 456.5 686.87 601.3 
ILMN_1656310 INDO 45.82 0.3 525.29 132.5 59.43 15.1 340.77 266.9 59.23 14.7 1360.05 819.0 49.24 4.0 86.92 18.1 44.89 0.2 2549.94 1035.2 
ILMN_1708375 IRF1 378.04 0.8 2621.77 246.6 196.84 19.1 4635.05 2186.4 1053.01 505.7 5612.52 2483.5 221.94 84.3 1715.14 649.4 214.73 193.6 2441.88 179.7 
ILMN_1695924 KLK11 53.19 0.2 50.59 4.5 802.88 179.3 10005.51 2019.0 47.30 4.5 50.59 3.4 49.22 4.6 47.91 4.3 55.29 5.9 50.29 3.1 
ILMN_1745570 KLK7 55.77 0.2 64.67 8.1 1300.40 728.1 15106.71 6679.6 84.20 49.4 68.63 11.9 56.67 3.9 56.57 9.1 48.37 2.7 47.63 1.7 
ILMN_1791545 KRT23 74.38 0.1 70.16 13.3 124.39 42.6 2088.33 1200.5 85.89 26.6 64.48 6.9 104.50 12.7 88.69 16.1 47.56 1.6 47.43 4.3 
ILMN_1705814 KRT80 77.66 0.5 48.93 5.6 87.15 29.0 7107.21 2982.1 551.53 267.0 197.97 88.2 50.82 3.3 48.89 2.5 303.35 22.4 223.93 1.7 
ILMN_2170814 LAMP3 55.19 0.4 119.83 127.9 76.10 21.9 1048.95 275.9 53.25 9.0 549.14 145.3 48.29 4.8 64.23 12.4 323.06 26.2 419.63 22.6 
ILMN_1808220 LCE3E 66.39 0.3 64.63 14.8 56.19 7.2 802.66 396.4 53.53 9.7 65.71 12.2 60.13 6.0 58.36 3.6 51.24 2.6 51.57 4.3 
ILMN_1659688 LGALS3BP 544.76 0.8 1396.51 911.7 644.97 299.3 1007.35 384.4 1181.26 513.3 2832.00 660.7 3228.87 1842.7 4620.85 2686.5 45.16 1.2 480.59 92.3 
ILMN_2412214 LGALS9 67.59 0.4 314.35 196.5 56.63 5.6 56.83 5.9 67.32 6.6 198.68 59.5 87.12 27.7 92.45 39.4 94.55 34.4 975.77 235.6 
ILMN_2332964 LGMN 627.24 0.5 560.58 70.3 424.37 80.7 5382.45 2008.1 505.11 46.6 1106.87 235.8 319.24 47.5 419.66 67.4 470.90 38.3 681.96 106.8 
ILMN_1815895 LOC649143 48.16 0.1 496.09 411.0 46.77 4.4 995.65 242.8 46.62 3.8 714.91 792.5 47.59 1.4 604.77 769.9 58.81 2.1 880.51 810.9 
ILMN_1722670 LYNX1 48.19 0.2 46.55 5.1 54.21 8.6 842.70 443.5 46.51 6.0 49.77 9.9 48.51 2.7 50.88 6.9 46.05 2.2 47.37 0.7 
ILMN_1718033 LYPD5 44.27 0.1 61.20 16.9 106.35 13.0 1951.04 1216.2 55.10 3.4 89.77 13.3 52.32 5.2 66.97 15.7 56.74 7.3 70.75 3.8 
ILMN_2388484 MAP2 59.78 0.3 82.31 24.2 98.60 18.6 1171.85 722.7 58.57 6.7 79.79 3.2 47.16 1.8 53.15 3.2 113.04 27.6 107.14 8.1 
ILMN_1801610 METRNL 536.69 0.3 591.33 251.6 63.46 4.9 694.96 345.5 62.40 7.5 74.02 12.3 117.07 24.8 138.34 14.0 131.82 14.2 115.86 13.4 
ILMN_2371911 MUC1 143.36 0.6 202.42 53.2 74.92 21.0 1000.48 263.6 1568.28 1073.0 2580.89 1351.5 73.54 7.5 77.76 8.5 49.12 2.2 60.31 16.0 
ILMN_1662358 MX1 718.26 1.9 10730.74 7371.9 5578.05 4398.0 17909.55 2646.0 2081.13 1510.0 13433.93 4637.0 20289.26 6972.0 19984.79 6859.6 309.04 70.4 2534.77 893.0 
ILMN_1713397 NCCRP1 50.95 0.2 53.63 2.8 105.54 46.3 2133.37 612.5 100.53 41.2 61.27 4.9 447.73 398.4 163.58 124.6 44.15 0.6 46.92 0.4 
ILMN_1674063 OAS2 253.92 0.6 4329.48 1836.7 3083.40 1274.9 7362.87 2188.3 117.20 106.3 1897.39 368.1 3043.40 1688.0 3615.51 1555.6 202.56 89.1 1208.07 194.9 
ILMN_1693192 PI3 48.98 0.1 44.36 1.9 965.35 557.7 11419.86 2677.6 283.62 195.0 65.43 10.3 50.67 3.8 48.72 2.4 43.94 2.9 42.29 0.7 
ILMN_1815023 PIM1 1176.16 1.1 901.48 359.0 354.74 45.6 4939.44 2578.8 747.24 343.8 943.70 416.6 102.64 21.6 96.69 19.9 87.08 32.5 96.57 23.4 
ILMN_2376108 PSMB9 187.57 0.7 2542.10 516.9 243.36 9.9 1042.49 419.2 288.94 29.2 2723.48 655.0 403.61 274.2 1086.98 313.4 78.08 47.5 1358.51 1202.1 
ILMN_1800091 RARRES1 52.02 0.2 118.93 82.1 48.70 2.1 1661.48 1005.2 89.68 18.2 193.27 89.9 55.11 6.2 58.95 2.3 62.65 6.4 69.09 10.6 
ILMN_1701613 RARRES3 286.89 0.7 12942.20 5804.9 128.36 21.7 8772.33 2324.2 2348.77 337.8 28950.28 602.9 171.05 44.9 383.49 106.1 62.17 22.9 1809.49 1367.0 
ILMN_1683179 RRAD 86.19 0.6 63.27 2.1 69.76 9.0 1201.41 880.7 1611.67 1019.4 1444.14 481.5 45.99 4.5 47.28 3.5 56.15 1.7 53.73 0.5 
ILMN_1801216 S100P 51.84 0.3 104.19 117.8 58.75 11.5 12726.25 1851.0 85.61 34.5 72.25 29.3 49.15 4.8 43.18 1.8 42.09 2.0 41.94 1.5 
ILMN_1712759 SBSN 244.46 1.0 182.80 167.6 300.96 100.3 14248.09 3514.4 51.16 3.9 47.55 3.8 53.46 2.9 51.97 3.7 42.26 0.9 44.32 2.9 
ILMN_1740917 SCNN1B 52.96 0.1 55.99 6.6 62.13 5.3 696.83 247.9 48.70 3.7 55.12 5.0 54.35 1.6 52.32 2.7 50.34 3.9 51.08 1.6 
ILMN_2114720 SLPI 51.63 0.2 50.64 4.5 597.01 197.4 6506.51 739.5 2139.08 1426.8 2184.73 951.3 49.57 2.3 44.48 1.3 42.82 3.4 43.37 0.4 
ILMN_1716591 SPRR1A 38.85 0.2 42.92 9.3 266.78 200.3 6084.44 5091.9 54.15 20.9 44.65 8.6 48.47 6.0 45.33 11.2 97.59 11.8 93.50 15.3 
ILMN_2191967 SPRR2D 44.58 0.2 44.37 2.3 420.01 416.6 13954.08 12217.5 44.87 3.5 46.25 4.0 44.24 4.0 44.30 1.6 57.09 1.7 52.51 3.3 
ILMN_1810835 SPRR3 50.74 0.1 50.81 2.4 85.75 37.2 5981.57 7827.6 49.48 1.7 52.13 5.5 52.04 5.8 55.10 2.4 46.01 2.2 42.43 0.2 
ILMN_1727589 SULT2B1 51.65 0.0 51.75 5.2 85.03 13.7 1457.46 235.2 53.49 7.5 52.54 3.6 69.51 16.2 68.01 8.1 44.97 3.0 48.06 4.8 
ILMN_1751079 TAP1 1236.54 0.5 13773.11 3210.4 1972.73 192.8 25648.96 2364.5 1434.62 544.7 15504.01 1948.7 3833.53 1618.3 14098.87 1982.3 654.16 334.6 10409.28 5849.2 
ILMN_1770922 TMEM45A 758.53 0.2 813.31 134.5 269.60 62.2 2767.81 917.2 73.13 27.7 53.04 3.3 139.19 49.0 122.61 33.8 137.64 90.3 126.11 71.7 
ILMN_1758418 TNFSF13B 74.69 0.4 697.88 321.1 57.43 1.9 180.66 74.8 65.40 12.7 819.94 7.5 75.92 16.8 226.77 79.1 60.31 3.9 260.83 9.5 
ILMN_1678841 UBD 49.53 0.1 68.58 16.1 50.81 13.0 1960.63 804.8 150.86 117.1 5551.24 826.5 47.89 2.2 100.32 33.1 73.61 16.0 1967.35 291.8 




Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_1752592 HLA-DRB4 80.20 0.5 4722.43 3240.0 63.89 14.3 9081.97 10653.3 61.87 5.8 2789.86 483.3 59.24 1.3 3116.55 2734.7 62.92 4.3 2740.59 2753.1 
ILMN_1697499 HLA-DRB5 61.78 0.5 439.61 775.9 48.06 3.4 1972.46 2024.2 47.41 3.7 2414.16 1278.0 45.96 6.1 1061.59 908.5 46.57 2.8 48.44 4.4 
ILMN_2066066 HLA-DRB6 52.99 0.1 231.58 66.0 56.97 10.1 396.13 36.8 56.42 1.2 371.08 101.0 55.20 7.1 264.19 36.0 49.87 5.4 702.18 568.2 
ILMN_2186806 HLA-F 216.76 0.6 815.38 143.3 364.69 75.9 2206.76 533.1 371.17 245.1 2035.55 946.4 519.52 295.8 1016.74 572.3 194.52 72.4 1946.75 103.7 
ILMN_2130441 HLA-H 1416.17 0.6 9505.64 1554.9 2118.79 133.5 11458.84 1271.5 2174.33 1698.4 13557.52 3087.1 4030.01 3242.4 10037.66 5575.5 651.59 351.7 9103.70 171.5 
ILMN_2316236 HOPX 45.94 0.1 42.92 5.1 138.08 76.0 2507.79 432.2 58.52 3.8 41.71 1.0 48.73 4.7 44.02 3.5 147.44 91.6 226.15 173.8 
ILMN_2058782 IFI27 632.45 0.9 8740.06 8071.3 14560.92 9119.4 25672.22 808.3 229.73 293.4 2802.31 1266.4 8251.50 9949.4 8078.30 4960.9 5575.76 389.9 7839.86 5570.8 
ILMN_1723912 IFI44L 88.38 0.7 1204.84 453.2 420.66 327.9 1397.99 544.1 254.71 135.9 3737.78 296.1 2091.36 981.5 3245.26 692.0 131.47 37.5 1500.45 753.1 
ILMN_1739428 IFIT2 164.99 0.2 2214.68 576.0 212.66 88.9 2151.56 1623.0 224.64 112.9 2156.26 265.6 1110.65 480.2 2026.69 486.0 61.63 0.6 176.29 27.0 
ILMN_1701789 IFIT3 277.23 0.5 5719.26 1860.9 600.17 448.6 5257.17 2311.6 339.85 126.6 4337.01 354.1 3155.73 1894.5 6597.25 2651.4 60.53 6.3 732.62 220.4 
ILMN_1801246 IFITM1 1117.55 1.2 9494.69 3342.8 3503.69 1844.2 17076.49 837.7 4407.33 2726.6 23031.44 893.8 3985.89 3134.6 14673.66 5747.0 155.79 87.8 1637.90 1283.6 
ILMN_2334296 IL18BP 121.12 0.1 4541.91 2733.1 73.80 19.9 1258.71 223.4 145.65 38.5 8542.26 2796.2 85.65 4.7 541.61 280.5 272.38 157.1 3289.94 212.3 
ILMN_1804901 IL1F5 49.36 0.2 52.07 7.8 72.91 6.4 888.23 86.5 49.05 2.4 54.00 2.2 52.98 4.0 55.31 3.1 42.38 3.4 41.52 2.2 
ILMN_2368530 IL32 57.32 0.2 210.39 74.3 74.24 6.8 1227.70 225.6 608.33 531.3 1470.46 1547.2 51.85 6.1 52.15 10.6 1922.19 1012.3 2679.37 1611.7 
ILMN_1778010 IL32 78.33 0.2 356.41 214.5 79.44 17.2 1033.18 452.3 454.47 337.1 815.64 698.4 53.89 3.4 51.30 0.8 526.22 456.5 686.87 601.3 
ILMN_1656310 INDO 45.82 0.3 525.29 132.5 59.43 15.1 340.77 266.9 59.23 14.7 1360.05 819.0 49.24 4.0 86.92 18.1 44.89 0.2 2549.94 1035.2 
ILMN_1708375 IRF1 378.04 0.8 2621.77 246.6 196.84 19.1 4635.05 2186.4 1053.01 505.7 5612.52 2483.5 221.94 84.3 1715.14 649.4 214.73 193.6 2441.88 179.7 
ILMN_1695924 KLK11 53.19 0.2 50.59 4.5 802.88 179.3 10005.51 2019.0 47.30 4.5 50.59 3.4 49.22 4.6 47.91 4.3 55.29 5.9 50.29 3.1 
ILMN_1745570 KLK7 55.77 0.2 64.67 8.1 1300.40 728.1 15106.71 6679.6 84.20 49.4 68.63 11.9 56.67 3.9 56.57 9.1 48.37 2.7 47.63 1.7 
ILMN_1791545 KRT23 74.38 0.1 70.16 13.3 124.39 42.6 2088.33 1200.5 85.89 26.6 64.48 6.9 104.50 12.7 88.69 16.1 47.56 1.6 47.43 4.3 
ILMN_1705814 KRT80 77.66 0.5 48.93 5.6 87.15 29.0 7107.21 2982.1 551.53 267.0 197.97 88.2 50.82 3.3 48.89 2.5 303.35 22.4 223.93 1.7 
ILMN_2170814 LAMP3 55.19 0.4 119.83 127.9 76.10 21.9 1048.95 275.9 53.25 9.0 549.14 145.3 48.29 4.8 64.23 12.4 323.06 26.2 419.63 22.6 
ILMN_1808220 LCE3E 66.39 0.3 64.63 14.8 56.19 7.2 802.66 396.4 53.53 9.7 65.71 12.2 60.13 6.0 58.36 3.6 51.24 2.6 51.57 4.3 
ILMN_1659688 LGALS3BP 544.76 0.8 1396.51 911.7 644.97 299.3 1007.35 384.4 1181.26 513.3 2832.00 660.7 3228.87 1842.7 4620.85 2686.5 45.16 1.2 480.59 92.3 
ILMN_2412214 LGALS9 67.59 0.4 314.35 196.5 56.63 5.6 56.83 5.9 67.32 6.6 198.68 59.5 87.12 27.7 92.45 39.4 94.55 34.4 975.77 235.6 
ILMN_2332964 LGMN 627.24 0.5 560.58 70.3 424.37 80.7 5382.45 2008.1 505.11 46.6 1106.87 235.8 319.24 47.5 419.66 67.4 470.90 38.3 681.96 106.8 
ILMN_1815895 LOC649143 48.16 0.1 496.09 411.0 46.77 4.4 995.65 242.8 46.62 3.8 714.91 792.5 47.59 1.4 604.77 769.9 58.81 2.1 880.51 810.9 
ILMN_1722670 LYNX1 48.19 0.2 46.55 5.1 54.21 8.6 842.70 443.5 46.51 6.0 49.77 9.9 48.51 2.7 50.88 6.9 46.05 2.2 47.37 0.7 
ILMN_1718033 LYPD5 44.27 0.1 61.20 16.9 106.35 13.0 1951.04 1216.2 55.10 3.4 89.77 13.3 52.32 5.2 66.97 15.7 56.74 7.3 70.75 3.8 
ILMN_2388484 MAP2 59.78 0.3 82.31 24.2 98.60 18.6 1171.85 722.7 58.57 6.7 79.79 3.2 47.16 1.8 53.15 3.2 113.04 27.6 107.14 8.1 
ILMN_1801610 METRNL 536.69 0.3 591.33 251.6 63.46 4.9 694.96 345.5 62.40 7.5 74.02 12.3 117.07 24.8 138.34 14.0 131.82 14.2 115.86 13.4 
ILMN_2371911 MUC1 143.36 0.6 202.42 53.2 74.92 21.0 1000.48 263.6 1568.28 1073.0 2580.89 1351.5 73.54 7.5 77.76 8.5 49.12 2.2 60.31 16.0 
ILMN_1662358 MX1 718.26 1.9 10730.74 7371.9 5578.05 4398.0 17909.55 2646.0 2081.13 1510.0 13433.93 4637.0 20289.26 6972.0 19984.79 6859.6 309.04 70.4 2534.77 893.0 
ILMN_1713397 NCCRP1 50.95 0.2 53.63 2.8 105.54 46.3 2133.37 612.5 100.53 41.2 61.27 4.9 447.73 398.4 163.58 124.6 44.15 0.6 46.92 0.4 
ILMN_1674063 OAS2 253.92 0.6 4329.48 1836.7 3083.40 1274.9 7362.87 2188.3 117.20 106.3 1897.39 368.1 3043.40 1688.0 3615.51 1555.6 202.56 89.1 1208.07 194.9 
ILMN_1693192 PI3 48.98 0.1 44.36 1.9 965.35 557.7 11419.86 2677.6 283.62 195.0 65.43 10.3 50.67 3.8 48.72 2.4 43.94 2.9 42.29 0.7 
ILMN_1815023 PIM1 1176.16 1.1 901.48 359.0 354.74 45.6 4939.44 2578.8 747.24 343.8 943.70 416.6 102.64 21.6 96.69 19.9 87.08 32.5 96.57 23.4 
ILMN_2376108 PSMB9 187.57 0.7 2542.10 516.9 243.36 9.9 1042.49 419.2 288.94 29.2 2723.48 655.0 403.61 274.2 1086.98 313.4 78.08 47.5 1358.51 1202.1 
ILMN_1800091 RARRES1 52.02 0.2 118.93 82.1 48.70 2.1 1661.48 1005.2 89.68 18.2 193.27 89.9 55.11 6.2 58.95 2.3 62.65 6.4 69.09 10.6 
ILMN_1701613 RARRES3 286.89 0.7 12942.20 5804.9 128.36 21.7 8772.33 2324.2 2348.77 337.8 28950.28 602.9 171.05 44.9 383.49 106.1 62.17 22.9 1809.49 1367.0 
ILMN_1683179 RRAD 86.19 0.6 63.27 2.1 69.76 9.0 1201.41 880.7 1611.67 1019.4 1444.14 481.5 45.99 4.5 47.28 3.5 56.15 1.7 53.73 0.5 
ILMN_1801216 S100P 51.84 0.3 104.19 117.8 58.75 11.5 12726.25 1851.0 85.61 34.5 72.25 29.3 49.15 4.8 43.18 1.8 42.09 2.0 41.94 1.5 
ILMN_1712759 SBSN 244.46 1.0 182.80 167.6 300.96 100.3 14248.09 3514.4 51.16 3.9 47.55 3.8 53.46 2.9 51.97 3.7 42.26 0.9 44.32 2.9 
ILMN_1740917 SCNN1B 52.96 0.1 55.99 6.6 62.13 5.3 696.83 247.9 48.70 3.7 55.12 5.0 54.35 1.6 52.32 2.7 50.34 3.9 51.08 1.6 
ILMN_2114720 SLPI 51.63 0.2 50.64 4.5 597.01 197.4 6506.51 739.5 2139.08 1426.8 2184.73 951.3 49.57 2.3 44.48 1.3 42.82 3.4 43.37 0.4 
ILMN_1716591 SPRR1A 38.85 0.2 42.92 9.3 266.78 200.3 6084.44 5091.9 54.15 20.9 44.65 8.6 48.47 6.0 45.33 11.2 97.59 11.8 93.50 15.3 
ILMN_2191967 SPRR2D 44.58 0.2 44.37 2.3 420.01 416.6 13954.08 12217.5 44.87 3.5 46.25 4.0 44.24 4.0 44.30 1.6 57.09 1.7 52.51 3.3 
ILMN_1810835 SPRR3 50.74 0.1 50.81 2.4 85.75 37.2 5981.57 7827.6 49.48 1.7 52.13 5.5 52.04 5.8 55.10 2.4 46.01 2.2 42.43 0.2 
ILMN_1727589 SULT2B1 51.65 0.0 51.75 5.2 85.03 13.7 1457.46 235.2 53.49 7.5 52.54 3.6 69.51 16.2 68.01 8.1 44.97 3.0 48.06 4.8 
ILMN_1751079 TAP1 1236.54 0.5 13773.11 3210.4 1972.73 192.8 25648.96 2364.5 1434.62 544.7 15504.01 1948.7 3833.53 1618.3 14098.87 1982.3 654.16 334.6 10409.28 5849.2 
ILMN_1770922 TMEM45A 758.53 0.2 813.31 134.5 269.60 62.2 2767.81 917.2 73.13 27.7 53.04 3.3 139.19 49.0 122.61 33.8 137.64 90.3 126.11 71.7 
ILMN_1758418 TNFSF13B 74.69 0.4 697.88 321.1 57.43 1.9 180.66 74.8 65.40 12.7 819.94 7.5 75.92 16.8 226.77 79.1 60.31 3.9 260.83 9.5 
ILMN_1678841 UBD 49.53 0.1 68.58 16.1 50.81 13.0 1960.63 804.8 150.86 117.1 5551.24 826.5 47.89 2.2 100.32 33.1 73.61 16.0 1967.35 291.8 
ILMN_1727271 WARS 1514.53 0.5 20408.54 7452.5 689.49 104.2 30022.06 501.3 913.46 79.7 18692.93 2211.8 6765.34 1591.4 27572.74 1562.6 914.36 61.8 14680.06 11560.4 
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_2337655 WARS 1370.47 0.3 13355.12 3647.9 708.45 93.3 20061.52 3727.7 996.92 110.2 16604.77 3358.1 8180.00 4406.7 22874.17 4982.5 1265.00 190.3 15696.13 8662.5 
ILMN_2079042 WFDC5 47.16 0.1 46.81 1.6 144.72 22.5 1549.36 417.2 73.51 50.8 49.54 5.7 46.09 5.5 48.74 5.9 52.45 0.1 49.06 0.8 
ILMN_1742618 XAF1 271.66 0.4 890.16 340.1 212.41 108.6 524.67 213.1 86.31 40.4 1080.09 306.0 666.42 19.6 1138.79 305.8 180.92 132.4 518.87 198.4 
 a Illumina probe IDs as included in the microarray database. b Official gene symbols are depicted for genes that are >10-fold up-regulated by IFN-γ in at least one non-hematopoietic cell 
type. c Fibroblasts (FB) cultured without IFN-γ. d Fibroblasts (FB) cultured with 100 IU/ml IFN-γ for 4 days. e Keratinocytes (KC) cultured without IFN-γ. f Keratinocytes (KC) cultured with 100 
IU/ml IFN-γ for 4 days. g Proximal tubular epithelial cells (PTEC) cultured without IFN-γ. h Proximal tubular epithelial cells (PTEC) cultured with 100 IU/ml IFN-γ for 4 days. i Melanocytes 
(MEL) cultured without IFN-γ. j Melanocytes (MEL) cultured with 100 IU/ml IFN-γ for 4 days. k Human umbilical vein endothelial cells (HUVEC) cultured without IFN-γ. l Human umbilical vein 
endothelial cells (HUVEC) cultured with 100 IU/ml IFN-γ for 4 days. m AVG and SD are the average and standard deviation of probe fluorescence as measured within the sample group, 
respectively. n Values in grey and bold indicate that the average probe fluorescence as measured in the sample group after culturing with IFN-γ is >10-fold higher than the fluorescence 




Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
752592 HLA-DRB4 80.20 0 5 4722 43 2 0 0 63.89 1 .3 9081.97 10653.3 61.87 5.8 2789.86 48 3 59.24 1.3 3116.55 2 34 7 62.92 4.3 2740 59 275 1
16974 9 HLA-DRB5 61.78 5 439.61 775.9 48 06 3.4 972 46 2024.2 47.41 3.7 2414 1 1278 0 4 96 6 1 1061.59 908 46.57 2.8 4 .44 4.4 
2066066 HLA-DRB6 52 99 1 231.58 66.0 56 7 10.1 396 1 3 8 56 42 1 2 371.08 101.0 5 20 7 1 264.19 36.0 9 87 5 702.18 568.2 
186806 H A-F 216.76 6 8 5 8 143.3 364.69 75.9 2 06 6 533 1 371 17 245 1 2035 55 946.4 519.52 295.8 1016.74 572.3 194.52 72.4 1946 75 103.7 
2130441 H A-H 1416.17 6 9505.64 1554.9 2118.79 133.5 11458.84 1271.5 2174.33 1698.4 135 7.52 3087.1 40 0.01 3242.4 10037.66 5575.5 651 59 3 1 7 9103.70 17 5
231 236 HOPX 94 1 42.92 5.1 138.08 76 0 2507.79 432 2 8 52 3.8 41.71 .0 8 73 7 44 0 3.5 147.44 91.6 226.15 173.8 
205 782 FI27 632 45 9 8740 06 8071.3 145 0.92 9 19.4 25672.22 808.3 229.73 293 4 280 31 1266 4 8251.50 99 9.4 8078 30 4960.9 5575.76 389 9 7839 6 5570.8 
723 12 IFI44L 88 38 7 12 4.84 453.2 420 66 327 9 1397.99 544.1 254.71 135.9 3737.78 296.1 20 1.36 981.5 3245.26 692.0 131.47 37.5 1 0.45 753.1 
39428 IFIT2 164.99 2214.68 576.0 212.66 88.9 2151.56 1 23 0 224.64 112.9 2156.26 265.6 1110.65 480.2 2026.69 486.0 61 63 0 6 176.29 27.0 
0 789 IFI 3 277.23 5 5 19.26 1860.9 600 17 448.6 5257 17 2311 6 339.85 126.6 4337.01 354.1 3155.73 1894.5 6597.25 2651.4 60 3 6 3 732.62 220.4 
8 1246 IFITM1 1117.55 1 2 9 94.69 3342.8 3503.69 1844.2 17076.49 837.7 4407.33 2726.6 23031.44 893.8 3985.89 3134.6 14673.66 5747.0 155 79 87 8 1637.90 1283.6 
334296 IL18BP 121.12 1 4541.91 2733.1 3 8 19 25 71 23 4 145.65 38.5 8542.26 2796.2 85 65 7 541.61 280.5 272 38 157.1 3289.94 212.3 
4901 IL1F5 49 6 2 52 07 7.8 72 91 6 4 88 23 86.5 49 05 2 4 54 00 2.2 52 98 4 5 1 1 42 38 3 4 4 2 2 2
2368530 I 32 57.32 2 210.39 74.3 74.24 6.8 22 70 225 6 608.33 31 1470 46 1547.2 51.85 6.1 5 .15 10.6 1922.19 101 .3 2679.37 1611.7 
17780 0 IL32 78 33 2 56 41 214 79 44 17.2 1033.18 4 2.3 454.47 337.1 815 4 698.4 53 89 3.4 51 30 0.8 526.22 456.5 686 8 601 3
1656310 INDO 45.82 3 25 29 132.5 59.43 15 1 340.77 266.9 59.23 14 7 360 05 819 0 49.24 4.0 86.92 18 1 44.89 0.2 2549.94 1035.2 
70837 IRF1 378.04 8 2621.77 246 6 196.84 19.1 4635.05 2186.4 1053.01 505.7 5612.52 2483.5 221.94 84.3 1715.14 64 4 214.73 193.6 2441.88 179 7
695924 KLK1 53 50 9 4 5 802.88 179.3 10005.51 2019.0 7 30 4 5 50 59 3 4 9 22 4 6 47 91 4 3 55 29 5 9 50 29 3 1
45570 KLK7 55 7 2 4 67 8.1 1300.40 728.1 15106.71 6679 6 84 2 49.4 68 63 1 9 6 67 3 9 5 5 9.1 48 37 2 7 47 63 1 7
1791545 KRT23 74 3 1 70 16 13 3 124.39 42 2088 33 1200.5 85 89 26.6 64 48 6 9 104.50 12.7 88 69 16.1 47.56 1.6 47.43 4 3
7 58 4 KRT80 77.66 5 48.93 .6 87 15 29.0 7107.21 2982.1 551.53 267.0 197.97 88 2 50.82 3.3 48.89 2.5 303 35 22 4 223 93 1.7 
1 08 4 LAMP3 55.19 4 119 83 127.9 6 10 9 48 95 75 9 3.25 9.0 549.14 145.3 48 29 4 8 64 23 12.4 323.06 26.2 419.63 22 6
808220 LCE3E 66.39 0 3 64.63 14.8 6.19 7.2 802.66 396.4 53.53 9.7 65.71 12.2 60.13 6.0 58.36 3.6 51.24 2.6 1.5  4.3 
659688 LGALS3BP 544.76 8 1396.51 911.7 644 97 299.3 1007 5 384 4 1181.26 513.3 2832.00 660.7 3228.87 1842.7 4620.85 2686.5 5 6 1 2 480.59 92.3 
2412214 LG LS9 67.59 4 314.35 196.5 56.63 5.6 5 .83 5.9 67.32 6.6 198.68 59.5 87.12 27.7 92.4  39.4 94.55 34 4 975.77 235 6
2332964 LGMN 627.24 5 560.58 70.3 424 7 80.7 5382.45 008 1 505 11 46.6 1106.87 235.8 319.24 47.5 419.66 67.4 470.90 38.3 681.96 1 6.8 
895 LOC649143 48.16 0 496 09 411 46.77 4.4 995.65 242.8 46.62 3.8 714 91 792 5 47.59 1.4 604.77 769.9 58 81 2.1 880.51 810.9 
1722670 LYNX1 48.19 2 46.55 5.1 54.21 8 6 842.70 43 5 46.51 6.0 49.77 9.9 48.51 2.7 50.88 6.9 46 5 2.2 47.37 0.7 
718 33 LYPD5 44 27 1 61.20 16 9 106.35 13.0 95 04 216 55 10 3.4 89.77 13 3 2 32 5 66 7 15.7 56 74 7 3 70 75 3.8 
2388484 MAP2 59.78 3 82.31 24.2 98.60 18 6 11 1 85 722.7 58.5  6.7 79.79 3.2 47.16 1.8 53.15 3.2 113.04 7 6 107.14 8.1 
801610 METRNL 536.69 3 591.33 251.6 3 4 4 9 694.96 345 5 2.40 7.5 7 .02 12.3 117.07 24.8 138.34 14.0 131.82 14.2 115.86 13.4 
237 9 1 MUC1 143.36 6 2 2 42 53.2 74 92 2 0 1000.48 263.6 1568.28 1073.0 2580.89 1351.5 73 54 7 5 77 76 8 5 9 12 2 60 31 16.0 
66 3 8 MX1 718 2 9 10730.74 7371.9 5578.05 4398.0 7909 55 2646 0 2081.13 1510.0 13433.93 4637.0 20289.26 6972.0 19984.79 6859.6 309.04 70.4 2534.77 893.0 
1339 N CRP1 0 5 2 3 63 2 8 105.54 46.3 2133.37 612 5 100.53 41.2 61 27 4 9 447.73 398.4 163.58 1 4.6 44 15 0 6 46 92 0 4
167 063 OAS2 253.92 6 4329. 8 1836.7 3083.40 1274.9 7362 87 2188.3 117.20 106.3 1897 39 368 1 3043.40 1688.0 3615.51 1555.6 202.56 89.1 1208.07 194.9 
6931 2 PI3 4 98 1 4 36 1 9 9 5 35 557 7 11419.86 2677 6 283.62 195.0 65 43 10.3 50 6 3 8 8 72 2.4 43 94 2.9 42 29 0.7 
1815023 IM1 1176.16 1 1 901.48 359.0 354 74 45.6 4939.44 2578.8 747.24 343.8 943.70 416.6 102.64 21.6 96 69 19.9 8 8 32.5 96 7 23.4 
2376108 PSMB9 187.57 7 2 42. 0 516.9 243.36 9.9 1042 49 419.2 288.94 29.2 27 3.48 6 5.0 403.61 274.2 1086.98 313.4 78 8 47.5 1358.51 120 .1 
800091 RARRES1 2 02 2 118.93 82.1 48 70 2.1 661 8 1005.2 89 68 18.2 193.27 89.9 55 1 6.2 5 95 2 3 62 65 6 4 69 9 10.6 
0 613 RARRES3 286.89 7 2942 20 5804 9 128.36 21.7 8772.33 2 2 2348 77 337 8 28950 28 602.9 171.05 44.9 383.49 106.1 62.17 22.9 1809.49 1367 0
683179 RRAD 86.19 6 63.27 2.1 69.76 9.0 1201 4 880 7 1611.67 1019.4 1444.14 481.5 45.99 4.5 47.28 3.5 56.15 1.7 53.73 0.5 
8012 6 S100P 51 84 3 104 19 117 8 8 75 11.5 12726.25 1851.0 8 61 34 5 72.25 29.3 49 15 4.8 43.18 1.8 42 09 2 0 41.94 1
712759 SBSN 244.46 1 0 182.80 167.6 300.96 100.3 14248.09 3514.4 51.16 3.9 47.55 3.8 53 46 9 51.97 3.7 42 26 0.9 44.32 2.9 
40917 SCNN1B 2.96 1 55.99 6.6 62.13 5.3 696.83 247 9 48.70 3.7 55.12 5.0 54.35 1.6 52.32 2.7 50.34 3.9 51. 8 1.6 
I 114720 SLPI 51.63 .2 50.64 4.5 597.01 197.4 6506.51 739.5 2139.08 1426.8 2184.73 951.3 49.57 2.3 44. 8 1.3 42.82 3.4 43.37 0.4 
I 1716591 SPRR1A 38.85 .2 2.92 9.3 266. 8 200.3 6084.44 5091.9 54.15 2 .9 4.65 8.6 8.47 6.0 5.33 11.2 97.59 11.8 93.50 15.3 
I 2191967 SPRR2D 44.58 .2 44.37 2.3 420.0  416.  13954.08 1 217.5 44.87 3.5 46.25 4.0 44.24 4.0 44.30 1.6 57.09 1.7 52.51 3.3 
ILMN_1810835 SPRR3 50.74 0.1 50.81 2.4 85.75 37.2 5981.57 7827.6 49.48 1.7 52.13 5.5 52.04 5.8 55.10 2.4 46.01 2.2 42.43 0.2 
ILMN_1727589 SULT2B1 51.65 0.0 51.75 5.2 85.03 13.7 1457.46 235.2 53.49 7.5 52.54 3.6 69.51 16.2 68.01 8.1 44.97 3.0 48.06 4.8 
ILMN_1751079 TAP1 1236.54 0.5 13773.11 3210.4 1972.73 192.8 25648.96 2364.5 1434.62 544.7 15504.01 1948.7 3833.53 1618.3 14098.87 1982.3 654.16 334.6 10409.28 5849.2 
ILMN_1770922 TMEM45A 758.53 0.2 813.31 134.5 269.60 62.2 2767.81 917.2 73.13 27.7 53.04 3.3 139.19 49.0 122.6  33.8 137.64 90.3 126.11 71.7 
ILMN_1758418 TNFSF13B 74.69 0.4 697.88 321.1 57.43 1.9 180.66 74.8 65.40 12.7 819.94 7.5 75.92 16.8 226.77 79.1 60.31 3.9 260.83 9.5 
ILMN_1678841 UBD 49.53 0.1 68.58 16.1 50.81 13.0 1960.63 804.8 150.86 117.1 5551.24 826.5 47.89 2.2 100.32 33.1 73.61 16.0 1967.35 291.8 
ILMN_1727271 WARS 1514.53 0.5 20408.54 7452.5 689.49 104.2 30022.06 501.3 913.46 79.7 18692.93 2211.8 6765.34 1591.4 27572.74 1562.6 914.36 61.8 14680.06 11560.4 
2
G




a Illumina probe IDs as included in the microarray database. b Official gene symbols are depicted for genes 
that are >10-fold up-regulated by IFN-γ in at least one non-hematopoietic cell type. c Fibroblasts (FB) 
cultured without IFN-γ. d Fibroblasts (FB) cultured with 100 IU/ml IFN-γ for 4 days. e Keratinocytes (KC) 
cultured without IFN-γ. f Keratinocytes (KC) cultured with 100 IU/ml IFN-γ for 4 days. g Proximal tubular 
epithelial cells (PTEC) cultured without IFN-γ. h Proximal tubular epithelial cells (PTEC) cultured with 100 
IU/ml IFN-γ for 4 days. i Melanocytes (MEL) cultured without IFN-γ. j Melanocytes (MEL) cultured with 100 
IU/ml IFN-γ for 4 days. k Human umbilical vein endothelial cells (HUVEC) cultured without IFN-γ. l Human 
umbilical vein endothelial cells (HUVEC) cultured with 100 IU/ml IFN-γ for 4 days. m AVG and SD are the 
average and standard deviation of probe fluorescence as measured within the sample group, respectively. 
n Values in grey and bold indicate that the average probe fluorescence as measured in the sample group 
after culturing with IFN-γ is >10-fold higher than the fluorescence measured in the same samples cultured 
in the absence of cytokines.
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_1752592 HLA-DRB4 80.20 0.5 4722.43 3240.0 63.89 14.3 9081.97 10653.3 61.87 5.8 2789.86 483.3 59.24 1.3 3116.55 2734.7 62.92 4.3 2740.59 2753.1 
ILMN_1697499 HLA-DRB5 61.78 0.5 439.61 775.9 48.06 3.4 1972.46 2024.2 47.41 3.7 2414.16 1278.0 45.96 6.1 1061.59 908.5 46.57 2.8 48.44 4.4 
ILMN_2066066 HLA-DRB6 52.99 0.1 231.58 66.0 56.97 10.1 396.13 36.8 56.42 1.2 371.08 101.0 55.20 7.1 264.19 36.0 49.87 5.4 702.18 568.2 
ILMN_2186806 HLA-F 216.76 0.6 815.38 143.3 364.69 75.9 2206.76 533.1 371.17 245.1 2035.55 946.4 519.52 295.8 1016.74 572.3 194.52 72.4 1946.75 103.7 
ILMN_2130441 HLA-H 1416.17 0.6 9505.64 1554.9 2118.79 133.5 11458.84 1271.5 2174.33 1698.4 13557.52 3087.1 4030.01 3242.4 10037.66 5575.5 651.59 351.7 9103.70 171.5 
ILMN_2316236 HOPX 45.94 0.1 42.92 5.1 138.08 76.0 2507.79 432.2 58.52 3.8 41.71 1.0 48.73 4.7 44.02 3.5 147.44 91.6 226.15 173.8 
ILMN_2058782 IFI27 632.45 0.9 8740.06 8071.3 14560.92 9119.4 25672.22 808.3 229.73 293.4 2802.31 1266.4 8251.50 9949.4 8078.30 4960.9 5575.76 389.9 7839.86 5570.8 
ILMN_1723912 IFI44L 88.38 0.7 1204.84 453.2 420.66 327.9 1397.99 544.1 254.71 135.9 3737.78 296.1 2091.36 981.5 3245.26 692.0 131.47 37.5 1500.45 753.1 
ILMN_1739428 IFIT2 164.99 0.2 2214.68 576.0 212.66 88.9 2151.56 1623.0 224.64 112.9 2156.26 265.6 1110.65 480.2 2026.69 486.0 61.63 0.6 176.29 27.0 
ILMN_1701789 IFIT3 277.23 0.5 5719.26 1860.9 600.17 448.6 5257.17 2311.6 339.85 126.6 4337.01 354.1 3155.73 1894.5 6597.25 2651.4 60.53 6.3 732.62 220.4 
ILMN_1801246 IFITM1 1117.55 1.2 9494.69 3342.8 3503.69 1844.2 17076.49 837.7 4407.33 2726.6 23031.44 893.8 3985.89 3134.6 14673.66 5747.0 155.79 87.8 1637.90 1283.6 
ILMN_2334296 IL18BP 121.12 0.1 4541.91 2733.1 73.80 19.9 1258.71 223.4 145.65 38.5 8542.26 2796.2 85.65 4.7 541.61 280.5 272.38 157.1 3289.94 212.3 
ILMN_1804901 IL1F5 49.36 0.2 52.07 7.8 72.91 6.4 888.23 86.5 49.05 2.4 54.00 2.2 52.98 4.0 55.31 3.1 42.38 3.4 41.52 2.2 
ILMN_2368530 IL32 57.32 0.2 210.39 74.3 74.24 6.8 1227.70 225.6 608.33 531.3 1470.46 1547.2 51.85 6.1 52.15 10.6 1922.19 1012.3 2679.37 1611.7 
ILMN_1778010 IL32 78.33 0.2 356.41 214.5 79.44 17.2 1033.18 452.3 454.47 337.1 815.64 698.4 53.89 3.4 51.30 0.8 526.22 456.5 686.87 601.3 
ILMN_1656310 INDO 45.82 0.3 525.29 132.5 59.43 15.1 340.77 266.9 59.23 14.7 1360.05 819.0 49.24 4.0 86.92 18.1 44.89 0.2 2549.94 1035.2 
ILMN_1708375 IRF1 378.04 0.8 2621.77 246.6 196.84 19.1 4635.05 2186.4 1053.01 505.7 5612.52 2483.5 221.94 84.3 1715.14 649.4 214.73 193.6 2441.88 179.7 
ILMN_1695924 KLK11 53.19 0.2 50.59 4.5 802.88 179.3 10005.51 2019.0 47.30 4.5 50.59 3.4 49.22 4.6 47.91 4.3 55.29 5.9 50.29 3.1 
ILMN_1745570 KLK7 55.77 0.2 64.67 8.1 1300.40 728.1 15106.71 6679.6 84.20 49.4 68.63 11.9 56.67 3.9 56.57 9.1 48.37 2.7 47.63 1.7 
ILMN_1791545 KRT23 74.38 0.1 70.16 13.3 124.39 42.6 2088.33 1200.5 85.89 26.6 64.48 6.9 104.50 12.7 88.69 16.1 47.56 1.6 47.43 4.3 
ILMN_1705814 KRT80 77.66 0.5 48.93 5.6 87.15 29.0 7107.21 2982.1 551.53 267.0 197.97 88.2 50.82 3.3 48.89 2.5 303.35 22.4 223.93 1.7 
ILMN_2170814 LAMP3 55.19 0.4 119.83 127.9 76.10 21.9 1048.95 275.9 53.25 9.0 549.14 145.3 48.29 4.8 64.23 12.4 323.06 26.2 419.63 22.6 
ILMN_1808220 LCE3E 66.39 0.3 64.63 14.8 56.19 7.2 802.66 396.4 53.53 9.7 65.71 12.2 60.13 6.0 58.36 3.6 51.24 2.6 51.57 4.3 
ILMN_1659688 LGALS3BP 544.76 0.8 1396.51 911.7 644.97 299.3 1007.35 384.4 1181.26 513.3 2832.00 660.7 3228.87 1842.7 4620.85 2686.5 45.16 1.2 480.59 92.3 
ILMN_2412214 LGALS9 67.59 0.4 314.35 196.5 56.63 5.6 56.83 5.9 67.32 6.6 198.68 59.5 87.12 27.7 92.45 39.4 94.55 34.4 975.77 235.6 
ILMN_2332964 LGMN 627.24 0.5 560.58 70.3 424.37 80.7 5382.45 2008.1 505.11 46.6 1106.87 235.8 319.24 47.5 419.66 67.4 470.90 38.3 681.96 106.8 
ILMN_1815895 LOC649143 48.16 0.1 496.09 411.0 46.77 4.4 995.65 242.8 46.62 3.8 714.91 792.5 47.59 1.4 604.77 769.9 58.81 2.1 880.51 810.9 
ILMN_1722670 LYNX1 48.19 0.2 46.55 5.1 54.21 8.6 842.70 443.5 46.51 6.0 49.77 9.9 48.51 2.7 50.88 6.9 46.05 2.2 47.37 0.7 
ILMN_1718033 LYPD5 44.27 0.1 61.20 16.9 106.35 13.0 1951.04 1216.2 55.10 3.4 89.77 13.3 52.32 5.2 66.97 15.7 56.74 7.3 70.75 3.8 
ILMN_2388484 MAP2 59.78 0.3 82.31 24.2 98.60 18.6 1171.85 722.7 58.57 6.7 79.79 3.2 47.16 1.8 53.15 3.2 113.04 27.6 107.14 8.1 
ILMN_1801610 METRNL 536.69 0.3 591.33 251.6 63.46 4.9 694.96 345.5 62.40 7.5 74.02 12.3 117.07 24.8 138.34 14.0 131.82 14.2 115.86 13.4 
ILMN_2371911 MUC1 143.36 0.6 202.42 53.2 74.92 21.0 1000.48 263.6 1568.28 1073.0 2580.89 1351.5 73.54 7.5 77.76 8.5 49.12 2.2 60.31 16.0 
ILMN_1662358 MX1 718.26 1.9 10730.74 7371.9 5578.05 4398.0 17909.55 2646.0 2081.13 1510.0 13433.93 4637.0 20289.26 6972.0 19984.79 6859.6 309.04 70.4 2534.77 893.0 
ILMN_1713397 NCCRP1 50.95 0.2 53.63 2.8 105.54 46.3 2133.37 612.5 100.53 41.2 61.27 4.9 447.73 398.4 163.58 124.6 44.15 0.6 46.92 0.4 
ILMN_1674063 OAS2 253.92 0.6 4329.48 1836.7 3083.40 1274.9 7362.87 2188.3 117.20 106.3 1897.39 368.1 3043.40 1688.0 3615.51 1555.6 202.56 89.1 1208.07 194.9 
ILMN_1693192 PI3 48.98 0.1 44.36 1.9 965.35 557.7 11419.86 2677.6 283.62 195.0 65.43 10.3 50.67 3.8 48.72 2.4 43.94 2.9 42.29 0.7 
ILMN_1815023 PIM1 1176.16 1.1 901.48 359.0 354.74 45.6 4939.44 2578.8 747.24 343.8 943.70 416.6 102.64 21.6 96.69 19.9 87.08 32.5 96.57 23.4 
ILMN_2376108 PSMB9 187.57 0.7 2542.10 516.9 243.36 9.9 1042.49 419.2 288.94 29.2 2723.48 655.0 403.61 274.2 1086.98 313.4 78.08 47.5 1358.51 1202.1 
ILMN_1800091 RARRES1 52.02 0.2 118.93 82.1 48.70 2.1 1661.48 1005.2 89.68 18.2 193.27 89.9 55.11 6.2 58.95 2.3 62.65 6.4 69.09 10.6 
ILMN_1701613 RARRES3 286.89 0.7 12942.20 5804.9 128.36 21.7 8772.33 2324.2 2348.77 337.8 28950.28 602.9 171.05 44.9 383.49 106.1 62.17 22.9 1809.49 1367.0 
ILMN_1683179 RRAD 86.19 0.6 63.27 2.1 69.76 9.0 1201.41 880.7 1611.67 1019.4 1444.14 481.5 45.99 4.5 47.28 3.5 56.15 1.7 53.73 0.5 
ILMN_1801216 S100P 51.84 0.3 104.19 117.8 58.75 11.5 12726.25 1851.0 85.61 34.5 72.25 29.3 49.15 4.8 43.18 1.8 42.09 2.0 41.94 1.5 
ILMN_1712759 SBSN 244.46 1.0 182.80 167.6 300.96 100.3 14248.09 3514.4 51.16 3.9 47.55 3.8 53.46 2.9 51.97 3.7 42.26 0.9 44.32 2.9 
ILMN_1740917 SCNN1B 52.96 0.1 55.99 6.6 62.13 5.3 696.83 247.9 48.70 3.7 55.12 5.0 54.35 1.6 52.32 2.7 50.34 3.9 51.08 1.6 
ILMN_2114720 SLPI 51.63 0.2 50.64 4.5 597.01 197.4 6506.51 739.5 2139.08 1426.8 2184.73 951.3 49.57 2.3 44.48 1.3 42.82 3.4 43.37 0.4 
ILMN_1716591 SPRR1A 38.85 0.2 42.92 9.3 266.78 200.3 6084.44 5091.9 54.15 20.9 44.65 8.6 48.47 6.0 45.33 11.2 97.59 11.8 93.50 15.3 
ILMN_2191967 SPRR2D 44.58 0.2 44.37 2.3 420.01 416.6 13954.08 12217.5 44.87 3.5 46.25 4.0 44.24 4.0 44.30 1.6 57.09 1.7 52.51 3.3 
ILMN_1810835 SPRR3 50.74 0.1 50.81 2.4 85.75 37.2 5981.57 7827.6 49.48 1.7 52.13 5.5 52.04 5.8 55.10 2.4 46.01 2.2 42.43 0.2 
ILMN_1727589 SULT2B1 51.65 0.0 51.75 5.2 85.03 13.7 1457.46 235.2 53.49 7.5 52.54 3.6 69.51 16.2 68.01 8.1 44.97 3.0 48.06 4.8 
ILMN_1751079 TAP1 1236.54 0.5 13773.11 3210.4 1972.73 192.8 25648.96 2364.5 1434.62 544.7 15504.01 1948.7 3833.53 1618.3 14098.87 1982.3 654.16 334.6 10409.28 5849.2 
ILMN_1770922 TMEM45A 758.53 0.2 813.31 134.5 269.60 62.2 2767.81 917.2 73.13 27.7 53.04 3.3 139.19 49.0 122.61 33.8 137.64 90.3 126.11 71.7 
ILMN_1758418 TNFSF13B 74.69 0.4 697.88 321.1 57.43 1.9 180.66 74.8 65.40 12.7 819.94 7.5 75.92 16.8 226.77 79.1 60.31 3.9 260.83 9.5 
ILMN_1678841 UBD 49.53 0.1 68.58 16.1 50.81 13.0 1960.63 804.8 150.86 117.1 5551.24 826.5 47.89 2.2 100.32 33.1 73.61 16.0 1967.35 291.8 
ILMN_1727271 WARS 1514.53 0.5 20408.54 7452.5 689.49 104.2 30022.06 501.3 913.46 79.7 18692.93 2211.8 6765.34 1591.4 27572.74 1562.6 914.36 61.8 14680.06 11560.4 
Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
ILMN_2337655 WARS 1370.47 0.3 13355.12 3647.9 708.45 93.3 20061.52 3727.7 996.92 110.2 16604.77 3358.1 8180.00 4406.7 22874.17 4982.5 1265.00 190.3 15696.13 8662.5 
ILMN_2079042 WFDC5 47.16 0.1 46.81 1.6 144.72 22.5 1549.36 417.2 73.51 50.8 49.54 5.7 46.09 5.5 48.74 5.9 52.45 0.1 49.06 0.8 
ILMN_1742618 XAF1 271.66 0.4 890.16 340.1 212.41 108.6 524.67 213.1 86.31 40.4 1080.09 306.0 666.42 19.6 1138.79 305.8 180.92 132.4 518.87 198.4 
 a Illumina probe IDs as included in the microarray database. b Official gene symbols are depicted for genes that are >10-fold up-regulated by IFN-γ in at least one non-hematopoietic cell 
type. c Fibroblasts (FB) cultured without IFN-γ. d Fibroblasts (FB) cultured with 100 IU/ml IFN-γ for 4 days. e Keratinocytes (KC) cultured without IFN-γ. f Keratinocytes (KC) cultured with 100 
IU/ml IFN-γ for 4 days. g Proximal tubular epithelial cells (PTEC) cultured without IFN-γ. h Proximal t bular epi helial cells (PTEC) cultured with 100 IU/ml IFN-  4 days. i Melanocytes
(MEL) cultured without IFN-γ. j Melanocytes (MEL) cultured with 100 IU/ml IFN-γ for 4 days. k Human umbilical vein endothelial cells (HUVEC) cultured without IFN-γ. l Human umbilical vein 
endothelial cells (HUVEC) cultured with 100 IU/ml IFN-γ for 4 days. m AVG and SD are the average and standard deviation of probe fluorescence as measured within the sample group, 
respectively. n Values in grey and bold indicate that the average probe fluorescence as measured in the sample group after culturing with IFN-γ is >10-fold higher than the fluoresc nc




Probe IDa Geneb FB
c FB + IFN-γd KCe KC + IFN-γf PTECg PTEC + IFN-γh MELi MEL + IFN-γj HUVECk HUVEC + IFN-γl 
AVGm SDm AVGn SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
I 752592 HLA-DRB4 80.20 0.5 4722.43 2 0.0 63.89 1 .3 9081.97 10653.3 61.87 5.8 2789.86 48 .3 59.24 1.3 3116.55 2 34.7 62.92 4.3 2740.59 275 .1 
I 16974 9 HLA-DRB5 61.78 .5 439.61 775.9 48.06 3.4 972.46 2024.2 47.41 3.7 2414.1  1278.0 4 .96 6.1 1061.59 908.  46.57 2.8 4 .44 4.4 
I 2066066 HLA-DRB6 52.99 .1 231.58 66.0 56. 7 10.1 396.1  3 .8 56.42 1.2 371.08 101.0 5.20 7.1 264.19 36.0 9.87 5.  702.18 568.2 
I 186806 H A-F 216.76 .6 8 5. 8 143.3 364.69 75.9 2 06. 6 533.1 371.17 245.1 2035.55 946.4 519.52 295.8 1016.74 572.3 194.52 72.4 1946.75 103.7 
I 2130441 H A-H 1416.17 .6 9505.64 1554.9 2118.79 133.5 11458.84 1271.5 2174.33 1698.4 135 7.52 3087.1 40 0.01 3242.4 10037.66 5575.5 651.59 3 1.7 9103.70 17 .5 
I 231 236 HOPX .94 .1 42.92 5.1 138.08 76.0 2507.79 432.2 8.52 3.8 41.71 .0 8.73 .7 44.0  3.5 147.44 91.6 226.15 173.8 
I 205 782 IFI27 632.45 .9 8740.06 8071.3 145 0.92 9 19.4 25672.22 808.3 229.73 293.4 280 .31 1266.4 8251.50 99 9.4 8078.30 4960.9 5575.76 389.9 7839. 6 5570.8 
I 723 12 IFI44L 88.38 .7 12 4.84 453.2 420.66 327.9 1397.99 544.1 254.71 135.9 3737.78 296.1 20 1.36 981.5 3245.26 692.0 131.47 37.5 1 0.45 753.1 
I 39428 IFIT2 164.99 .  2214.68 576.0 212.66 88.9 2151.56 1 23.0 224.64 112.9 2156.26 265.6 1110.65 480.2 2026.69 486.0 61.63 0.6 176.29 27.0 
I 0 789 IFI 3 277.23 .5 5 19.26 1860.9 600.17 448.6 5257.17 2311.6 339.85 126.6 4337.01 354.1 3155.73 1894.5 6597.25 2651.4 60. 3 6.3 732.62 220.4 
I 8 1246 IFITM1 1117.55 1.2 9 94.69 3342.8 3503.69 1844.2 17076.49 837.7 4407.33 2726.6 23031.44 893.8 3985.89 3134.6 14673.66 5747.0 155.79 87.8 1637.90 1283.6 
I 334296 IL18BP 121.12 .1 4541.91 2733.1 3.8  19.  25 .71 23.4 145.65 38.5 8542.26 2796.2 85.65 .7 541.61 280.5 272.38 157.1 3289.94 212.3 
I 4901 IL1F5 49. 6 .2 52.07 7.8 72.91 6.4 88.23 86.5 49.05 2.4 54.00 2.2 52.98 4.  5. 1 .1 42.38 3.4 4 . 2 2.2 
I 2368530 I 32 57.32 .2 210.39 74.3 74.24 6.8 22 .70 225.6 608.33 31.  1470.46 1547.2 51.85 6.1 5 .15 10.6 1922.19 101 .3 2679.37 1611.7 
I 17780 0 IL32 78.33 .2 56.41 214.  79.44 17.2 1033.18 4 2.3 454.47 337.1 815. 4 698.4 53.89 3.4 51.30 0.8 526.22 456.5 686.8  601.3 
I 1656310 INDO 45.82 .3 25.29 132.5 59.43 15.1 340.77 266.9 59.23 14.7 360.05 819.0 49.24 4.0 86.92 18.1 44.89 0.2 2549.94 1035.2 
I 70837  IRF1 378.04 .8 2621.77 246.6 196.84 19.1 4635.05 2186.4 1053.01 505.7 5612.52 2483.5 221.94 84.3 1715.14 64 .4 214.73 193.6 2441.88 179.7 
I 695924 KLK1  53.  .  50. 9 4.5 802.88 179.3 10005.51 2019.0 7.30 4.5 50.59 3.4 9.22 4.6 47.91 4.3 55.29 5.9 50.29 3.1 
I 45570 KLK7 55.7  .2 4.67 8.1 1300.40 728.1 15106.71 6679.6 84.2  49.4 68.63 1.9 6.67 3.9 5 .5  9.1 48.37 2.7 47.63 1.7 
I 1791545 KRT23 74.3  .1 70.16 13.3 124.39 42.  2088.33 1200.5 85.89 26.6 64.48 6.9 104.50 12.7 88.69 16.1 47.56 1.6 47.43 4.3 
I 7 58 4 KRT80 77.66 .5 48.93 .6 87.15 29.0 7107.21 2982.1 551.53 267.0 197.97 88.2 50.82 3.3 48.89 2.5 303.35 22.4 223.93 1.7 
I 1 08 4 LAMP3 55.19 .4 119.83 127.9 6.10 .9 48.95 75.9 3.25 9.0 549.14 145.3 48.29 4.8 64.23 12.4 323.06 26.2 419.63 22.6 
I 808220 LCE3E 66.39 0.3 64.63 14.8 6.19 7.2 802.66 396.4 53.53 9.7 65.71 12.2 60.13 6.0 58.36 3.6 51.24 2.6 1.5  4.3 
I 659688 LGALS3BP 544.76 .8 1396.51 911.7 644.97 299.3 1007. 5 384.4 1181.26 513.3 2832.00 660.7 3228.87 1842.7 4620.85 2686.5 5. 6 1.2 480.59 92.3 
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Letter to the Editor
In HLA-matched allogeneic hematopoietic stem cell transplantation, donor T 
cells can mediate graft-versus-leukemia/lymphoma (GvL) reactivity and graft-
versus-host disease (GvHD) by recognition of minor histocompatibility antigens 
(MiHA)1-4. Only a minority of MiHA shows hematopoiesis-restricted expression, 
and donor T cells for these MiHA may induce beneficial GvL reactivity without 
GvHD. The number of well-characterized MiHA with therapeutic relevance based 
on hematopoiesis-restricted expression remains limited and only 25% and 40% 
of recipients transplanted with sibling and unrelated donors, respectively, are 
eligible for therapies targeting known hematopoietic MiHA3,4. Therefore, to 
increase efficacy and applicability of cellular therapy for selective GvL induction, 
more hematopoiesis-restricted MiHA with balanced population frequencies in 
common HLA molecules must be identified. Here, we investigated the therapeutic 
significance of a MiHA encoded by ARHGDIB5. We demonstrated hematopoiesis-
restricted gene expression with the exception of intermediate mRNA expression 
in endothelial cells and showed that T cells recognized LB-ARHGDIB-1R presented 
by HLA-B*07:02 on primary leukemic cells, but not on (IFN-γ treated) fibroblasts 
(FB) and keratinocytes (KC). To evaluate potential toxicity against endothelial 
cells, we tested T-cell recognition of LB-ARHGDIB-1R on human umbilical vein 
endothelial cells (HUVEC) and found only limited reactivity under inflammatory 
conditions. Furthermore, we demonstrated in vivo targeting of LB-ARHGDIB-1R 
in 8 out of 10 patients who were screened for post-transplant specific T-cell 
responses. In one patient with relapsed lymphoma, high T-cell frequencies 
were induced after donor lymphocyte infusion (DLI) coinciding with long-lasting 
anti-lymphoma immunity without GvHD. Our data thus support the relevance 
of LB-ARHGDIB-1R as therapeutic target with potential to induce selective GvL 
reactivity. 
We previously demonstrated that CD8 T cells specific for a MiHA (LB-
ARHGDIB-1R) encoded by the ARHGDIB gene were induced in a patient with 
myelodysplastic syndrome who responded to DLI after HLA-matched alloSCT5. 
LB-ARHGDIB-1R is translated from the normal ARHGDIB transcript (NM_001175) 
in an alternative reading frame. Since ARHGDIB has been described to be 
expressed in hematopoietic cells6,7, we investigated the therapeutic value of 
LB-ARHGDIB-1R to stimulate GvL reactivity after alloSCT without GvHD. We 
first examined ARHGDIB expression by microarray gene expression analysis 
using Illumina HT-12 v3/4 BeadChips8 and compared gene expression between 
(malignant) hematopoietic and non-hematopoietic cells, which were cultured 
in the absence or presence of IFN-γ to mimic inflammation. ARHGDIB showed 
strong overexpression in the majority of (malignant) hematopoietic versus 
(IFN-γ pre-treated) non-hematopoietic cells. The ARHGDIB expression profile 
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Figure 1: LB-ARHGDIB-1R as target with therapeutic relevance for leukemia.
(A) Expression profiles for ARHGDIB and GEMIN4 as determined by microarray gene expression analysis. 
GEMIN4 has been selected as representative gene for MiHA with ubiquitous expression on (non-)
hematopoietic cells5. Indicated is the probe fluorescence as measured on Illumina Human HT-12 v3/4 
BeadChips8. Hematopoietic cells included bone marrow and peripheral blood mononuclear cells (BMMC and 
PBMC), B cells, T cells, monocytes (Mono), macrophages type I and II (MØ1 and MØ2), (im)mature DC (imDC 
and matDC), hematopoietic stem cells (HSC), EBV-B and PHA-T cells. Malignant hematopoietic cells included 
acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic 
lymphocytic leukemia (CLL) and multiple myeloma (MM). Non-hematopoietic cells included fibroblasts (FB) 
and keratinocytes (KC) cultured from skin biopsies in the absence or presence of IFN-γ and hepatocytes, colon 












was comparable to the strictly hematopoietic HMHA1 and MYO1G (Figure 1A 
and data not shown). 
Next, we investigated T-cell recognition of different leukemic samples and both 
primary FB and KC cultured from skin biopsies in the absence or presence of IFN-γ. 
Samples were collected from patients and healthy individuals after approval by 
the Leiden or Radboud UMC Institutional Review Board and informed consent 
according to the Declaration of Helsinki. Recognition of (non-)hematopoietic 
cell types by LB-ARHGDIB-1R specific T cells was measured by IFN-γ ELISA after 
overnight co-incubation. The data confirmed hematopoiesis-restricted T-cell 
recognition of LB-ARHGDIB-1R in HLA-B*07:02 on all MiHA-positive leukemic 
cells, but not on (IFN-γ pre-treated) FB and KC (Figure 1B). T cells for LB-ARHGDIB-
1R were also shown to recognize healthy hematopoietic cell types, including 
EBV-B, PHA-T and dendritic cells (Figure 1B and data not shown), indicating that 
alternative translation of LB-ARHGDIB-1R is not restricted to malignant cells. T 
cells for LB-ARHGDIB-1R also showed specific lysis of patient, but not donor, 
EBV-B cells and specific lysis of a leukemic sample (ALL #1) in a 10 h 51Cr-release 
assay (Figure 1C). Lysis of other ALL and AML samples was not detected by 51Cr-
release, but could be measured after 48 h co-incubation in a flow cytometry-
based cytotoxicity assay, while (IFN-γ pre-treated) patient FB were not lysed 
(Figure 1D and data not shown). The data showed that T cells for LB-ARHGDIB-
1R can specifically lyse hematological malignancies of different origins. 
In addition to hematopoietic cells, ARHGDIB can also be expressed in endothelial 
B-D) Recognition and lysis of (non-)hematopoietic cells as mediated by T cells for LB-ARHGDIB-1R (clone H10)5. 
All samples were positive for HLA-B*07:02. Cell types included EBV-B and PHA-T cells from patient (PAT EBV 
#1 and PHA #1) or donor (DON EBV #2) origin or from third party individuals (EBV #3, EBV #4 and PHA #3) as 
well as primary ALL (ALL #1-3) and AML (AML #1-3) samples. One representative example of two independent 
experiments is shown. 
(B) Recognition of LB-ARHGDIB-1R in HLA-B*07:02 as expressed on (malignant) hematopoietic cells, but 
not on (IFN-γ pre-treated) FB and KC. Malignant cells were isolated by flow cytometry cell sorting based on 
CD19 (ALL) or CD33 (AML) expression. T cells for LB-GEMIN4-1V (clone Z1)  were included as positive control. 
Genotyping results (+ or -) for the SNPs encoding LB-ARHGDIB-1R (filled bars) and LB-GEMIN4-1V (gray bars) 
are shown. Mean release of IFN-γ of duplicate wells as measured by ELISA after overnight co-incubation of T 
cells and stimulator cells at a ratio of 1:6 is depicted. 
(C) Cytolysis of primary leukemic blasts as mediated by T cells for LB-ARHGDIB-1R in a 51Cr-release assay. 
Target cells (1x103) labeled with Na2
51CrO4 (Perkin Elmer, Waltham, MA, USA) were co-incubated with T cells 
for 10 hours (h) at effector:target ratios of 10:1, 3:1 and 1:1. Mean specific lysis of triplicate wells is shown 
for patient and donor EBV-B (upper and middle graphs, respectively) and ALL #1 expressing LB-ARHGDIB-1R 
and HLA-B*07:02 (lower graph). Patient and donor EBV-B and ALL #1 were positive for HLA-A*02:01 and 
negative for LB-GEMIN4-1V. Allo-HLA-A*02:01 reactive T cells (clone HSS12) and T cells for LB-GEMIN4-1V 
were included as controls.
(D) Cytolysis of primary leukemic blasts and patient FB as mediated by T cells for LB-ARHGDIB-1R in a 48 h flow 
cytometry-based cytotoxicity assay. T cells (2.5x104) were labeled with PKH67 (Sigma-Aldrich, St. Louis, MO, 
USA) and co-incubated for 48 h with AML or ALL samples or FB cultured from a skin biopsy of the patient in the 
absence or presence of IFN-γ (1x104). After co-incubation, cultures were stained with CD33-APC (AML), CD19-
PE (ALL) or CD90-PE (FB). Sytox blue was added to gate on viable cells and flow count fluorospheres (Beckman 
Coulter, Brea, CA, USA) were added to calculate specific lysis. T cells recognizing HA-2 in HLA-A*02:01 (clone 
9H11), T cells for LB-GEMIN4-1V and allo-HLA-A*02:01 reactive T cells were included as controls. Mean lysis 
of triplicate wells is depicted.
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cells9. We therefore addressed potential toxicity and measured T-cell reactivity 
against endothelial cells. We confirmed intermediate ARHGDIB gene expression 
in HUVEC under both steady-state and inflammatory conditions by microarray 
gene expression analysis (Figure S1A, upper panel). Increased ARHGDIB mRNA 
expression in HUVEC as compared to FB was also detectable by q-PCR (see 
supplemental methods) (Figure S1A, lower panel). To investigate whether gene 
expression in HUVEC can lead to T-cell recognition, we measured reactivity 
against two LB-ARHGDIB-1R positive HUVEC samples by IFN-γ ELISA. T cells for 
LB-ARHGDIB-1R were only capable of recognizing one HUVEC sample (#2) after 
IFN-γ pre-treatment, which is known to up-regulate HLA, co-stimulatory and 
adhesion molecules and to increase the antigen processing and presentation 
capacity (Figure S1B)10,11. However, recognition of HUVEC #2 was low compared 
to EBV-B cells and (IFN-γ pre-treated) HUVEC #1 was not or hardly recognized 
by specific T cells. Altogether, we demonstrate that ARHGDIB gene expression 
in HUVEC leads to low surface presentation of LB-ARHGDIB-1R that trigger 
only minimal T-cell reactivity under inflammatory conditions. Our results thus 
support the value of LB-ARHGDIB-1R as target for T-cell therapy to selectively 
augment GvL reactivity after alloSCT with a limited risk for GvHD. 
Finally, we determined the in vivo immunogenicity of LB-ARHGDIB-1R and 
investigated its relevance as T-cell target in clinical responses after alloSCT. The 
population frequency of LB-ARHGDIB-1R in Caucasians is 77% (www.hapmap.
org), resulting in a disparity rate in which a LB-ARHGDIB-1R positive patient 
is transplanted with a negative donor of 18%. HLA-B*07:02 is expressed in 
approximately 20% of Caucasians12. In our cohort of 93 HLA-B*07:02 patient-
donor pairs, 14 LB-ARHGDIB-1R positive patients were transplanted with a 
MiHA-negative donor and samples at relevant time points were available for 
10 patients. PBMC were stained with APC- and PE-conjugated HLA-B*07:02 
tetramers containing LB-ARHGDIB-1R directly ex vivo as well as after 7 days of in 
vitro peptide stimulation as previously described13. PBMC obtained after alloSCT 
(and DLI) were analyzed for tetramer positive T cells, and LB-ARHGDIB-1R specific 
T cells were detected in 4 patients ex vivo (Figure 2A) and in 4 additional patients 
after in vitro peptide stimulation (Figure 2B), resulting in 8 of 10 patients (80%) 
in total. 
All patients were treated with partial T-cell depleted alloSCT followed by at least 
4 months of immunosuppression with cyclosporin A as GvHD prophylaxis. Six 
of 10 patients received DLI after alloSCT (Table S1). In 3 of 6 patients treated 
with DLI, tetramer positive T cells were detected ex vivo at frequencies between 
0.06-0.92%. Five patients received prophylactic DLI, and a clinical response 
against (malignant) hematopoietic cells of patient origin could therefore not be 








Figure 2: LB-ARHGDIB-1R as immunogenic target with relevance for GvL reactivity.
PBMC from 10 LB-ARHGDIB-1R and HLA-B*07:02 positive patients transplanted with HLA-matched negative 
donors were screened for LB-ARHGDIB-1R specific CD8 T cells directly ex vivo as well as after one week of in 
vitro peptide stimulation (IVS)13. 
(A)  Patients with detectable LB-ARHGDIB-1R tetramer positive T cells ex vivo. Numbers indicate the percentage 
of CD8 T cells that are positive for both LB-ARHGDIB-1R tetramers (PE and APC) in the Sytox blueneg, CD8pos, 
CD4neg, CD14neg, CD16neg, and CD19neg T-cell population.
(B) Dot plots of patients with detectable LB-ARHGDIB-1R tetramer positive T cells after in vitro peptide 
stimulation: day 0 (upper panels) and day 7 (lower panels). Numbers indicate the percentage of CD8 T cells 
that are positive for both LB-ARHGDIB-1R tetramers (PE and APC). 
(C) Ex vivo frequencies of LB-ARHGDIB-1R specific T cells and clinical response in patient 5 who was treated 







by lymph node biopsy, received therapeutic DLI that in the absence of additional 
(chemo-)therapy induced a long-lasting complete remission (>16 yrs) without 
any signs of GvHD. T cells for LB-ARHGDIB-1R were measured in 3 patients with 
GvHD after DLI (patients 2, 6 and 7). These T cells were detectable ex vivo (0.92%) 
in patient 2 and after in vitro stimulation in the other two patients. Although 
it cannot be excluded that T cells for LB-ARHGDIB-1R may have contributed 
to GvHD in these patients, we consider it more likely that T cells with other 
specificities mediated GvHD, since we previously demonstrated that often a 
variety of MiHA are targeted in patients with GvHD5,14 and that the majority of 
these MiHA are ubiquitously expressed on (non-)hematopoietic tissues. This is 
further supported by the observation that T cells for LB-ARHGDIB-1R were also 
measured ex vivo (0.13%) in patient 5. Induction of tetramer positive T cells 
in this patient two months after DLI coincided with long-lasting GvL reactivity 
without GvHD. Dynamic analysis of LB-ARHGDIB-1R tetramer positive T cells in 
this patient demonstrated high frequencies not only after DLI, but also within 
the first weeks after alloSCT during immunosuppression with cyclosporin A 
(Figure 2C). Although the long-lasting GvL response in patient 5 suggests that LB-
ARHGDIB-1R specific T cells are capable of mediating strong anti-tumor immunity, 
T cells with other specificities than LB-ARHGDIB-1R may also be involved in the 
therapeutic effect of DLI. Systemic toxicity as a result of vascular damage has not 
been observed in any of the patients with circulating LB-ARHGDIB-1R specific T 
cells. Thus, clinical observations support the therapeutic value of LB-ARHGDIB-
1R and do not show evidence for specific attack of endothelial cells as might 
be suggested based on detectable ARHGDIB gene expression and low T-cell 
recognition of endothelial cells in vitro. 
In conclusion, our data support the relevance of LB-ARHGDIB-1R as highly 
immunogenic and hematopoiesis-restricted MiHA with potential to shift the 
delicate balance between GvL reactivity and GvHD in favor of desired anti-tumor 
reactivity. At the Radboud UMC, we started a clinical trial in which transplanted 
patients are vaccinated with donor DC loaded with mRNA and included ARHGDIB 
as one of the transcripts for hematopoiesis-restricted MiHA (Dutch Trial Registry 
#NTR4128). Future clinical data will therefore show definite evidence whether 
T cells for LB-ARHGDIB-1R are capable of inducing selective GvL responses. In 
addition to hematopoietic cells, ARHGDIB has been reported to be expressed 
in several solid tumors correlating with advanced tumor stage and metastatic 
potential15. As such, LB-ARHGDIB-1R may have broad value as target for T-cell 
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Cell samples and culture
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical 
cords according to Jaffe et al.1 using a cannula sized to fit the vein. HUVEC were 
cultured up to passage 4 in EGM-2 medium supplemented with the EGM-2 
bullet kit (Lonza BioWhittaker, Basel, Switzerland) and refreshed every 3 days. 
Fibroblasts (FB), keratinocytes (KC) and HUVEC were cultured in the absence 
or presence of 200 IU/ml IFN-γ (Boehringer-Ingelheim, Ingelheim am Rhein, 
Germany) for 3 days. Retroviral transduction of the HLA-B*07:02 restriction 
allele was performed as described previously2. 
Quantitative RT-PCR
Expression of ARHGDIB mRNA was measured by quantitative real-time PCR using 
Taqman Universal Master Mix II, without UNG and Taqman gene expression 
assays for ARHGDIB (Hs00171288_m1) and normalized as a ratio of GAPDH 
(Hs99999905_m1) expression (all from Applied Biosystems, Life Technologies, 
Carlsbad, CA, USA). Amplifications were started with 10 minutes at 95°C, followed 
by 50 cycles of 15 seconds for denaturing at 95°C, 30 seconds of annealing at 
60°C, and 30 seconds extension at again 60°C.
Figure S1: LB-ARHGDIB-1R as target with potential toxicity for endothelial cells
(A) ARHGDIB gene expression in FB and HUVEC relative to EBV-B cells by microarray gene expression analysis 
(upper panel) and quantitative RT-PCR (q-PCR; lower panel). FB and HUVEC were cultured in the absence or 
presence of IFN-γ. Gene expression by q-PCR was corrected for GAPDH expression.
(B) Reactivity of LB-ARHGDIB-1R specific T cells (clone H10) against HUVEC by IFN-γ ELISA. LB-ARHGDIB-1R 
positive HUVEC #1 and #2 were retrovirally transduced with HLA-B*07:02 (B7td) and cultured in the absence 
(upper panel) or presence (lower panel) of IFN-γ. LB-ARHGDIB-1R negative HUVEC #3 expressing HLA-B*07:02 
endogenously (B7pos) and after retroviral introduction (B7td) were included as negative controls. T-cell 
reactivity was also measured against EBV-B cells and FB of patient origin expressing HLA-B*07:02 endogenously 
(PAT EBV and FB) as well as EBV-B cells and FB from patient HDV expressing HLA-B*07:02 after retroviral 
transduction (HDV EBV-B7td and FB-B7td). EBV-B cells of donor origin (DON EBV) and EBV-B cells from LB-
ARHGDIB-1R negative patient MAE expressing HLA-B*07:02 after retroviral transduction (MAE EBV-B7td) 
were included as negative controls. In addition to LB-ARHGDIB-1R specific T cells (clone H10), T cells for LB-
GEMIN4-1V (clone Z1) and allo-HLA-A*02:01 (clone HSS12) were included. Genotyping results (+ or -) for SNPs 
encoding LB-ARHGDIB-1R (filled bars), LB-GEMIN4-1V (grey bars) and HLA-A*02:01 (open bars) are shown. 
Mean release of IFN-γ of duplicate wells is shown.
(C) LB-ARHGDIB-1R negative MAE EBV-B7td as well as LB-ARHGDIB-1R positive HDV FB-B7td and HUVEC #2-
B7td were cultured in the absence of IFN-γ and pulsed with exogenous LB-ARHGDIB-1R at titrated peptide 
concentrations. These cells were subsequently compared for their capacity to stimulate T cells for LB-
ARHGDIB-1R (clone H10) by IFN-γ ELISA (left panel). In addition, LB-ARHGDIB-1R negative HUVEC #3 B7pos 
and B7td were cultured in the absence of IFN-γ and compared for their stimulatory capacity (middle panel) 
as well as LB-ARHGDIB-1R positive HUVEC #2 B7td cultured in the absence or presence of IFN-γ (right panel). 
Mean release of IFN-γ of duplicate wells is shown.
(D) HLA-B*07:02 surface expression on EBV-B, FB and HUVEC B7pos or B7td by flow cytometry. FB and HUVEC 
were cultured in the presence of IFN-γ and stained with a PE-labeled antibody against HLA-B*07:02 (clone 
BB7.1). HLA-B*07:02 surface expression is shown by dark grey histograms. Light grey histograms represent 
non-stained EBV-B, FB and HUVEC and open histograms indicate antibody staining of EBV-B, FB and HUVEC 
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To investigate whether gene expression in HUVEC leads to surface presentation 
of LB-ARHGDIB-1R at levels that can be recognized by specific T cells, we cultured 
LB-ARHGDIB-1R positive HUVEC #1 and #2 and measured T-cell recognition by 
IFN-γ ELISA after retroviral introduction of the HLA-B*07:02 restriction allele. 
Figure S1B shows that T cells for LB-ARHGDIB-1R were only capable of recognizing 
HUVEC #2 after IFN-γ pre-treatment, which is known to enforce high expression 
of HLA, co-stimulatory and adhesion molecules as well as molecules involved in 
antigen processing and presentation3, 4. However, recognition of HUVEC #2 was 
low as compared to EBV-B cells and (IFN-γ pre-treated) HUVEC #1 was not or 
hardly recognized by specific T cells. Peptide-loaded control experiments (Figure 
S1C) illustrated that HLA-B*07:02 surface expression on HUVEC was sufficient to 
mediate strong T-cell reactivity, which is in line with detection of these surface 
molecules by flow cytometry (Figure S1D). Altogether, the data demonstrate 
that ARHGDIB gene expression in HUVEC leads to low surface presentation 
of LB-ARHGDIB-1R at levels that trigger only minimal T-cell reactivity under 
inflammatory conditions. Our results thus support the value of LB-ARHGDIB-1R 
as target for T-cell therapy to selectively augment GvL reactivity after alloSCT 
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The identification of minor histocompatibility antigens (minor H Ag) is an important step towards understanding their 
immunobiology and therapeutic application. Specific induction 
of cytotoxic T-cell responses against hematopoiesis-restricted 
minor H Ags may represent an effective immunotherapy 
for hematological malignancies after allogeneic stem cell 
transplantation. Recently, we developed a novel identification 
strategy based on the 1000 Genomes Project and we now 
utilized a variation of this approach for identification of minor 
H Ag LB-TTK-1D, which could not be identified with previous 
whole genome association scanning studies. Using an ‘inferred 
correlation’ analysis based on the results of a previously 
executed whole genome association scanning analysis, we 
identified rs240226 to be the encoding genetic variation for 
this minor H Ag. Strikingly, this SNP is located in an alternative 
transcript of the gene TTK, containing a premature termination 
codon in the fourth of its five exons. This premature termination 
codon targets the transcript for nonsense mediated decay 
(NMD), leading to rapid degradation of the mRNA. This is the 
first identification of an endogenous T-cell epitope that is 
translated from an NMD transcript. Importantly, our T cells fail 
to recognize the majority of tumor cells that are positive for the 
minor H Ag, underscoring potential pitfalls of targeting NMD-
derived epitopes as immunotherapeutic approach. Our finding 
can be useful for prospective minor H Ag identification studies 
and provides novel insights in the biology behind the source of 
transcripts producing antigenic epitopes in effective immune 
responses. 
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Allogeneic stem cell transplantation (alloSCT) followed by donor lymphocyte 
infusion (DLI) is a potentially curative treatment for hematological malignancies. 
The therapeutic, so-called graft-versus-tumor (GvT) effect of alloSCT and 
DLI is mainly mediated by allo-reactive donor T cells recognizing minor 
histocompatibility antigens (minor H Ag) on the remaining tumor cells. Minor 
H Ags are immunogenic peptides, resulting from natural genetic variations, 
presented by HLA on recipient cells that can be recognized by alloreactive 
T-cells1. As minor H Ags are “non-self” to the transplanted immune system, 
donor T cells are capable of inducing potent responses against the malignant 
cells of the patient, while the new donor derived - and thus minor H Ag negative 
- cells are spared2,3. 
Clinical outcome in patients treated with alloSCT and DLI may, however, 
be threatened by the development of Graft-versus-Host disease (GvHD), 
which is caused by donor T cells recognizing minor H Ags on healthy tissues. 
Immunotherapy in which hematopoietic cell lineage restricted minor H Ags are 
specifically targeted may therefore provide or stimulate antitumor immunity 
without the risk for GvHD. For this purpose, the identification of hematopoiesis 
specific minor H Ags has been the focus of intensive research over the past 
decades, resulting in the development of increasingly efficient identification 
strategies4,5. Since natural genetic variation constitutes the basis of minor H Ags, 
genome-wide genetic correlation analyses whereby an association between the 
minor H Ag phenotype and the genotypes of the same individuals is sought, 
appears a highly efficient minor H Ag identification strategy6. Recently, we 
improved the genome-wide correlation analysis based identification strategies 
by implementing data of the 1000 Genomes Project (1000GP)7,8.  We now used 
these data to pinpoint the encoding genetic variation of a minor H Ag for which 
we previously identified strongly correlating non-coding SNPs using the so-
called whole genome association scanning (WGAs) analysis, but were unable 
to exactly identify the encoding variation6. This strategy led to identification of 
the new minor H Ag LB-TTK-1D, which is encoded by a SNP in the intron of 
the primary TTK transcript, but translated as non-synonymous coding variant 
in an alternative transcript that is degraded by nonsense-mediated decay 
(NMD)9,10. The discovery of this minor H Ag provides the first endogenous 
evidence that NMD transcripts can serve as a source of antigenic peptides. This 
finding improves our understanding of the biology behind epitope generation in 




Cell samples, culture conditions and isolation of T-cell clones
The CD8 minor H Ag-specific cytotoxic T-cell (CTL) clones 10-4 and 10-5, 
designated as clone type H4, recognizing LB-TTK-1D were generated as described 
previously6. In short, T cells were isolated from a patient with myelodysplastic 
syndrome (patient 5852) who converted to 100% donor chimerism after 
treatment with alloSCT and DLI. T-cell clones were generated by single cell 
sorting of HLA-DR CD8 positive cells by flow cytometry. T cells were cultured 
in IMDM supplemented with 5% FBS, 5% human serum, interleukin 2 (100 IU/
mL), and re-stimulated every 14 days with irradiated allogeneic peripheral blood 
mononuclear cells (PBMC) and phytohemagglutinin (0.8 μg/mL, Murex Biotec 
Limited). PBMC and bone marrow mononuclear cells (BMMC) were obtained 
from patients and healthy individuals after approval by the Leiden UMC 
Institutional Review Board and informed consent according to the Declaration 
of Helsinki. Mononuclear cells were isolated by Ficoll-Isopaque separation and 
cryopreserved. Fibroblasts (FB), keratinocytes (KC), EBV-transformed B (EBV-
LCL) cells, CD40L cultured B cells, PHA-T blasts and allo-HLA-A*02:01 reactive T 
cells (clone HSS12)13 were cultured as described previously14,15. FB and KC were 
cultured in the absence or presence of 200 IU/ml IFN-γ (Boehringer Ingelheim, 
Alkmaar, the Netherlands) for 3 days.
Whole Genome Association scanning
Clone 10-5 was tested for recognition of 80 SNP-genotyped EBV-LCLs by IFN-γ 
ELISA. T-cell recognition was investigated for association with 1.1M SNPs by 
WGAs using Fisher’s exact test as described previously6.
1000 Genomes Project correlation analysis
We retrieved the genotypes for the highest associating SNP as identified by 
WGAs (rs608962) of 50 Caucasian (CEU) individuals from the 1000GP16. The 
probable minor H Ag phenotype for each of those individuals was inferred 
from these data and used to calculate which other SNPs on chromosome 6 
(where rs608962 is located) correlated with the minor H Ag in the 50 Caucasian 
individuals using our previously described algorithm in R8. The top correlating 
SNPs were further analyzed for translational consequences using Ensembl 
(https://www.ensembl.org). Peptide HLA-binding predictions were made using 
the NetMHC 3.2 server17. 
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Cryopreserved PBMC from patient 5852 obtained after alloSCT 6 weeks before 
(148 days after alloSCT) and 6 and 7 weeks after DLI (231 and 237 days after 
alloSCT) were thawed and stained with PE-conjugated UV-exchange tetramers 
containing LB-TTK-1D and APC-conjugated tetramers containing LB-ERAP1-
1R. Tetramers were constructed as described previously18,19. Acquisition was 
performed on a FACS Calibur analyzer (BD) using CellQuest software and 
analyzed using FlowJo (Tree Star, Ashland, OR). 
T-cell reactivity assays
Stimulator cells (5-15 × 103 cells/well) and T cells (2 × 103 cells/well) were co-
incubated overnight in 384-wells plates (Greiner Bio-One, Frickenhausen, 
Germany). IFN-γ release was measured by ELISA (Sanquin, Amsterdam, The 
Netherlands). To identify the antigenic epitope, peptides were synthesized, 
dissolved in DMSO and pulsed at titrated concentrations in IMDM on EBV-LCLs 
from the stem cell donor. After 2h of pulsing at 37°C, T cells were added, and 
IFN-γ production in the supernatant was measured after overnight co-incubation 
by IFN-γ ELISA. T-cell recognition of healthy and malignant cells, which included 
PHA-blasts, CD40L cultured B cells, dendritic cells, FB, KC and leukemic cells of 
different origins (ALL, AML, CLL and CML), as well as of donor EBV-LCLs either 
transduced with TTK-007 construct or a mock vector was tested in a similar 
manner. 
Quantitative RT-PCR and Sanger Sequencing
For quantitative RT-PCR and sequencing analysis, total RNA was isolated using 
the RNAqueous Micro-Kit and Small Scale Kit (Ambion, Life Technologies) 
for a maximum of 0.5 × 106 and 10 × 106 cells, respectively, following 
manufacturer’s instructions. cDNA was synthesized from total RNA using 
Moloney murine leukemia virus reverse transcriptase (Invitrogen). For q-PCR, 
TTK expression was measured on the Roche Lightcycler 480 using Fast Start 
TaqDNA Polymerase (both Roche) and EvaGreen (Biotium, Hayward, CA) 
with forward primer 5’-ACCTTACTGATGAACTAAGCTTGAA-3’ and reverse 
primer 5’-TCCCGAGTTATCTGTAGTATCAGC-3’ for the full-length TTK transcript 
and forward primer 5’-ACTTTGAATGGTGTCTGGCACA-3’ and reverse primer 
5’-CTCTGGGTTGTTTGCCATCAT-3’ for the alternative TTK transcript. Expression 
was normalized to the HMBS reference gene. For Sanger Sequencing of 
the alternative transcript, we performed two sequential rounds of PCR on 
cDNA of patient EBV-LCLs using two primer sets each containing one primer 
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that was specific for the alternative (and not the full-length) transcript. 
In the first round, forward primer 1 5’-ATGGAATCCGAGGATTTAAGTG-3’ 
and reverse primer 1 5’-TGTGCCAGACACCATTCAAAG-3’ as well as forward 
primer 2 5’-ACTTTGAATGGTGTCTGGCACA-3’ and reverse primer 2 5’- 
GTAGTCACGTGCATCATCTG-3’ were used to produce two bands, which were 
combined to one fragment in a second round of amplification using forward 
primer 1 and reverse primer 2. The alternative TTK transcript was confirmed by 
Sanger sequencing in both directions. 
Minigene cloning and transduction
A construct for the alternative TTK transcript containing exon 1-5 was 
cloned into a pLZRS vector containing a truncated ΔNGFR marker gene 
linked by an IRES. The construct was cloned from patient 5852 cDNA 
(homozygous for the minor H Ag encoding SNP) using a two-step PCR with 
forward primer 1 5’-CGCGGATCCACCATGGAATCCGAGGATTTAAGTG-3’ and 
reverse primer 1 5’-TGTGCCAGACACCATTCAAAG-3’ as well as forward 
primer 2 5’-ACTTTGAATGGTGTCTGGCACA-3’ and reverse primer 2 5’- 
TATATACTCGAGGTAGTCACGTGCATCATCTG -3’ in the first round to produce two 
bands, which were combined to one fragment in a second round of amplification 
using forward primer 1 and reverse primer 2. Fragments were digested with 
BamHI and XhoI for cloning and the transcript construct was confirmed by 
Sanger Sequencing. Retroviral supernatant was obtained by transfecting wild-
type Φnx-A packaging cells as previously described20 with the exception that 
the Fugene HD transfection kit (Roche) was used. Viral supernatant was used 
for transduction on plates coated with recombinant human fibronectin CH 296 
(Takara Shuzo).
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Selection and analysis of T-cell clones for a novel minor H Ag
We previously isolated several T-cell clones, designated clone type H4, specific 
for a single minor H Ag from a patient after alloSCT and DLI6. In total 14 clones 
using 2 different TCRBV recognized a minor H Ag with a population frequency 
of 50% in HLA-A*02:01. To identify the polymorphic epitope that is recognized 
by clone type H4, T-cell recognition was tested against a panel of EBV-LCLs that 
are genotyped for 1.1 × 106 SNPs by the 1M Illumina array (Figure 1A). WGAs 
was performed by calculating the correlation between T-cell recognition and 
the genotypes of those SNPs. We identified 13 SNPs that associated with p < 
3.0 × 10-16, of which the strongest associating SNP rs608962 had a p-value of 
3.64 × 10-20 (Figure 1B). These SNPs were all located in introns of the TTK gene 
(SNP rs608962 in intron 20) or in other regions located outside coding exons, 
and were therefore unlikely to be responsible for generation of the minor H Ag. 
Sanger sequencing of the primary transcript of TTK did not identify differences 
between patient and stem cell donor (data not shown). Thus, the minor H Ag 
recognized by the H4 clones could not be identified by WGAs using genotypes 
for 1.1 × 106 SNPs.
Extended correlation analysis using 1000 Genome Project genotype 
data
With the development of novel identification strategies using whole genome 
data8, we initiated a second attempt to identify the minor H Ag recognized 
by the H4 clones. Therefore, in an “inferred correlation” analysis, we sought 
strong correlations between these noncoding SNPs and coding SNPs present in 
the databases of 1000 GP. Because these so-called haplotype blocks may differ 
per ethnic population and because the original WGAs was based on minor H 
Ag phenotypes of Dutch individuals, we selected 50 individuals of European 
descent within the 1000GP for this extended correlation analysis. 
For these 50 individuals, the strongest associating SNP as identified by WGAs 
(rs608962) was investigated for association with each SNP on chromosome 
6 within the 1000GP by a Fisher’s exact test. This analysis yielded 93 fully 
correlating SNPs (Figure 2A, B), of which only SNP rs240226 is translated as non-
synonymous coding variant in an alternative TTK transcript, encoding a glutamic 
acid (E) to aspartic acid (D) change. Based on NetMHC HLA-peptide binding 
predictions17, we hypothesized that epitope RLHDGRVFV was the most likely 
candidate to be recognized by clone type H4 with RLHEGRVFV being the allelic 
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Figure 1. Identification of associating SNPs in the TTK gene by whole genome association scanning
(A) Recognition of a panel of 80 EBV-LCLs genotyped for 1.1M SNPs was measured for T-cell clone type H4. 
Each symbol indicates IFN-γ production as measured by ELISA after overnight co-incubation.
(B) Whole genome association results for clone type H4 (minus logarithm of the p-value of each SNP is plotted, 
each dot represents a single SNP). SNPs are grouped by their location on chromosomes (x-axis). SNPs with a 
p-value <10-1 are displayed. All SNPs associating with a p-value < 10-15 are shown in the inserted table with 
their individual p-values. The strongest associating SNP rs608962 is located in intron 20 of the TTK gene.
variant. Indeed, T-cell experiments confirmed that RLHDGRVFV is the minor H 
Ag (LB-TTK-1D) as it was potently recognized by clone type H4 with picomolar 
affinity, while the allelic variant (E-variant) was not recognized. The two different 
TCRs for LB-TTK-1D represented by clone 10-4 (TRBV19) and clone 10-5 (TRBV3-
1) showed similar peptide affinity (Figure 2C). 
T cells for LB-TTK-1D were detectable after DLI
Next, we investigated the in vivo frequency of T cells for LB-TTK-1D as compared 
to minor H Ag LB-ERAP1-1R, which was identified as dominant target in the 
same patient after DLI6. PBMC obtained 6 weeks before DLI and 6 and 7 weeks 
after DLI were stained with tetramers for LB-TTK-1D and LB-ERAP1-1R. Both 
LB-TTK-1D and LB-ERAP1-1R specific T cells were detected 6 weeks after DLI 
(0.08% and 0.14% of total lymphocytes, respectively) and further increased at 
week 7 (0.25% and 0.58%, respectively), while absent prior to DLI (Figure 3). 
This indicates that a polyclonal T-cell response was induced, which was partially 
directed at LB-TTK-1D and coincided with conversion to full donor chimerism.
Presentation of LB-TTK-1D on (non-)hematopoietic cell types 
To determine the tissue specificity of LB-TTK-1D, we tested T-cell recognition 
of different cell types of (non-)hematopoietic origin. Patient EBV-LCL and 
A B
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PHA-T cells were strongly recognized by clone type H4, while donor EBV-LCL 
and PHA-T cells remained negative (Figure 4A). The T cells also recognized 
CD40 activated B cells and mature dendritic cells from HLA-A*02:01 and minor 
H Ag positive individuals, but failed to react with peripheral blood and bone 
marrow mononuclear cells as well as immature dendritic cells. Of the non-
hematopoietic cells tested, T-cell reactivity against patient fibroblasts (FB) as 
well as FB from third party minor H Ag positive individuals was measured and 
recognition increased after pre-treatment with IFN-γ. Keratinocytes, however, 
remained negative even when cultured under inflammatory conditions (Figure 
4B). We then selected primary leukemia samples of different origins and an 
ALL-cell line based on SNP status and expression of HLA-A*02:01. One CML 
sample was strongly recognized, but all other leukemic samples were negative, 
despite strong recognition by the allo-HLA-A*02:01 control clone (Figure 4C). 
Pre-treatment with IFN-γ did not induce T-cell recognition as tested for one CML 
sample (data not shown). In summary, LB-TTK-1D specific T cells recognized cell 
types of hematopoietic (EBV-LCL, PHA-T cells, mature dendritic cells and CD40L 
cultured B cells) as well as non-hematopoietic (FB) origin, but showed reactivity 
Figure 2. Identification of LB-TTK-1D by 
1000 Genome Project association analysis 
(A) Histogram showing p-values for all 
SNPs on chromosome 6 from the 1000 
Genomes Project in an extended association 
analysis with SNP rs608962 for 50 European 
individuals (minus logarithm of the p-value of 
each SNP is plotted). Each bar represents a 
single SNP. Only SNPs with p < 0.05 are shown 
and ordered by location on chromosome 6 
on the x-axis.
(B) Zoom view of the significant area on 
chromosome 6, showing a clear haplotype 
block with 93 SNPs that fully correlate.
(C) Identification of the HLA-A*02:01 
restricted epitope as recognized by T-cell 
clone 10-4 and 10-5. Peptides RLH(D/E)
GRVFV, which were both predicted to bind 
to HLA-A*02:01 by NetMHC with a binding 
affinity <50 nM were titrated on donor EBV-
LCLs and co-incubated with T-cell clones 10-4 
and 10-5. T-cell recognition after overnight 






against only one CML sample, indicating a specific recognition profile that is not 
restricted to (malignant) hematopoietic cells and depends on other factors than 
presence of the HLA-A*02:01 restricted minor H Ag. 
LB-TTK-1D is encoded within an NMD transcript.  
Minor H Ag LB-TTK-1D is generated by SNP rs240226 in intron 2-3 of the main 
TTK transcript, of which specific sequences are retained as alternative exon 
3 in a transcript annotated as TTK-007 in Ensembl (Figure 5A). To establish 
whether minor H Ag LB-TTK-1D is derived from alternative transcript TTK-007, 
we cloned TTK-007 from patient cDNA (homozygous for SNP rs240226) and 
retrovirally introduced this construct into donor EBV-LCL. LB-TTK-1D specific T 
cells recognized donor EBV-LCL upon retroviral transduction with the construct 
(Figure 5B), confirming processing and presentation of LB-TTK-1D as minor H Ag 
from transcript TTK-007. 
Interestingly, TTK-007 contains a premature termination codon (PTC) in exon 4, 
which renders this transcript susceptible for nonsense mediated decay (NMD). 
To confirm endogenous presence of this NMD transcript, we performed a PCR-
strategy to specifically amplify this transcript followed by Sanger sequencing 
(illustrated in Figure 5A). This analysis confirmed the presence of NMD transcript 
TTK-007 in cDNA of patient EBV-LCL.
NMD transcripts are rapidly degraded through a surveillance mechanism to 
prevent the formation of aberrant dysfunctional proteins9,10. To investigate 
whether the specific recognition profile of clone 10-5 as shown in Figure 4 
could be explained by cell type-specific differences in expression of the TTK-
Figure 3. Detection of LB-TTK-1D specific T cells after DLI
PBMC from patient 5852 before (-6 weeks) and 6 and 7 weeks after DLI were thawed and stained with PE-
labeled HLA-peptide UV-exchange tetramers for LB-TTK-1D and APC-labeled HLA-peptide tetramers for LB-
ERAP-1R. Numbers indicate the percentage of cells that are positive for the specific tetramer within the 
lymphocyte gate.
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Figure 4. T-cell recognition of LB-TTK-1D on (non-)hematopoietic cell types
Reactivity of clone 10-5 (filled bars) measured by IFN-γ ELISA against healthy hematopoietic (A) and non-
hematopoietic (B) cells as well as malignant hematopoietic cells (C) of different origins. The allo-HLA-A*02:01 
reactive T-cell clone HSS1213 was included as positive control (white bars). All samples were HLA-A*02:01 
positive and presence or absence of the LB-TTK-1D genotype is indicated by + or -. 
(A) Hematopoietic samples included patient and donor EBV-B and PHA T cells as well as PBMC, BMMC, 
immature and mature dendritic cells and B cells cultured on CD40L expressing cells from third party LB-TTK-
1D positive healthy donors.
(B) Non-hematopoietic samples included patient fibroblasts (FB) as well as FB from third party LB-TTK-1D 
positive donors that were cultured in the absence or presence of IFN-γ. Of one of these donors, skin-derived 
keratinocytes were also included. Patient and donor EBV-LCLs as well as LB-TTK-1D negative FB were included 
as controls. 
(C) Malignant hematopoietic cells of different origins included ALL, CLL, AML and CML samples as well as an 
ALL cell line (cell-line GD) and its primary sample (ALL GD). Patient and donor EBV-LCLs and LB-TTK-1D negative 
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Figure 5: LB-TTK-1D is encoded by alternative transcript TTK-007
(A) Both full-length and alternative TTK transcripts are depicted. Coding (filled rectangles) and non-coding 
(white rectangles) regions of the transcripts are shown as well as intronic sequences that are spliced out 
to form the mature transcript (black lines) and primer binding sites used for Sanger sequencing. A detailed 
view of the intron 2-3 sequence that is retained as exon 3 in alternative transcript TTK-007 is inserted. SNP 
rs240662 encodes an amino acid change from E in donor to D in recipient cells, resulting in RLHDGRVFV as 
minor H antigen LB-TTK-1D recognized by clones type H4.
(B) Reactivity of clone 10-5 (filled bars) measured by IFN-γ ELISA against patient and donor EBV-LCLs and 
donor EBV-LCL retrovirally transduced with mock or the TTK-007 minigene. The allo-HLA-A*02:01 reactive 
T-cell clone HSS1213 was included as positive control (white bars).
(C) Expression of the full-length (right panel) and alternative (left panel) transcripts of TTK as measured by 
quantitative RT-PCR are shown. Expression was measured for healthy and malignant hematopoietic cell types 
as well as ALL cell line GD. Patient FB cultured in the absence or presence of IFN-γ were also included. All 
samples were positive for SNP rs240226. Donor EBV-LCL transduced with the TTK-007 construct were included 
as positive control for the transcript specific q-PCR. Expression of the full-length and alternative TTK transcript 








007 transcript, we designed a transcript-specific q-PCR with primers that 
were validated using the TTK-007 construct and measured expression of the 
alternative NMD as well as full-length TTK transcripts in cDNA produced for 
the same (non-)hematopoietic cell types as selected for T-cell recognition. 
In all cell types tested, expression of the NMD transcript was low and barely 
detectable as compared to the full-length TTK transcript (Figure 5C), suggesting 
that the TTK-007 mRNA is rapidly degraded as expected for an NMD transcript. 
Strikingly, expression levels of the NMD transcript were in a similar range in 
different cell types in and did not associate with T-cell recognition as shown in 
Figure 4. These data indicate that the specific recognition profile of clone 10-5 
cannot be explained by expression of TTK-007, suggesting that other factors are 
involved in cell type specific surface presentation of LB-TTK-1D. Altogether, LB-
TTK-1D is derived from an alternative TTK protein whose mRNA is a template for 
NMD, indicating that antigenic epitopes in effective immune responses can be 




In this paper we report the identification of a new minor H Ag that is derived from 
a short alternative protein encoded by an NMD targeted transcript. LB-TTK-1D 
was identified by combining conventional WGAs with a 1000GP-based analysis. 
For the HLA-A*02:01 restricted minor H Ag recognized by T-cell clones of type 
H4, WGAs revealed a number of highly correlating SNPs located within or in close 
proximity of the TTK gene on chromosome 6, but identification of the antigenic 
epitope failed. We therefore hypothesized that the true encoding variation 
was absent in the 1.1M SNPs as measured by the Illumina array, but might be 
included in the comprehensive data of the 1000GP. Since no experimental data 
for individuals included in the 1000GP were available, we performed an in silico 
analysis in which the most significant hit as identified by WGAs was investigated 
for association with all genetic variations as present on chromosome 6 in the 
1000GP. This ‘inferred correlation’ led to identification of rs240226 as the 
minor H Ag encoding SNP with peptide RLHDGRVFV as the recognized epitope, 
confirming the power of 1000GP based identification strategies. 
SNP rs240226 was found to be located in an intron region of the main TTK 
transcript that is retained as unique exon in alternative transcript TTK-007. 
As TTK-007 contains a PTC, it will be subjected to the surveillance mechanism 
of NMD leading to rapid mRNA degradation. Despite its low expression, we 
confirmed the presence of the NMD transcript in EBV-LCLs, and demonstrated 
that the transcript is sufficiently expressed for efficient induction of T cells in 
vivo and T-cell recognition of LB-TTK-1D on various (non-)hematopoietic cells in 
vitro. Recognition of LB-TTK-1D on EBV-LCL was partly abolished by proteasome 
inhibitor bortezomib (data not shown), indicating that the antigenic peptide 
is processed via the canonical route of the ubiquitin-proteasome system. 
Remarkably, T-cell recognition of LB-TTK-1D on different cell types of (non-)
hematopoietic origin did not correlate with expression of the TTK-007 NMD 
transcript. This may be explained by a discrepancy between mRNA levels of the 
TTK-007 NMD-transcript and protein expression or turnover21. Alternatively, 
peptide source-independent differences in antigen processing may be 
responsible for this finding, such as variations in TAP expression or proteasome 
activity between tested cells. 
Over the past years there has been much debate about the intracellular location 
and timing of NMD and how much protein is actually produced by NMD 
transcripts22,23. Evidence from in vitro data using model antigens accumulates, 
stating that NMD transcripts lead to newly-synthesized but dysfunctional 
proteins that are rapidly degraded via the ubiquitin-proteasome pathway, also 
defined as a subgroup of defective ribosomal products (DRiPs). These DRiPs are 
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presumably generated in the pioneering rounds of translation, and artificial 
DRiPs encoded by NMD transcripts have been shown to produce significant 
amounts of peptides for MHC class I presentation9,12,24. However, the endogenous 
contribution of these DRiPs relative to stable mature proteins to the total pool of 
antigenic peptides remains unclear11,12,22,25. 
Our data now demonstrate for the first time that endogenous NMD transcripts 
can function as a relevant source for antigenic peptides. Epitopes originating 
from DRiPs have been proposed to provide useful target antigens for antitumor 
immunotherapy9,26-28. It is expected that the repertoire of antigenic peptides on 
tumor cells will be increased upon inhibition of the rapid degradation process of 
NMD. This is supported by the finding that specific inhibition of NMD resulted in 
production of neoantigens and induction of specific immune responses, leading 
to tumor rejection in vivo28. Strikingly, in our experiments only one of eleven 
HLA-A*02:01 and LB-TTK-1D positive leukemic cell samples was recognized 
by our endogenous DRiP recognizing T-cell clone 10-5, while expression levels 
of the NMD transcript were comparable according to q-PCR, suggesting that 
targeting DRiP-derived peptides may not necessarily be a powerful anti-tumor 
strategy. 
Taken together, the strategy behind the discovery of this new minor H Ag is 
relevant for future epitope identification studies. More importantly, the finding 
that this endogenous antigen is encoded by an NMD transcript and only 
occasionally expressed on tumor cells provides novel insights in the specificity 
and potential risks of DRiP-directed immunotherapeutic applications.
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Hematopoiesis-restricted minor histocompatibility antigens (MiHA) are relevant targets for immunotherapy, 
since donor T cells for these antigens stimulate anti-tumor 
immunity after HLA-matched allogeneic hematopoietic stem 
cell transplantation (alloSCT) without undesired side effects. 
We here identified LB-ITGB2-1 as hematopoiesis-restricted 
MiHA that is presented on leukemic cells, but not on non-
hematopoietic cells, by a new approach in which whole genome 
and transcriptome analysis are combined. In this approach, 
RNA-sequence data were analyzed and LB-ITGB2-1 was shown 
to be encoded by an alternative transcript in which intron 
sequences are retained. Our data show that (1) LB-ITGB2-1 is 
a relevant antigen to stimulate donor T cells after alloSCT by 
vaccination or adoptive transfer and (2) RNA-sequence analysis 
is a valuable tool to identify immune targets that are encoded 








Purpose: In HLA-matched allogeneic hematopoietic stem cell 
transplantation (alloSCT), donor T cells recognizing minor histocompatibility 
antigens (MiHA) can mediate desired anti-tumor immunity as well as 
undesired side effects. MiHA with hematopoiesis-restricted expression 
are relevant targets to augment anti-tumor immunity after alloSCT 
without side effects. To identify therapeutic MiHA, we analyzed the in 
vivo immune response in a patient with strong anti-tumor immunity after 
alloSCT. 
Experimental design: T-cell clones recognizing patient, but not donor, 
hematopoietic cells were selected for MiHA discovery by whole genome 
association scanning. RNA-sequence data from the GEUVADIS project 
were analyzed to investigate alternative transcripts and expression 
patterns were determined by microarray analysis and q-PCR. T-cell 
reactivity was measured by cytokine release and cytotoxicity.
Results: T-cell clones were isolated for two HLA-B*15:01-restricted 
MiHA. LB-GLE1-1V is encoded by a non-synonymous single nucleotide 
polymorphism (SNP) in exon 6 of GLE1. For the other MiHA, an associating 
SNP in intron 3 of ITGB2 was found, but no SNP disparity was present in 
the normal gene transcript between patient and donor. RNA-sequence 
analysis identified an alternative ITGB2 transcript containing part of intron 
3. Q-PCR demonstrated that this transcript is restricted to hematopoietic 
cells and SNP positive individuals. In silico translation revealed LB-ITGB2-1 
as HLA-B*15:01-binding peptide, which was validated as hematopoietic 
MiHA by T-cell experiments. 
Conclusions: Whole genome and transcriptome analysis identified LB-
ITGB2-1 as MiHA encoded by an alternative transcript. Our data support 
the therapeutic relevance of LB-ITGB2-1 and illustrate the value of RNA-





Patients with hematological malignancies can be successfully treated with 
allogeneic hematopoietic stem cell transplantation (alloSCT)1. Unfortunately, 
the desired anti-tumor effect often coincides with undesired side effects against 
healthy tissues, a complication known as Graft-versus-Host Disease (GvHD)2. In 
HLA-matched alloSCT, donor-derived T cells recognize polymorphic peptides 
presented by HLA molecules on patient cells. These polymorphic peptides or 
so-called minor histocompatibility antigens (MiHA) are not expressed on donor 
cells due to differences in single nucleotide polymorphisms (SNPs) between 
patient and donor. Donor T cells recognizing MiHA with ubiquitous expression 
on (non-)hematopoietic tissues induce not only the desired anti-tumor or Graft-
versus-Leukemia (GvL) effect, but also undesired GvHD3. T-cell depletion of the 
stem cell graft significantly reduces the incidence and severity of GvHD, but it 
also diminishes the GvL effect. Therefore, to preserve GvL reactivity, donor T 
cells are administered after alloSCT as donor lymphocyte infusion (DLI)2,4. The 
development of GvL reactivity after DLI can be accelerated by co-administration 
of interferon-α (IFN-α)5,6. Analysis of the diversity and tissue distribution of 
MiHA targeted in T-cell responses after alloSCT (and DLI) provides insight into 
the immunobiology of GvL reactivity and GvHD. Moreover, MiHA with restricted 
expression on cells of the hematopoietic lineage are relevant targets for T-cell 
therapy to stimulate GvL reactivity after alloSCT without GvHD, since donor T 
cells for these MiHA will eliminate all patient hematopoietic cells, including the 
malignant cells, while sparing healthy hematopoiesis of donor origin.
Since 2009, MiHA discovery accelerated due to development of whole genome 
association scanning (WGAs). In WGAs as exploited in our laboratory, association 
between T-cell recognition and SNP genotype is investigated for a panel of 80 
EBV-B cell lines, which have been genotyped for 1.1x106 SNPs7-14. Associating 
SNPs as identified by WGAs may directly encode MiHA or serve as genetic markers 
for antigen-encoding SNPs that are in linkage disequilibrium with associating 
SNPs, but which have not been captured by the array. In general, MiHA can be 
easily identified by WGAs if one or more associating SNPs are present in coding 
gene regions. However, antigen discovery is more difficult if associating SNPs are 
found in genomic regions that are unknown to code for protein. In a number of 
cases, we sequenced the primary gene transcript as derived from the associating 
genomic region, but failed to determine any SNP disparity between patient and 
donor, suggesting that the MiHA may be encoded by an alternative transcript. 
MiHA encoded by alternative transcripts have previously been reported for ACC-
615 and ZAPHIR16. Although MiHA discovery may become more efficient when 
EBV-B cell lines are used which have been sequenced for their entire genome to 








by alternative transcripts from these regions may remain difficult to discover.
In this study, we explored whether RNA-sequence data as available in the 
GEUVADIS project18,19 can be used to identify MiHA encoded by alternative 
transcripts. With the rapid advances in sequence technology, the GEUVADIS 
consortium set out to combine whole genome and transcriptome data and 
sequenced all mRNA expressed in 462 EBV-B cell lines from the 1000 Genomes 
Project (1000GP)20. We analyzed RNA-sequence data to unravel alternative 
transcripts from ITGB2 located in a genomic region that has been identified by 
WGAs for a T-cell clone recognizing an HLA-B*15:01-restricted MiHA. Our data 
showed the successful discovery of LB-ITGB2-1 as MiHA encoded by an alternative 
ITGB2 transcript by RNA-sequence analysis. We showed that the alternative ITGB2 
transcript is hematopoiesis-restricted and specifically expressed in SNP-positive 
individuals. Moreover, T-cell experiments demonstrated specific recognition and 
lysis of malignant (and healthy) hematopoietic cells, but no reactivity against 
skin-derived fibroblasts. As such, our data support the therapeutic relevance of 
LB-ITGB2-1 as hematopoiesis-restricted MiHA to augment GvL reactivity after 





Patient 6940 (HLA-A*01:01; A*02:01, B*07:02, B*15:01, C*04:01, C*07:02) 
is a female patient with chronic myeloid leukemia (CML) in blast crisis, who 
was transplanted with a T-cell depleted stem cell graft from her HLA-matched 
brother (donor 7034). She developed a cytogenetic relapse 5.5 months after 
alloSCT for which she was successfully treated with DLI and IFN-α. GvL reactivity 
after DLI was accompanied with acute GvHD grade II of the skin that evolved 
into chronic GvHD.
Cell samples and culture
Peripheral blood, bone marrow and skin biopsies were obtained from patient 
6940, donor 7034 and third party individuals after approval by the LUMC 
Institutional Review Board and informed consent according to the Declaration 
of Helsinki. Peripheral blood and bone marrow mononuclear cells (PBMC 
and BMMC) were isolated by Ficoll-Isopaque separation and cryopreserved. 
Fibroblasts (FB), EBV-B cells and T cells were cultured as described previously9,10. 
In house generated EBV-B cell lines were authenticated using short-tandem 
repeat profiling upon freezing of stock vials. FB were cultured in the absence or 
presence of 200 IU/ml IFN-γ (Boehringer Ingelheim, Alkmaar, The Netherlands) 
for 4 days. Patient CML cells in blast crisis in a PBMC sample obtained at diagnosis 
prior to alloSCT were in vitro modified into professional antigen-presenting cells 
(CML-APC) as described previously21.
Isolation of T-cell clones
T cells were isolated from patient PBMC obtained 9 weeks after DLI using the 
MACS pan T isolation kit according to manufacturer’s instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). CML-APC and CD3 T cells were co-incubated for 
48h at a 1:10 stimulator: responder ratio. Cultures were stained with CD8-FITC 
and CD137-APC monoclonal antibodies and activated CD137-positive CD8 T 
cells were single cell-sorted by flow cytometry. Isolated T cells were stimulated 
with irradiated feeders, phytohemagglutinin and IL-2 as previously described9. 
Growing T-cell clones were analyzed for reactivity and restimulated every 14 









Stimulator cells (5-15x103 cells/well) and T cells (2x103 cells/well) were co-
incubated overnight in 384-wells plates (Greiner Bio-One, Frickenhausen, 
Germany). IFN-γ release was measured by ELISA (Sanquin, Amsterdam, The 
Netherlands). In chromium release assays, target cells (1x103 cells/well) were 
labeled for 1h at 37°C with 100μCi (3.7MBq) Na2
51CrO4 and co-incubated with 
T cells for 10h at a 10:1 effector-target ratio. Specific lysis was calculated as 
previously described10.
Whole Genome Association scanning
SNP-genotyped EBV-B cell lines (n=71) were transduced with an LZRS retroviral 
vector22 encoding HLA-B*15:01. Mean transduction efficiency was 24% (range 
12-34%) and T-cell recognition was measured by IFN-γ ELISA. WGAs was 
performed as described previously9.
RNA-sequence analysis
EBV-B cell lines for which RNA-sequence data (.bam files) are available in 
the GEUVADIS project18,19 were selected for SNP genotype (+/+, +/- and -/-) 
from the 1000 Genomes Project20. For each SNP (rs760462 and rs9945924), 
two representative individuals per genotype were selected and bigwig files 
containing RNA-sequence coverage and mapping and split coordinates of 
individual sequence reads in the region of interest for these EBV-B cell lines 
were uploaded to the UCSC genome browser23.
Prediction of HLA binding peptides
Transcript sequences were translated in forward reading frames and protein 
sequences were fed into the NetMHC algorithm24,25 to search for peptides with 
predicted binding to HLA class I alleles. Peptides were synthesized, dissolved in 
DMSO and tested for T-cell recognition by IFN-γ ELISA9. 
Microarray gene expression and q-PCR analysis
Malignant and healthy hematopoietic cells and untreated as well as IFN-γ 
pretreated non-hematopoietic cells of different origins were processed 
and hybridized on Human HT-12 v3/4 Expression BeadChips (Illumina, San 
Diego, CA, USA) as described previously26. The data have been deposited 
in NCBI’s Gene Expression Omnibus27 and are accessible through GEO Series 
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Figure 1: T-cell clones 1-30 and 1-55 recognize HLA-B*15:01-restricted minor histocompatibility antigens
(A) Reactivity of T-cell clones 1-30 (open bars) and 1-55 (filled bars) was measured against patient FB, which 
were cultured in the absence or presence of IFN-γ, and against HLA-B*15:01 positive, MiHA-positive and 
-negative EBV-B cells (third party EBV 6703 and DON EBV, respectively). T-cell reactivity was measured by IFN-γ 
ELISA after overnight co-incubation. 
(B) Recognition of a panel of 71 SNP-genotyped EBV-B cell lines after retroviral transduction with HLA-B*15:01 
was measured for T-cell clones 1-30 and 1-55. Each symbol represents IFN-γ production as measured by ELISA 
after overnight co-incubation of the T-cell clone with each individual EBV-B cell line.
(C-D) Association was measured between T-cell recognition of 71 EBV-B cell lines transduced with HLA-B*15:01 
and each of the 1.1x106 SNPs as measured by the Illumina 1M array. SNPs are grouped by their location on 
chromosomes (x-axis). SNPs with p-value <10-3 are displayed. 
(C) Whole genome association scanning results for clone 1-30 are depicted. Strong association was found for 
SNP rs2275260 (p=1.08x10-13) located in exon 6 of the GLE1 gene, which encodes an amino acid change in a 
peptide with strong predicted binding to HLA-B*15:01 by NetMHC: GQ(V/I)RLRALY.
(D) Whole genome association scanning results for clone 1-55 are depicted. Strong association was found for 












accession number GSE76340 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE76340). For quantitative RT-PCR, RNA isolation, cDNA synthesis 
and q-PCR were performed as described previously28. ITGB2 expression 
was measured using forward primer 5’-CTCTCTCAGGAGTGCACGAA-3’ and 
reverse primer 5’-CCCTGTGAAGTTCAGCTTCTG-3’ for the normal ITGB2 
transcript and forward primer 5’-CAGCAGCTGCCGGGAATG-3’ and reverse 
primer 5’-CTCAGTCCGAGGACAGACGG-3’ for the alternative ITGB2 transcript. 
Expression was normalized for expression of the HMBS reference gene.
Colony Forming Assay
Bone marrow or peripheral blood samples from patients with CML were pre-
incubated with irradiated (35 Gy) T-cell clones at E:T ratios of 3:1. After overnight 
co-inucbation, single cell suspensions (2x104 target cells) were seeded in 30-mm 
culture dishes containing IMDM with methylcellulose and growth factors (GM-
CSF, stem cell factor, IL-3, erythropoietin and other supplements (MethoCult 
H4434, STEMCELL technologies SARL, Grenoble, France). As controls, single 
cell suspensions and irradiated T cells at E:T ratios of 3:1 were seeded without 
pre-incubation. After 14 days of culture, colony forming units for granulocyte/
macrophage (CFU-GM, CFU-G, CFU-M) and erythroid (CFU-E, BFU-E) lineages 
were enumerated as well as colony forming units containing early progenitors 




























































NA07048 -/- NA11893 +/- NA11994 +/+
Figure 2: Discovery of an alternative ITGB2 gene transcript by whole transcriptome analysis 
ITGB2 is located on chromosome 21q22.3 and is encoded on the reverse strand. Graphs (A-C) are screenshots 
from the UCSC genome browser at http://genome.ucsc.edu. Exons are indicated by black rectangles. The 
genomic location of associating SNP rs760462 as identified by WGAs is indicated by the vertical dotted lines.
(A) RNA-sequence reads aligning with exon 2 to 4 of the ITGB2 gene in the human HG19 reference genome are 
shown for 6 individuals representing different genotype groups for associating SNP rs760462 (+/+, +/- and -/-). 
The y-axis indicates the total number of RNA-sequence reads aligning with the indicated ITGB2 gene region as 
summarized peaks. Substantial numbers of RNA-sequence reads aligned with exon regions of the ITGB2 gene 
in all 6 individuals irrespective of genotyping for SNP rs760462.  












Isolation of T-cell clones for HLA-B*15:01-restricted MiHA
To identify MiHA that are targeted in effective GvL responses, CD8 T-cell clones 
were isolated from a patient with CML in blast crisis who entered into complete 
remission upon treatment with DLI after HLA-matched alloSCT. Development 
of anti-tumor immunity after DLI was accompanied with grade II skin GvHD. 
CD3 T cells isolated from patient PBMC after DLI were stimulated with a patient 
CML sample obtained at diagnosis prior to alloSCT. This sample consisted of a 
heterogeneous population, containing 63% mature myelocytes, 17% immature 
CD34-negative cells and 17% immature CD34-positive cells. To enhance antigen-
presentation by the stimulator cells, patient CML cells were modified in vitro into 
professional APC (CML-APC). After 48h of stimulation, CD8 T cells were single 
cell sorted by flow cytometry based on expression of activation marker CD137. 
Growing CD8 T-cell clones (n=112) were tested for reactivity against patient 
CML-APC, donor EBV-B, donor EBV-B pulsed with a mix of known MiHA peptides 
and patient FB, which were cultured in the absence or presence of IFN-γ to 
mimic the inflammatory environment of the early post-transplantation period. 
T-cell clones recognizing known MiHA peptides were specific for LB-ADIR-1F29 
and LRH-130. T-cell clones 1-30 and 1-55 recognized unknown MiHA.  
T-cell clones 1-30 and 1-55 both showed strong reactivity against patient CML-
APC (data not shown) as well as EBV-B cells from an HLA-B*15:01 third party 
individual, but not against donor EBV-B (Figure 1A). In contrast to clone 1-30 
that strongly recognized patient FB after pretreatment with IFN-γ, T-cell clone 
1-55 lacked reactivity against (IFN-γ pretreated) FB. To identify the epitopes that 
are recognized by clones 1-30 and 1-55, WGAs was performed to investigate 
association between T-cell recognition and all individual SNPs as measured by 
the array (Figure 1B)9. For clone 1-30, WGAs identified 4 SNPs that associated 
with T-cell recognition of HLA-B*15:01-transduced EBV-B cells with the same 
in intron 3 that are transcriptionally active, as indicated by black rectangles in (A). The intron 3 region located 
upstream (right panel) of associating SNP rs760462 was transcribed in individuals who were +/+ for this SNP, 
but not in individuals who were -/- for this SNP. Since this region is not transcribed in +/- individuals, we 
concluded that this region is unlikely to encode the MiHA. In contrast, the intron 3 region located downstream 
of associating SNP rs760462 (left panel) was transcribed in both +/- and +/+ individuals, but not in -/- individuals, 
and we therefore analyzed this region in more detail. 
(C) Single RNA-sequence reads aligning within the gene region spanning exon 3 to exon 4 of ITGB2 in the 
human HG19 reference genome are shown for 3 individuals representing different SNP genotypes (+/+, +/- 
and -/-). RNA-sequence reads that aligned with continuous 75bp sequences that do not cross exon boundaries 
(exon reads) were excluded from the analysis. All other RNA-sequence reads, which included intron reads 
and split reads, are shown. Split reads are indicated by two boxes connected with a horizontal line and are 
the result of distinct genomic sequences that are joined in a transcript due to splicing. All split reads in -/- 
individuals contained exon 3 connected to exon 4, indicating expression of the normal ITGB2 gene transcript. 
In addition to split reads for the normal gene transcript, split reads in which exon 3 was connected to intron 3 
sequences located downstream of the associating SNP were measured in +/- and +/+ individuals. These data 
indicate that in addition to the normal gene transcript, an alternative ITGB2 transcript in which part of intron 
3 is retained is expressed in individuals who are positive for associating SNP rs760462. 
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p-value of 1.08x10-13 (Figure 1C). These 4 SNPs were located in a genomic 
region on chromosome 9 comprising the GLE1 gene. One non-synonymous SNP 
(rs2275260) in exon 6 encoded an amino acid change in the GLE1 protein. Patient 
and donor peptides GQ(V/I)RLRALY with predicted binding to HLA-B*15:01 by 
NetMHC24,25 were identified and the V-variant (LB-GLE1-1V) was recognized by 
clone 1-30. 
For clone 1-55, WGAs identified a single SNP on chromosome 21 with a p-value 
of 4.26x10-13 (Figure 1D). This SNP rs760462 A/G (A; recognized allele) is located 
in intron 3 (region between exon 3 and exon 4) of the ITGB2 gene. Sanger 
sequencing of the normal ITGB2 transcript did not detect any SNP differences 
between patient and donor. In addition, intron sequences comprising rs760462 
were translated in silico in different reading frames, but no peptide with 
predicted binding to HLA-B*15:01 was found (data not shown).
Whole transcriptome analysis enabled discovery of a MiHA encoded by 
an alternative ITGB2 gene transcript.
Since no SNP differences were found between patient and donor in the normal 
ITGB2 transcript, we explored the possibility that the MiHA as recognized by 
clone 1-55 may be encoded by an alternative transcript. RNA-sequence data 
were analyzed as online available in the GEUVADIS project18,19 for 462 EBV-B 
cell lines for which corresponding whole genome sequences are available 
in the 1000GP. Based on SNP genotypes, EBV-B cell lines were selected from 
individuals who were homozygous positive (A/A; +/+), heterozygous (A/G; +/-) or 
homozygous negative (G/G; -/-) for associating SNP rs760462. For 6 individuals, 
RNA-sequence reads were aligned with the ITGB2 gene in the human HG19 
reference genome. Figure 2A depicts transcriptional activity summarized as 
RNA-sequence read coverage surrounding SNP rs760462. Significant numbers 
of reads aligned with exon regions in the ITGB2 gene, but also two regions in 
intron 3 were transcribed. The intron region located upstream of associating 
SNP rs760462 (Figure 2B, right) was transcriptionally active in individuals who 
were +/+, but not in individuals who were +/- or -/- for this SNP. Since this region 
was not transcribed in +/- individuals, we considered it unlikely that this region 
Frame Length (aa) Peptide Logscore Affinity Bind Level
2 9 GQAPGGNYL 0.545 136 WB
2 10 GQAGFFPSPF 0.735 17 SB
2 11 EQGGQAPGGNY 0.435 451 WB
2 11 LGQAGFFPSPF 0.613 65 WB








encoded the MiHA. In contrast, the intron 3 region downstream from rs760462 
was transcribed in both +/- and +/+, but not in -/- individuals (Figure 2B, left) and 
we therefore investigated this region in more detail.
To determine the sequence composition of the alternative transcript, we 
evaluated alignments of split reads in the region that spanned exon 3 to exon 
4 (Figure 2C). Split reads are the result of distinct genomic sequences that are 
joined in a transcript due to splicing. In -/- individuals, all split reads contained 
exon 3 connected to exon 4, indicating expression of the normal ITGB2 
transcript. In contrast, in +/- and +/+ individuals, split reads for the normal ITGB2 
transcript were found as well as split reads in which exon 3 was connected to 
intron 3 sequences located two nucleotides downstream from the associating 
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Figure 3: Discovery of a MiHA that is encoded by the alternative ITGB2 gene transcript
(A) The exact sequence composition of the alternative ITGB2 transcript in which exon 3 is connected to a 
region in intron 3 located downstream from associating SNP rs760462 was deduced from split read analysis 
as shown in Figure 2C. The alternative transcript was translated and a peptide with strong predicted binding 
(SB) to HLA-B*15:01 as revealed by NetMHC is depicted by the dark gray bar. Sequences are depicted using 
Geneious (version 7.1.5 created by Biomatters, available from http://www.geneious.com/)
(B) Identification of the HLA-B*15:01-restricted epitope as recognized by T-cell clone 1-55. Peptide 
GQAGFFPSPF, which has been identified as peptide with strong predicted binding to HLA-B*15:01 by NetMHC, 
was titrated on donor EBV-B cells and co-incubated with T-cell clone 1-55. T-cell recognition after overnight 
co-incubation was measured by IFN-γ ELISA.
(C) Intron 3 sequences of ITGB2 for patient and donor including rs760462 (in bold) are depicted. SNP rs760462 
likely creates a splice acceptor site (CAG), resulting in retention of intron sequences located 2 nucleotides 





SNP. These data demonstrate expression of an alternative ITGB2 gene transcript 
in which part of intron 3 is retained. Expression of the alternative transcript 
was restricted to SNP-positive individuals, likely due to rs760462 introducing a 
cryptic splice acceptor site. 
Next, we translated the alternative ITGB2 transcript in silico (Figure 3A) and 
protein sequences starting from exon 3 were fed into the NetMHC algorithm24,25 
to identify peptides with predicted binding to HLA-B*15:01. Four peptides 
were identified (Table 1) including one 10-mer peptide with strong predicted 
binding to HLA-B*15:01. T-cell experiments confirmed that GQAGFFPSPF is 
the MiHA (LB-ITGB2-1) that is recognized by clone 1-55 with picomolar affinity 
(Figure 3B). In conclusion, RNA-sequence analysis revealed an alternative ITGB2 
transcript in which associating SNP rs760462 generates a splice acceptor site, 
thereby creating a transcript in which part of intron 3 is retained (Figure 3C). 
This alternative transcript encoded the MiHA recognized by T-cell clone 1-55. 
As such, whole transcriptome analysis enabled discovery of LB-ITGB2-1 as MiHA 
encoded by an alternative ITGB2 transcript.
Whole transcriptome analysis also allows discovery of antigens 
generated by exon skipping
To explore the value of RNA-sequence analysis for identification of antigens 
beyond LB-ITGB2-1, we analyzed RNA-sequence data for ACC-6, an HLA-B*40:01-
restricted MiHA encoded by an HMSD splice variant15. Expression of ACC-6 is 
associated with SNP rs9945924 in intron 2 of HMSD located 5 bp downstream of 
exon 2. We selected EBV-B cell lines from GEUVADIS and compared HMSD gene 
transcription between individuals with different genotypes for the associating 
SNP (+/+, +/- and -/-). In contrast to ITGB2, no transcriptional activity was found 
outside exon regions of HMSD (Figure S1A). Furthermore, we noticed that exon 2 
was not transcribed in +/+ individuals, while transcription was clearly detectable 
in -/- and +/- individuals, indicating that SNP rs9945924 is associated with exon 
2 skipping. Split read analysis revealed that only the full-length HMSD transcript 
was expressed in -/- individuals, whereas both the full-length transcript as well 
as an alternative transcript in which exon 1 was connected to exon 3 were 
detectable in +/- individuals (Figure S1B). In +/+ individuals, only the alternative 
transcript was expressed in which exon 2 is skipped. In silico translation of the 
full-length and alternative HMSD transcripts revealed that exon 2 skipping 
deleted the ATG start site, thereby producing a shorter protein in an alternative 
reading frame (Figure S2). We searched the alternative protein for peptides with 
predicted binding to HLA-B*40:01 and identified 8 peptides (Table S1), including 
ACC-6 epitope MEIFIEVFSHF15, in which M is encoded by the first start codon in 
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Figure 4: Expression of the alternative ITGB2 transcript is hematopoiesis-restricted
(A) Expression of ITGB2 and GLE1 as determined by microarray gene expression analysis. GLE1 is broadly 
expressed, whereas expression of ITGB2 is hematopoiesis-restricted. Indicated is the probe fluorescence 
as measured on Illumina Human HT-12 v3/4 BeadChips. Hematopoietic cells included bone marrow and 
peripheral blood mononuclear cells (BMMC and PBMC), B cells, T cells, monocytes (Mono), macrophages type 
I and II (MØ1 and MØ2), (im)mature DC (imDC and matDC), hematopoietic stem cells (CD34 HSC), EBV-B and 
PHA-T cells. Malignant hematopoietic cells included acute lymphoblastic leukemia (CD19 ALL), acute myeloid 
leukemia (CD33 AML), chronic myeloid leukemia (CD34 CML), chronic lymphocytic leukemia (CD5 CD19 CLL) 
and multiple myeloma (CD138 MM), which were sorted by flow cytometry based on the indicated markers. 
Non-hematopoietic cells as indicated by the shaded panel included skin FB and KC which were cultured in the 
absence or presence of IFN-γ, hepatocytes, colon and small intestine epithelial cells and lung epithelial cells. 
(B) Expression of normal and alternative ITGB2 transcripts as measured by quantitative RT-PCR in various cell 
types. Malignant hematopoietic samples included unselected PBMC or BMMC samples obtained at diagnosis 
with >30% malignant cells. Genotyping results (+ or -) for LB-ITGB2-1 associating SNP rs760462 are depicted. 
Expression of the normal (open bars) and alternative (filled bars) ITGB2 transcripts is shown after correction 





also allows discovery of antigens encoded by alternative transcripts that are 
generated by exon skipping.  
T cells for LB-ITGB2-1 were detected after DLI
Next, we investigated the in vivo immunodominance of LB-ITGB2-1 during GvL 
reactivity and compared the T-cell frequency for LB-ITGB2-1 at 9 weeks after 
DLI with other MiHA that were targeted in patient 6940 (LB-ADIR-1F, LRH-1 
and LB-GLE1-1V). Tetramer analysis in Figure S3 shows that T cells for LB-ADIR-
1F (0.46%), LRH-1 (0.35%), LB-ITGB2-1 (0.14%) and LB-GLE1-1V (0.08%) are 
involved in the immune response after DLI. T-cell frequencies prior to DLI were 
absent or significantly lower for all MiHA, indicating induction and expansion of 
a polyclonal T-cell response targeting multiple MiHA during GvL reactivity. 
Expression of the alternative ITGB2 transcript is hematopoiesis-
restricted
Since T-cell clone 1-55 recognized patient CML-APC, but failed to react with FB 
(Figure 1A), and expression of ITGB2 has been reported to be hematopoiesis-
restricted31, we investigated whether T cells for LB-ITGB2-1 could contribute to 
GvL responses. Microarray gene expression analysis26 confirmed that the normal 
ITGB2 transcript was expressed in malignant and healthy hematopoietic cells, 
but not in non-hematopoietic cells from organs that are often targeted in GvHD 
Figure 5: T cells for LB-ITGB2-1 showed specific recognition and lysis of primary leukemic cells
(A) Reactivity of T-cell clones 1-55 (left panel) and 1-30 (middle panel) was measured against CML-APC and FB 
cultured in the absence or presence of IFN-γ of patient 6940 as well as patient PBMC obtained at diagnosis (PAT 
CML) and samples from other HLA-B*15:01 patients suffering from CML or AML who were positive for SNP 
rs760462 (LB-ITGB2-1) or rs2275260 (LB-GLE1-1V). Donor EBV-B cells and third party HLA-B*15:01 individuals 
negative for one or both SNPs were included as controls. The allo-HLA-A*02:01 reactive T-cell clone HSS1238 
(right panel) was included as a control clone. Genotyping results (+ or -) for LB-ITGB2-1 (left panel), LB-GLE1-1V 
(middle panel) and HLA-A*02:01 (right panel) are indicated for the selected samples. Mean release of IFN-γ 
of duplicate wells as measured by IFN-γ ELISA after overnight co-incubation of T cells and stimulator cells is 
depicted.
(B) Lysis of patient CML-APC as well as other primary leukemic samples from HLA-B*15:01 patients who were 
positive for SNP rs760462 (LB-ITGB2-1) was measured in a 10h chromium-release assay. Clone 1-30 (LB-GLE1-
1V), clone HSS12 (allo-HLA-A*02:01) and clone FK47 (HA-1H)39 were included as controls. Genotyping results 
(+ or -) for LB-ITGB2-1 (upper left panel), LB-GLE1-1V (upper right panel), HLA-A*02:01 (lower left panel) and 
HA-1H (lower right panel) are shown. Mean specific lysis of triplicate wells is depicted.
(C) Lysis of CML progenitor cells from patient 6940 (PAT CML 6940) and patient 1159 (CML 1159) in a colony 
forming assay. Peripheral blood or bone marrow samples were pre-incubated overnight in the absence or 
presence of T cells at an E:T ratio of 3:1. After overnight co-incubation, single cell suspensions were seeded 
and colony forming units were enumerated for the granulocyte/macrophage (CFU-GM, CFU-G, CFU-M) and 
erythroid (CFU-E, BFU-E) lineages as well as for mixed granulocyte/macrophage/erythroid lineages. Indicated 
are the number of CFU for the LB-ITGB2-1 specific T-cell clone 1-55, the HA-1H specific T-cell clone FK47 
and the HLA-A*02:01 specific alloreactive T-cell clone HSS12. Patient 6940 is positive for LB-ITGB2-1 and 
HLA-A*02:01, but negative for HA-1H. Patient 1159 is positive for HLA-A*02:01, but negative for LB-ITGB2-1 
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(skin, liver, gut, lung) (Figure 4A). In contrast, the GLE1 gene, which encodes 
the MiHA recognized by clone 1-30, was ubiquitously expressed in (non-)
hematopoietic tissues.
Since LB-ITGB2-1 is encoded by a splice variant, we investigated the tissue 
distribution of this alternative transcript and compared expression with the 
normal transcript by quantitative RT-PCR. In line with RNA-sequence data 
(Figure 2), the alternative transcript was only detected in SNP rs764062-
positive individuals, while the normal transcript was measured in all individuals 
irrespective of SNP genotype (Figure 4B). In all hematopoietic samples from 
SNP-positive individuals, expression of the ITGB2 splice variant followed the 
same pattern as the normal transcript. Moreover, both normal and alternative 
transcripts were undetectable in non-hematopoietic (IFN-γ pretreated) FB, 
indicating that these gene products are regulated by the same hematopoiesis-
restricted transcriptional control elements. 
T cells for LB-ITGB2-1 showed specific recognition and lysis of primary 
leukemic cells
To investigate whether LB-ITGB2-1 has therapeutic potential, we selected 
leukemic cells of different origins and compared T-cell recognition of these 
samples as measured by IFN-γ ELISA with FB cultured in the absence or 
presence of IFN-γ. Figure 5A shows that clone 1-55 recognized patient CML-APC 
as well as EBV-B cells and (im)mature DC from HLA-B*15:01 individuals who 
were positive for SNP rs760462 (left panel). EBV-B cells were strongly recognized 
by clone 1-55, while ITGB2 gene expression was low (Figure 4B), which can be 
explained by high surface expression of HLA class I, costimulatory and adhesion 
molecules as well as other molecules involved in intracellular antigen processing 
and presentation. In addition, various CML and AML samples from SNP-positive 
patients were recognized, while the T-cell clone failed to recognize (IFN-γ 
pretreated) patient FB as well as FB from another SNP-positive individual. Clone 
1-55 also failed to recognize patient CML cells obtained at diagnosis and CML 
cells from another SNP-positive patient. Both CML samples expressed low levels 
of the alternative ITGB2 transcript by quantitative RT-PCR (Figure 4B). One AML 
sample (AML 1235) was only moderately recognized by clone 1-55, while the 
ITGB2 gene was highly expressed, which can be due to suboptimal expression of 
HLA class I or other accessory molecules in antigen processing and presentation. 
Furthermore, we showed that T cells for LB-ITGB2-1 mediated specific lysis of 
primary leukemic cells in a 10h chromium-release assay (Figure 5B, left upper 
panel). T-cell clone 1-55 mediated specific lysis of patient CML-APC, whereas 








CML samples from other SNP-positive individuals were lysed. 
To investigate the capacity of LB-ITGB2-1 specific T cells to recognize primary 
AML cells directly ex vivo, we performed a flow cytometry experiment in 
which we measured upregulation of activation marker CD137 on LB-ITGB2-1 
tetramer-positive T cells as circulating in peripheral blood after DLI. The data 
showed significant upregulation of CD137 on T-cell clone 1-55 after 36h of 
stimulation with unmanipulated AML cells that were positive for LB-ITGB2-1 and 
HLA-B*15:01 as compared to HLA-B*15:01 positive AML cells that were negative 
for LB-ITGB2-1 (Figure S4). However, numbers of LB-ITGB2-1 tetramer-positive T 
cells in peripheral blood were too low to draw firm conclusions.
Finally, we performed a colony forming assay to investigate the capacity of LB-
ITGB2-1 specific T cells to kill the malignant hematopoietic progenitor cells 
as present in peripheral blood from our patient with CML at diagnosis. After 
overnight co-incubation of CML precursor cells with clone 1-55, a 50% reduction 
was measured in number of colonies differentiated into the granulocyte/
macrophage (CFU-GM, CFU-G and CFU-M) or erythroid (CFU-E and BFU-E) 
lineage as well as in number of colonies from more early progenitor cells 
containing a mixture of cells differentiated into granulocyte/macrophage/
erythroid lineages (Figure 5C). No decrease in number of colonies was observed 
when the sample was co-incubated with a negative control T-cell clone for HA-
1H and no decrease in number of colonies was measured when clone 1-55 was 
co-incubated with a bone marrow sample from another patient with CML who 
was negative for LB-ITGB2-1 (CML 1159). In conclusion, the data demonstrated 
that LB-ITGB2-1 specific T cells are capable of mediating specific cytolysis of 
malignant hematopoietic (progenitor) cells, further supporting the therapeutic 
value of LB-ITGB2-1 as target for immunotherapy to induce GvL reactivity after 




In this study, we identified two HLA-B*15:01-restricted MiHA targeted by CD8 T 
cells in a CML patient who reached complete remission after alloSCT and DLI. T 
cells for these MiHA showed strong recognition of patient CML-APC, but different 
reactivity against patient FB. Whereas clone 1-30 strongly recognized patient FB 
after pretreatment with IFN-γ, clone 1-55 consistently failed to recognize (IFN-γ 
pretreated) FB. We performed WGAs and identified SNP rs2275260 in the GLE1 
gene that encodes LB-GLE1-1V, the MiHA recognized by clone 1-30. For clone 
1-55, associating SNP rs760462 in intron 3 of the ITGB2 gene was found, but 
no SNP disparity could be detected in the normal ITGB2 transcript between 
patient and donor. We here demonstrated that RNA-sequence analysis enabled 
discovery of LB-ITGB2-1 as MiHA encoded by an alternative transcript. LB-GLE1-
1V and LB-ITGB2-1 have population frequencies of 35% and 21% in Caucasians 
(www.hapmap.org), resulting in disparity rates of 24% and 23%, respectively. 
LB-GLE1-1V and LB-ITGB2-1 are the first MiHA presented by HLA-B*15:01, 
which is expressed in approximately 7% of Caucasians32. As such, these MiHA 
may contribute to broaden immunotherapy to treat patients with hematological 
malignancies after alloSCT. 
Since no SNP disparity was found in the normal ITGB2 transcript, we investigated 
whether an alternative transcript could encode the MiHA. Alternative transcripts 
have previously been reported to encode ACC-615 and ZAPHIR16. ACC-6 is a MiHA 
that has been identified by screening a cDNA library, whereas ZAPHIR has been 
discovered by WGAs followed by cloning and screening transcript variants as 
detected by PCR. For ITGB2, we failed to detect splice variants by PCR using 
different primers. Retrospectively, this failure can be explained by absence of 
the forward or reverse primer binding site in the alternative ITGB2 transcript. We 
therefore investigated ITGB2 gene transcription by RNA-sequence analysis. In 
the GEUVADIS project, RNA-sequencing has been performed for EBV-B cell lines 
for which also whole genome data are available in the 1000GP, allowing us to 
select samples for the associating SNP as identified by WGAs. We demonstrated 
that associating SNP rs760462 functions as splice acceptor site, thereby creating 
an alternative transcript in which part of intron 3 is retained that encodes LB-
ITGB2-1. We also demonstrated that antigens encoded by alternative transcripts 
that are generated by exon skipping can be elucidated by RNA-sequence analysis. 
As such, RNA-sequence analysis is a powerful tool to identify MiHA, but its value 
will extend beyond the field of alloSCT, since neoantigens and other immune 








In human melanoma and small cell lung carcinoma, tumor-specific mutations 
can create neoantigens. Neoantigens resemble minor histocompatibility 
antigens in that peptides are presented by HLA surface molecules and 
recognized by specific T cells33. The chance that neoantigens are targeted after 
antibody or T-cell therapy is dependent on mutational load and tumors with 
<1 mutations per Mb coding DNA have been proposed to present neoantigens 
only occasionally. This prediction, however, is based on the presence of tumor-
specific mutations in coding exons leading to single amino acid changes in the 
normal protein reading frame, whereas alternative splicing, a mechanism that 
is frequently deregulated in cancer34,35, has not been taken into consideration. 
However, when tumor-specific mutations in pre-mRNA sequences, spliceosomal 
components or regulatory factors lead to aberrant splicing, transcript variants 
can be produced that encode entirely new protein products. By producing these 
aberrant proteins, alternative splicing may create a repertoire of neoantigens 
that is larger than expected based on mutational load. Since alternative 
transcripts can be elucidated by RNA-sequence analysis, this technique may also 
be relevant to apply to cancer neoantigen discovery.  
Since T cells for LB-ITGB2-1 strongly recognized patient CML-APC, but lacked 
reactivity against patient FB, and ITGB2 has been reported as gene with 
hematopoiesis-restricted expression, we investigated whether LB-ITGB2-1 may 
be a new MiHA with therapeutic relevance. We confirmed hematopoiesis-
restricted expression of the normal ITGB2 transcript by microarray gene 
expression analysis and demonstrated that the alternative ITGB2 transcript 
followed the same pattern of expression by q-PCR (Figure 4). Therapeutic 
relevance of LB-ITGB2-1 was supported by recognition and lysis of leukemic 
samples of different origins by specific T cells. Only two CML samples, both 
expressing low levels of the alternative ITGB2 transcript, were not recognized. 
One sample was obtained from our patient at diagnosis prior to alloSCT. This 
sample mainly consisted of mature myelocytes, which are poor stimulators of an 
immune response. Previous work in our laboratory demonstrated that leukemic 
APC can be generated from CD34-positive CML precursor cells as illustrated by 
detection of BCR-ABL36. We therefore in vitro modified patient CML cells and 
used CML-APC to stimulate and isolate T cells after DLI. Our data demonstrated 
that CML-APC expressed increased levels of the alternative ITGB2 transcript 
(Figure 4B) and mediated specific T-cell recognition and lysis (Figure 5). Thus, T 
cells for LB-ITGB2-1 as present in the DLI may have contributed to GvL reactivity 
in vivo by eliminating BCR-ABL positive CML precursor cells as detected during 
cytogenetic relapse after alloSCT. This is further substantiated by the finding 
that T cells for LB-ITGB2-1 are capable of mediating specific cytolysis of CML 
progenitor cells in a colony forming assay. Moreover, T cells for LB-ITGB2-1 may 
have contributed to GvL reactivity by eliminating CML cells with an acquired APC 
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phenotype in vivo either by co-infusion of IFN-α, which is known to accelerate 
the GvL response5,6 or indirectly upon cytokine release by T cells with other 
specificities than LB-ITGB2-1. We previously demonstrated in a NOD/scid mouse 
model that human CML cells in lymphoid blast crisis can become professional 
APC after treatment with DLI37. In our patient, T cells for three other MiHA than 
LB-ITGB2-1 were detected after DLI (Figure S3), including LB-GLE1-V, which is 
strongly recognized on patient CML cells at diagnosis (Figure 5A). As such, T cells 
for LB-ITGB2-1 may have cooperated with other immune cells in mediating the 
anti-tumor response. In contrast to patient CML cells at diagnosis, the majority 
of unmodified leukemic samples were directly recognized and lysed by clone 
1-55, suggesting that in most patients, T cells for LB-ITGB2-1 are capable of 
mediating GvL reactivity independent of whether the leukemic cells become 
professional APC. 
In our patient, GvL reactivity after DLI was accompanied with development 
of grade II skin GvHD. Since ITGB2 is not expressed in non-hematopoietic cell 
types and LB-ITGB2-1 could not be recognized on FB even after treatment 
with inflammatory cytokines, we consider it more likely that T cells with other 
specificities than LB-ITGB2-1 as measured in our patient after DLI (Figure S3) 
mediated or contributed to development of GvHD.
In summary, an integrated strategy of whole genome and transcriptome analysis 
enabled identification of LB-ITGB2-1 as HLA-B*15:01-restricted MiHA encoded 
by an alternative transcript. The alternative ITGB2 transcript was shown to be 
expressed in leukemic cells of different origins, whereas no expression was found 
in non-hematopoietic cell types from organs that are often targeted in GvHD. 
In addition, T cells specifically recognized and lysed leukemic cells of different 
origins, whereas no reactivity was measured against patient FB. As such, our 
data demonstrate the discovery of a new hematopoiesis-restricted MiHA with 
therapeutic value to augment GvL reactivity after alloSCT without GvHD and 
illustrate the relevance of RNA-sequence analysis to identify immune targets 
that are encoded by alternative transcripts and created by genetic variants. 
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PBMC from patient 6940 prior to DLI (168 days after alloSCT) and 9 weeks after 
DLI (232 days after alloSCT) were stained with PE-conjugated HLA-B*15:01 
tetramers containing LB-ITGB2-1 (GQAGFFPSPF) or LB-GLE1-1V (GQVRLRALY), 
PE-conjugated HLA-A*02:01 tetramer containing LB-ADIR-1F1, or APC-
conjugated HLA-B*07:02 tetramer containing LRH-12. Cells were subsequently 
stained with Alexa Fluor 700-conjugated CD8 (Invitrogen, Life Technologies, 
Carlsbad, CA, USA) in combination with FITC-conjugated CD4, CD14 and CD19 
(BD/Pharmingen, San Diego, CA, USA). Propidium Iodide (PI) was added to 
exclude dead cells. Tetramer-positive T cells were measured within CD8-positive 
cells that were negative for CD4, CD14 and CD19. Tetramers were constructed 
as described previously3 with minor modifications. Acquisition was performed 
on a LSRII analyzer (BD, San Jose, CA, USA) using DIVA software. 
Ex vivo T-cell activation assay
PBMC from patient 6940 obtained 9 weeks after DLI (232 days after alloSCT) 
were thawed and CD8 T cells were isolated using the MACS CD8 untouched 
isolation kit according to manufacturer’s instructions (Miltenyi Biotec). Primary 
AML-M5 samples were depleted of CD8 T cells using CD8 microbeads (Miltenyi 
Biotec). Peripheral blood CD8 T cells or clone 1-55 (7x104) were co-incubated 
for 36 hours with primary AML samples in a 1:1 stimulator:responder ratio. 
Cultures were stained with LB-ITGB2-1 or LB-ADIR-1F tetramers as described 
above, followed by staining with Alexa Fluor 700-conjugated CD8 (Invitrogen) 
and APC-conjugated CD137 in combination with FITC-conjugated CD4, CD14, 
CD19, CD33 and CD34 (BD/Pharmingen, San Diego, CA, USA). Propidium Iodide 
(PI) was added to exclude dead cells. Activated T cells that were double positive 
for CD137 and tetramer were measured within CD8-positive cells that were 
negative for CD4, CD14, CD19, CD33 and CD34. Acquisition was performed on a 
LSRII analyzer (BD) and analysis was performed using FlowJo Software (Tree Star, 








61,617,000 61,618,000 61,619,000 61,620,000 61,621,000 61,622,000
Ensembl Gene Predictions - archive Ensembl 75 - feb2014





































































exon 3exon 2exon 1



















Supplemental Figure 1: RNA-sequence analysis allows discovery of antigens generated by exon skipping. 
HMSD is located on chromosome 18q22.1 and is encoded on the forward strand. Graphs (A-B) are screenshots 
from the UCSC genome browser at http://genome.ucsc.edu. Exons are indicated by black rectangles. The 
genomic location of SNP rs9945924 is indicated by the vertical dotted line.
(A) RNA-sequence reads aligning with the HMSD gene in the HG19 human reference genome are shown 
as summarized peaks for 6 individuals representing different genotype groups for MiHA associating SNP 
rs9945924 (+/+, +/- and -/-). 
(B) Single RNA-sequence reads aligning with the HMSD gene in the HG19 reference genome are shown for 3 
individuals with different genotyping for MiHA associating SNP (+/+, +/- and -/-). All exon reads were excluded 
from this analysis, whereas intron and split reads were retained. Analysis of split reads (indicated by boxes 
connected with horizontal lines) showed that in -/- individuals, only reads for the full-length HMSD transcript 
(exon 1 connected to exon 2 and exon 2 connected to exon 3) are present. In +/- individuals, split reads for 
both the full-length as well as an alternative transcript (exon 1 connected to exon 3) are found, whereas only 
split reads for the alternative transcript were measured in +/+ individuals. These data show expression of an 












Supplemental Figure 2: Sequence composition of the alternative HMSD transcript. 
Nucleotide and translated protein sequences as deduced from split read analysis are shown for the full-length 
and alternative HMSD transcripts. The alternative HMSD transcript is generated by exon 2 skipping, resulting in 
a transcript in which exon 1 is connected to exon 3 in which the normal translational start site is deleted. The 
alternative transcript was translated in three forward reading frames and the known ACC-6 epitope is depicted 



























specific tetramer - PE or APC
Pre-DLI
Post-DLI
LB-ITGB2-1 LB-ADIR-1F LRH-1 LB-GLE1-1V
0.04 0.04 0.13 0.01
0.14 0.46 0.35 0.08
1041030 105 1041030 105-807
-9741041030 105-807 1041030 105-807 1041030 105 1041030 105-807
Supplemental Figure 3: T cells for LB-ITGB2-1 are detected after DLI
PBMC from patient 6940 before (upper panels) and 9 weeks after DLI (lower panels) were stained with PE-
labeled HLA-tetramers for LB-ITGB2-1, LB-ADIR-1F or LB-GLE1-1V or the APC-labeled tetramer for LRH-1. 
Tetramer-positive T cells were measured within CD8-positive cells that were negative for CD4, CD14 and CD19. 
Indicated is the percentage of CD8 cells that are positive for the specific tetramer.
Frame Length (aa) Peptide Logscore Affinity (nM) Bind Level
2 9 GELGHFVLV 0.739 16 SB
2 9 SEVKMEIFI 0.619 61 WB
2 11 SEVKMEIFIEV 0.603 73 WB
2 11 MEIFIEVFSHF* 0.578 96 WB
2 9 IEVFSHFLL 0.825 6 SB
2 11 IEVFSHFLLQL 0.747 15 SB
2 9 TELTLNMCL 0.621 60 WB
2 11 TELTLNMCLEL 0.672 34 SB
















































































Supplemental Figure 4: Ex vivo activation of LB-ITGB2-1 specific T cells
CD8 T cells from PBMC from patient 6940 obtained 9 weeks after DLI (left and middle panels) and clone 1-55 
(right panels) were co-incubated with primary AML-M5 samples for 36 hours. Cultures were stained with PE-
labeled HLA-tetramers for LB-ITGB2-1 (middle and right panels) or LB-ADIR-1F (left panels) and subsequently 
with APC-labeled CD137 monoclonal antibody. Activated CD137-tetramer-double positive T cells were 
measured within CD8-positive cells that were negative for CD4, CD14, CD19, CD33 and CD34. Indicated is the 
percentage of CD8 cells that are double positive for the specific tetramer and CD137.
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Allogeneic stem cell transplantation (alloSCT) can be a curative treatment 
for hematological malignancies. However, the desired anti-tumor or Graft-
versus-Leukemia (GvL) effect is often accompanied by undesired side effects, 
a complication known as Graft-versus-Host Disease (GvHD). GvL and GvHD are 
both caused by donor-derived T cells recognizing alloantigens on patient cells. 
The main challenge for treatment of hematological malignancies with alloSCT is 
to evoke an effective GvL response, while limiting the risk of severe GvHD. 
One strategy to reduce GvHD is depletion of donor T cells from the stem cell 
graft. However, T-cell depletion also reduces the anti-tumor effect, and therefore, 
donor T cells are often administered after alloSCT by donor lymphocyte 
infusion (DLI) to reinstall GvL reactivity. In HLA-matched alloSCT, alloantigens 
recognized by donor T cells are polymorphic peptides presented by HLA surface 
molecules on patient cells, the so-called minor histocompatibility antigens 
(MiHA). Depending on the tissue distribution of the MiHA that are targeted, 
donor T cells can mediate GvL in the absence or presence of GvHD. Donor T cells 
recognizing MiHA on the malignant hematopoietic cells of the patient mediate 
GvL reactivity, whereas donor T cells recognizing MiHA that are expressed on 
healthy non-hematopoietic tissues induce GvHD. MiHA with hematopoiesis-
restricted expression are relevant targets for immunotherapy, since donor T cells 
for these MiHA will attack the malignant cells of the patient, while sparing healthy 
hematopoietic cells of donor origin. In this thesis, in vivo immune responses after 
alloSCT and DLI were analyzed with respect to specificity, diversity, frequency 
and dynamics of MiHA-specific T cells. This analysis is relevant (1) to provide 
insight into the immunobiology of GvL and GvHD after alloSCT and (2) to identify 
MiHA with restricted expression on hematopoietic cells as potential targets for 
T-cell therapy to stimulate GvL reactivity after alloSCT without GvHD. 
MiHA can be identified by strategies in which alloreactive T cells from patients 
with clinical immune responses after alloSCT are isolated and characterized for 
their specificity and potential role in GvL and GvHD. In Whole Genome Association 
scanning (WGAs), T-cell recognition of a panel of test cells is investigated for 
association with individual SNPs to discover new MiHA. Most MiHA identified 
thus far are generated by non-synonymous SNPs in primary gene transcripts. 
However, the frequencies of MiHA encoded by other genetic variations are likely 
to be underestimated, since polymorphisms in coding regions are generally 
more easily identified by current discovery techniques. This thesis is focused 
on efficient characterization of MiHA with potential therapeutic relevance, 
including MiHA that are encoded or produced by alternative transcripts.
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In chapter 2 we describe a microarray gene expression database in which cell 
types are included that are often targeted in GvL and GvHD. The dataset was 
designed to provide a platform for efficient generation of expression profiles. 
Malignant and healthy hematopoietic cell samples as well as non-hematopoietic 
cell types cultured under normal and inflammatory conditions were included. 
Gene expression was investigated by Illumina HT12.0 microarrays and quality 
control analysis confirmed the cell-type origin of the samples and excluded 
contamination with peripheral blood cells. Microarray data were validated by 
quantitative RT-PCR (q-PCR) and a strong correlation in gene expression was 
observed between both platforms. We also established an inflammatory gene 
signature by comparing microarray data from different non-hematopoietic 
cells after pre-treatment with IFN-γ. Furthermore, we demonstrated the value 
of the microarray dataset to estimate efficacy and toxicity of potential targets 
for immunotherapy of hematological malignancies and concluded that our 
microarray database provides a relevant platform to analyze and select candidate 
antigens with hematopoietic (lineage)-restricted expression as potential targets 
for immunotherapy of hematological cancers.
In chapter 3 we characterized LB-ARHGDIB-1R as MiHA with potential 
therapeutic relevance after alloSCT. Using microarray gene expression analysis 
as described in chapter 2, we demonstrated that expression of ARHGDIB is 
hematopoiesis-restricted with the exception of intermediate mRNA expression 
in endothelial cells. T-cell recognition experiments confirmed hematopoiesis-
restricted expression, since skin-derived fibroblasts and keratinocytes were not 
recognized even when cultured under inflammatory conditions. Intermediate 
ARHGDIB gene expression in endothelial cells was confirmed by q-PCR, but 
recognition of endothelial cells by LB-ARHGDIB-1R-specific T cells was limited 
and only observed under inflammatory conditions. In contrast, recognition of 
primary leukemic cells was strong and LB-ARHGDIB-1R-specific T cells were 
capable of mediating specific lysis in long-term cytotoxicity assays. Finally, we 
investigated the in vivo immunogenicity of LB-ARHGDIB-1R and found specific T 
cells in 8 out of 10 transplanted patients of which 4 responses could be measured 
directly ex vivo. One patient with relapsed Non-Hodgkin’s lymphoma showed 
high T-cell frequencies after DLI, coinciding with induction of long-lasting GvL 
reactivity without GvHD. The data thus support the relevance of LB-ARHGDIB-
1R as therapeutic target with potential to induce selective GvL reactivity after 
alloSCT.
Although WGAs is an efficient method, MiHA discovery failed for 20-30% of 
T-cell clones for which associating SNPs were successfully identified by WGAs 
using a panel of EBV-B cell lines that are genotyped for 1.1M SNPs. For these 







disparities were present in primary gene transcripts. Therefore, in chapter 4 we 
adopted an ‘inferred correlation’ approach using whole genome data from the 
1000 Genomes Project and identified LB-TTK-1D as new MiHA. SNP rs240226 
was identified as the genetic variation that encodes this MiHA and the SNP 
was shown to be located in an alternative transcript of the TTK gene. In this 
alternative transcript, which is composed of 5 exons, a premature termination 
codon is present in exon 4, that targets the transcript to rapid degradation by 
nonsense mediated decay (NMD). LB-TTK-1D has been identified as first human 
natural T-cell target that is translated from an endogenous NMD transcript. 
Expression of the alternative TTK transcript was barely detectable as confirmed 
by q-PCR and LB-TTK-1D-specific T cells were shown to recognize cell types 
of hematopoietic as well as non-hematopoietic origin. Strikingly, despite low 
expression of the alternative TTK transcript, T cells for LB-TTK-1D showed robust 
recognition of EBV-LCLs while they failed to recognize the majority of primary 
leukemic samples, indicating that T-cell recognition also depends on other factors 
than gene expression and presence of the SNP and HLA-A*02:01 restriction 
allele. These findings are important for prospective MiHA identification studies 
and contribute to our understanding of the biology behind epitope generation 
in effective immune responses.  
In chapter 5, we implemented whole transcriptome analysis in our WGAs 
approach and successfully identified LB-ITGB2-1 as MiHA encoded by an 
alternative transcript. WGAs identified an associating SNP rs760462 in the 
ITGB2 gene and subsequent RNA-sequence analysis revealed a region with 
transcriptional activity in intron 3 directly downstream from the associating 
SNP. Analysis of single RNA-sequence reads showed that rs760462 introduced 
a cryptic splice site and created an alternative transcript that is only expressed 
in MiHA-positive individuals. The immunogenic epitope was translated from the 
alternative transcript downstream from the SNP. We also demonstrated that 
RNA-sequence analysis allows discovery of antigens generated by exon skipping 
as illustrated for ACC-6, which is a MiHA translated from an alternative transcript 
of HMSD. We further analyzed the therapeutic value of LB-ITGB2-1 and found 
that the tissue distribution of the alternative transcript followed expression of 
the normal ITGB2 transcript. Expression of the normal and alternative ITGB2 
transcripts was hematopoiesis-restricted, which was confirmed by lack of T-cell 
reactivity against fibroblasts even under inflammatory conditions. In contrast, 
LB-ITGB2-1-specific T cells were clearly capable of mediating specific recognition 
and cytolysis of malignant hematopoietic (progenitor) cells, further supporting 
the therapeutic value of LB-ITGB2-1 as target for immunotherapy to induce GvL 
reactivity after alloSCT without GvHD. 
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In summary, we efficiently identified and characterized various MiHA that are 
generated by different mechanisms. Microarray gene expression data were 
successfully used to estimate the tissue distribution of the MiHA and whole 
genome and transcriptome data were implemented in the WGAs approach to 
allow identification of MiHA encoded by alternative transcripts. By combining 
these strategies, we are now able to efficiently identify a large variety of 
MiHA, evaluate their role in GvL or GvHD and select hematopoiesis-restricted 








Discovery of minor histocompatibility antigens 
Most currently known MiHA have been identified by a forward approach 
in which T cells isolated from in vivo immune responses are used to identify 
antigens1. To focus forward approaches on discovery of MiHA with therapeutic 
relevance, T cells can be specifically isolated for their reactivity against patient 
leukemic cells or other hematopoietic cells of patient origin based on surface 
expression of activation marker CD137 after in vitro stimulation. Furthermore, 
T cells can be screened for their reactivity against patient fibroblasts cultured 
in the absence or presence of IFN-γ already in the first round of screening to 
rapidly separate T-cell clones for broadly expressed MiHA from T-cell clones 
recognizing potential hematopoiesis-restricted MiHA. This strategy has been 
followed in chapter 5 and led to successful discovery of LB-ITGB2-1 as new 
MiHA with potential therapeutic relevance. In reverse strategies, peptides 
encoded by genes with hematopoiesis-restricted expression are selected to 
search for specific T cells2. Although the reverse strategy allows for more direct 
identification of hematopoietic MiHA, the method is based on prediction of HLA 
binding peptides by computer algorithms and often leads to detection of T cells 
that fail to recognize antigens that are naturally processed and presented on 
malignant cells3. Inclusion of an additional step for selection of peptides that 
are present in the HLA ligandome of EBV-LCL or leukemic cells improves the 
efficiency of the reverse strategy to identify antigens that are truly presented 
on the cell surface4,5, but decreases the sensitivity of the approach, since not all 
T-cell epitopes can be detected as eluted peptides in the HLA ligandome by mass 
spectrometry. Furthermore, in reverse strategies, a number of HLA alleles need 
to be selected to predict HLA binding by the algorithm and, if pMHC-multimers 
are needed for T-cell isolation, only HLA alleles can be selected for which these 
complexes can be produced. 
In a reverse strategy that has been followed in our laboratory by Hombrink et 
al.3, peptides encoded by the hematopoiesis-restricted ITGB2 gene were initially 
selected as candidate targets with therapeutic relevance, but no high avidity T 
cells for these peptides could be found. In chapter 5 of this thesis, LB-ITGB2-1 
has successfully been identified as new hematopoiesis-restricted MiHA by a 
forward approach. There are several reasons why discovery of this epitope by 
the reverse strategy failed. First, LB-ITGB2-1 is presented by HLA-B*15:01, which 
has not been selected as HLA class I allele in the NetMHC prediction algorithm 
of the reverse strategy. Second, the MiHA is encoded by an alternative transcript 
in which intron sequences are retained and only peptide candidates encoded 
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by exon regions were included in the reverse strategy. Finally, the SNP that is 
present in the patient and absent in the donor genome functioned as splice 
acceptor site and created a new transcript. The MiHA was not directly encoded 
by the SNP, but translated from an intron region that is located downstream 
from the SNP, while only peptide candidates with polymorphic amino acids that 
are directly encoded by SNPs were selected in the reverse strategy. As such, 
the MiHA as identified in this thesis by forward approaches provide relevant 
insight into which steps of the reverse approach should be improved to make 
the strategy more efficient. 
Whole Genome Association scanning 
WGAs is an efficient method for MiHA discovery. In WGAS, T-cell recognition of a 
panel of test cells is investigated for association with individual SNP genotypes6-9. 
This strategy led to successful discovery of LB-ARHGDIB-1R (chapter 3), LB-
TTK-1D (chapter 4) and LB-ITGB2-1 (chapter 5). Although WGAS is an efficient 
method, MiHA discovery still fails for approximately 20-30% of T-cell clones for 
which associating SNPs in intron regions have been found, but no SNP disparity 
is present in the primary gene transcript. These MiHA are likely encoded by 
alternative transcripts in which intron sequences are retained. In this thesis, we 
successfully implemented publicly available whole genome and transcriptome 
data to enable discovery of MiHA encoded by alternative transcripts. 
Recently, Oostvogels et al.10 described the use of whole genome data from the 
1000 Genomes Project11 for identification of a MiHA that could not be elucidated 
with EBV-LCL that were SNP-genotyped with lower resolution. Publicly available 
whole genome data can thus successfully be applied to increase the efficiency 
of MiHA discovery. In chapter 4, we followed a similar approach and applied 
whole genome data from the 1000 Genomes Project in an ‘inferred correlation’ 
analysis for identification of LB-TTK-1D. The strongest associating SNP in the 
‘inferred correlation’ is located in an intron region that is included as alternative 
exon in a transcript splice variant. In contrast to LB-ITGB2-1, the SNP directly 
encodes the MiHA and the alternative transcript is expressed in both patient 
and donor cells. Identification of LB-TTK-1D thus illustrates that MiHA discovery 
is most efficient when WGAs is performed with a panel of test cells of which all 
SNPs as present in the entire genome are known. Furthermore, in chapter 5 
we investigated whether publicly available RNA-sequence data can be used to 
elucidate alternative transcripts, thereby facilitating discovery of MiHA that are 
encoded by intron sequences or other regions located outside known exons. We 
developed an integrated whole genome and transcriptome analysis method in 
which WGAs and RNA-sequence data are combined and successfully identified 







sequence data is that the exact architecture of the transcript can be revealed 
and that actual gene sequences are shown that are involved in transcription and 
splicing. As such, whole genome and transcriptome methods may significantly 
contribute to discovery of MiHA that are encoded by alternative transcripts, 
a category of MiHA that has previously been underestimated as compared to 
MiHA that are encoded by non-synonymous SNPs in primary gene transcripts. 
Characterization of MiHA that are encoded by alternative transcripts also 
provides additional insight into mechanisms of transcription, translation and 
antigen processing and presentation. LB-TTK-1D, for example, is a MiHA encoded 
by a transcript that is targeted by nonsense mediated RNA decay. As shown in 
chapter 4, the alternative transcript of TTK is barely detectable in all cell types 
tested, but the MiHA is produced in EBV-B cells at levels that are sufficient to be 
consistently recognized by the T-cell clone, demonstrating that aberrant protein 
products as translated from alternative transcripts can provide a relevant source 
of T-cell antigens.  
Therapeutic minor histocompatibility antigens
Targeting therapeutic MiHA allows for selective induction of GvL after 
alloSCT without GvHD. However, only a limited number of MiHA have thus 
far been reported to be therapeutically relevant. Effective identification and 
characterization methods have resulted in an increase in known MiHA and 
the criteria for therapeutic relevance need to be strictly defined to distinguish 
therapeutic MiHA from other antigens. In this thesis, the following criteria for 
therapeutic MiHA have been taken into consideration. First, gene expression for 
therapeutic MiHA should be hematopoiesis-restricted. Second, hematopoiesis-
restricted expression of the MiHA should be confirmed by T-cell recognition. 
Third, MiHA-specific T cells should be capable of mediating specific lysis of primary 
leukemic cells. Finally, MiHA should be relevant targets for immunotherapy in a 
substantial number of transplanted patients based on population frequency of 
the MiHA (optimal frequency between 20-80%) and HLA class I restriction allele 
(frequency of at least 5%) and presence of donor T cells in the transplanted 
immune system that are capable of targeting the MiHA. The latter criterion 
is only required if MiHA-specific T cells in therapeutic strategies need to be 
induced in vivo or isolated from in vivo immune responses. 
As first step in MiHA characterization, gene expression profiles are determined 
to select MiHA with hematopoiesis-restricted expression. Microarray and RNA-
sequence data allow efficient analysis of gene expression profiles irrespective of 
HLA type and MiHA status. Although gene expression data from various platforms 
have become increasingly available over the years through online tools such as 
Gene Expression Omnibus, the value of these datasets for selection of genes 
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with hematopoiesis-restricted expression remains limited due to potential 
contamination of non-hematopoietic tissues with peripheral blood cells and 
no possibility to investigate gene expression under inflammatory conditions. 
We therefore performed microarray gene expression analysis as described in 
chapter 2 on various cell types involved in GvL and GvHD and cultured specific 
non-hematopoietic cell types in the absence and presence of IFN-γ to exclude 
contamination with peripheral blood cells and enable gene expression analysis 
under inflammatory conditions. We showed that expression of largely the same 
set of genes is induced by IFN-γ as compared to T-cell culture supernatant in 
which multiple cytokines including IFN-γ, IL-13, TNF-α and IL-2 were released. 
As such, we established a gene expression signature for inflammation and 
demonstrated that IFN-γ can be used as single agent to mimic inflammation.  
Disadvantages of microarray data are that reliable gene expression analysis 
between different cell types requires good probe quality and that quantitative 
expression analysis between different genes is not possible due to differences in 
probe quality. Collection of RNA-sequence data from a panel of hematopoietic 
and non-hematopoietic cell types would be ideal to enable direct comparison 
of gene expression irrespective of probe quality. RNA-sequence data would 
also provide the additional advantage to investigate expression of alternative 
transcripts. As described in chapter 4, we developed q-PCR to measure expression 
of the normal TTK transcript, since quality of the microarray probe was poor and 
did not allow gene expression analysis. This in contrast to the microarray probe 
for the normal ITGB2 transcript for which a reliable hematopoiesis-restricted 
gene expression profile could be established in chapter 5. In both chapters, we 
also developed q-PCR to measure expression of the alternative transcripts that 
encode LB-TTK-1D and LB-ITGB2-1, illustrating the benefit that RNA-sequence 
data would provide as high-throughput platform to measure and compare 
expression of normal and alternative gene transcripts. 
The question remains how strict the requirement for hematopoiesis-restricted 
expression needs to be followed in order to use MiHA as targets for immunotherapy 
for selective GvL induction. In chapter 3, we showed intermediate expression of 
ARHGDIB in endothelial cells, but there was no evidence for systemic toxicity as 
a result of vascular damage in any of the patients with circulating LB-ARHGDIB-
1R-specific T cells, suggesting that MiHA with predominant expression in 







As second step, T-cell recognition experiments are performed to confirm 
hematopoiesis-restricted expression of the MiHA. MiHA will only be selected 
as candidates with potential therapeutic relevance when their specific T 
cells are capable of recognizing primary leukemic cells and fail to recognize 
non-hematopoietic cell types. This approach is limited by the availability of 
samples that are positive for the relevant MiHA and HLA restriction allele. Skin-
derived fibroblasts can be quite easily obtained and cultured and are therefore 
commonly included as non-hematopoietic targets. In our T-cell recognition 
experiments, skin fibroblasts are also pre-treated for 4 days with IFN-γ, since 
we previously noticed that T-cell recognition is often significantly enhanced 
when skin fibroblasts are cultured under inflammatory conditions12,13. This is 
probably due to stimulated intracellular antigen processing and presentation 
and increased surface expression of HLA class I, adhesion and co-stimulatory 
molecules, thereby lowering the threshold for T-cell recognition. This is also 
illustrated for LB-GLE-1V in chapter 5. T cells for this broadly expressed MiHA 
strongly react with skin fibroblasts after pre-treatment with IFN-γ, whereas they 
fail to recognize these cells when cultured in the absence of IFN-γ. In chapter 
3 we investigated potential toxicity of LB-ARHGDIB-1R-specific T cells against 
endothelial cells, since intermediate ARHGDIB expression was measured in 
these cells by microarray expression analysis and q-PCR. The data showed that T 
cells for LB-ARHGDIB-1R strongly recognized primary leukemic cells of different 
origin, while T-cell reactivity against human umbilical vein endothelial cells was 
limited even when cultured under inflammatory conditions. The necessity to 
measure T-cell recognition of primary leukemic cells and non-hematopoietic cell 
types is also illustrated by T cells for LB-TTK-1D. Induction of T cells for LB-TTK-
1D coincided with GvL reactivity and EBV-LCL are strongly recognized in WGAs, 
but T cells for LB-TTK-1D failed to recognize the majority of primary leukemic 
samples in chapter 4, while fibroblasts were recognized. This demonstrates that 
gene expression can be used as first step to distinguish hematopoiesis-restricted 
MiHA with potential therapeutic relevance from other MiHA that are more 
broadly expressed, but that T-cell recognition experiments remain required to 
demonstrate surface presentation of the MiHA on primary leukemic cells and 
confirm lack of reactivity against non-hematopoietic cells. 
As third step cytotoxicity assays are performed to confirm actual lysis of primary 
leukemic cells by the MiHA-specific T cells. Cytotoxicity assays include 4 hours 
chromium-release assays, overnight to 48 hours FACS-based survival assays 
and colony forming assays after overnight co-incubation of hematopoietic 
progenitor cells with MiHA-specific T cells. We selected all hematopoiesis-
restricted MiHA for which T-cell mediated lysis could be detected in any assay as 
MiHA with potential therapeutic relevance, but noticed significant differences 
in cytotoxic potential. As described in chapter 3 and 5, T cells for LB-ARHGDIB-
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1R and LB-ITGB2-1 mediated specific lysis of primary leukemic samples only 
after long-term co-incubation, whereas T cells for HA-1 were already capable of 
mediating specific lysis of primary leukemic cells after 4 hours of co-incubation. 
It is unknown whether this difference in cytolytic capacity between MiHA-
specific T cells is entirely mediated by the affinity of the TCR for its peptide-HLA 
complex or whether also other factors such as expression of adhesion and co-
stimulatory or co-inhibitory molecules or T-cell maturation contribute to their 
capacity to degranulate and release cytotoxic mediators. Therefore, TCR gene 
transfer experiments in which different MiHA-specific TCRs are introduced into 
the same virus-specific T cells are relevant to confirm that the affinity of the TCR 
for the MiHA as presented by HLA class I on primary leukemic cells is sufficiently 
high to mediate strong specific lysis. The actual contribution of MiHA-specific 
T cells to the anti-tumor response, however, still requires detailed analysis of 
the specificity, diversity and frequency of in vivo immune responses in GvL and 
GvHD. This analysis may provide relevant insight whether the requirement for 
cytotoxic potential of MiHA-specific T cells as measured in vitro needs to be 
more strictly defined. 
The fourth step in selection of MiHA with potential therapeutic relevance is 
to determine their immunogenicity. However, this step is only relevant for 
therapies in which MiHA-specific T cells are induced in vivo or isolated from 
in vivo immune responses after alloSCT. In chapter 3 we demonstrate that LB-
ARHGDIB-1R is immunogenic in 80% of MiHA-disparate patient-donor pairs and 
is therefore the most immunogenic MiHA identified thus far14. Different factors 
may contribute to in vivo immunogenicity, including the number and affinity of 
different TCRs that are capable of recognizing the MiHA in the naïve repertoire 
of donor T cells, to which extent the peptide is “foreign” for the donor immune 
system and the level of surface expression of the MiHA on antigen presenting 
cells, which is relevant for induction of an effective immune response. More 
insight into these mechanisms would allow better application of different active 
and passive forms of immunotherapy for hematological malignancies in which 
MiHA are used as targets. 
Immunobiology of GvL and GvHD
Although in vivo immune responses as induced after alloSCT have been analyzed 
in detail in a number of patients, the exact composition and difference in immune 
responses in GvL and GvHD is still not fully understood. GvL and GvHD are both 
mediated by polyclonal T-cell responses in which multiple MiHA are targeted, 
but frequencies of MiHA-specific T cells in patients with GvHD are higher than in 
patients without GvHD (van Bergen et al., 2016, submitted). Furthermore, there 







since T cells for broadly-expressed and hematopoiesis-restricted MiHA are 
induced in both patient groups. The MiHA-specificities as described in chapter 5 
of this thesis showed a similar pattern: T cells for hematopoiesis-restricted LRH-
1 and LB-ITGB2-1 and T cells for broadly expressed LB-ADIR-1F and LB-GLE1-1V 
were isolated from the same patient with combined GvL and GvHD after DLI. 
Since immune responses in GvHD are generally strong, it can be hypothesized 
that T-cell reactivity against non-hematopoietic tissues needs to exceed a certain 
threshold in order to develop GvHD. This suggests that for selective induction 
of GvL, MiHA with predominant expression in hematopoietic cells may also be 
therapeutically relevant as long as recognition of non-hematopoietic tissues 
remains below the threshold. 
Analysis of the in vivo immune response in chapter 5 also resulted in T-cell 
isolation for known MiHA, i.e. LRH-1 and LB-ADIR-1F. The finding that T cells 
for known MiHA are often found in different patients has been described 
previously14,15, but is unexpected based on the number of non-synonymous SNPs 
that two unrelated individuals differ from each other (~10,000) and suggests 
that the total number of existing MiHA may be restricted and follow rules for 
immunodominance which cannot be predicted by measuring SNP disparities. 
It is unknown which factors determine the immunogenicity of an HLA binding 
peptide. Surface expression of the MiHA on professional APC may be critical, 
since these cells are known to prime specific T cells in the initiation phase of the 
immune response. However, the affinity and diversity of TCRs as expressed by 
T cells in the naïve donor repertoire that are able to react with a specific MiHA 
is probably also important and may depend on surface expression of the MiHA 
on the APC. If the total number of existing MiHA is indeed restricted, it can 
be expected that the majority of MiHA will be identified in the coming years. 
This would allow composition of a toolbox of pMHC-multimers to measure and 
follow MiHA-specific T cells in GvL and GvHD in the majority of patients treated 
with alloSCT (and DLI). Such an analysis would confer significant knowledge 
to the composition of in vivo immune responses in GvL and GvHD and allow 
analysis and comparison of efficacy and toxicity of different alloSCT treatment 
modalities. Although processing and presentation of peptides is important, the 
presence of a specific TCR in the naïve repertoire of donor T cells is probably 
the most limiting factor for an HLA-binding peptide to become a MiHA that can 
be recognized by specific T cells. This repertoire of specific TCR on donor T cells 
is shaped by negative selection as a result of presentation of self-peptides in 
the thymus. If many self-peptides are highly similar to MiHA, the total number 
of existing MiHA that can be recognized by specific TCR with high affinity may 
be more limited than suggested based on genetic disparity. Therefore, actual 
MiHA-specific T-cell responses instead of SNP disparities need to be measured 
in order to correlate MiHA with clinical outcome. Thus, characterization of MiHA 
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in patients with GvL and GvHD can both contribute to increase the repertoire 
of MiHA that are available for immunotherapy as well as understanding of the 
immunobiology of GvL and GvHD.
Manipulation of GvL and GvHD
Patients with hematological malignancies can be successfully treated with 
alloSCT and DLI16,17. Unfortunately, there are still patients who do not develop 
an effective anti-tumor response, emphasizing the need to increase the efficacy 
of this treatment modality. Moreover, many patients suffer from side effects 
as a result of damage to healthy organs that are targeted by donor T cells, 
illustrating that there is also a strong need to reduce toxicity of the treatment 
while maintaining the GvL effect. An improved balance between GvL and GvHD 
is relevant to increase quality of life, improve efficacy and broaden applicability 
of alloSCT as treatment modality for hematological malignancies. 
MiHA can be exploited by immunotherapy to selectively induce GvL while limiting 
the risk of GvHD. Several different strategies are currently explored to augment 
GvL after alloSCT. These strategies include adoptive transfer of MiHA-specific T 
cells that are produced or isolated in vitro from the naïve donor repertoire or 
engineered by TCR gene transfer as well as in vivo vaccination protocols in which 
DNA, RNA or peptides are directly administered or used as antigen sources to 
load antigen-presenting cells. LB-ARHGDIB-1R and LB-ITGB2-1 as described 
in chapter 3 and 5, respectively, can be easily targeted in such approaches 
when patients are HLA-B*07:02 or B*15:01 positive. Other approaches aim to 
reduce the risk for GvHD. These approaches include non-specific depletion of 
alloreactive T cells or specific depletion of T cells for broadly expressed MiHA 
from the DLI. In most immunotherapies, newly identified MiHA can be easily 
implemented and may therefore contribute to increase efficacy and reduce 
toxicity of alloSCT as treatment modality for hematological malignancies.
Vaccination approaches are aimed at in vivo priming of immune responses. 
Peptides, mRNA or DNA can be directly injected or pulsed on professional APC 
to ensure efficient antigen processing and presentation. However, vaccination 
often fails to induce an effective anti-tumor response for various reasons. First, 
numbers of MiHA-specific T cells as present in the transplanted immune system 
of the donor may be too low. Furthermore, T-cell priming may be suboptimal 
as a result of low expression of co-activation, adhesion or other accessory 
molecules on the APC or high expression of co-inhibitory molecules. Finally, 
antigen doses as injected or loaded on APC by peptides, mRNA or DNA may 
exceed the amount of antigens that are endogenously processed and presented 







efficient recognition of leukemic cells and therefore fail to mount an effective 
anti-tumor response. 
Another strategy to augment GvL is adoptive transfer of MiHA-specific T cells 
that have been isolated from the naïve donor repertoire or from in vivo immune 
responses after alloSCT. These T cells can be transferred directly into the patient 
after isolation by pMHC-multimers or administered after in vitro expansion. 
The advantage of direct infusion of donor T cells after isolation is that long-
term in vitro culture, which is known to limit in vivo survival and expansion, is 
not required. Moreover, multiple pMHC complexes for different MiHA can be 
easily combined. This allows for isolation of T cells for a cocktail of MiHA with 
different HLA restriction alleles, which may contribute to increase efficacy and 
reduce the risk for antigen escape variants after treatment. A disadvantage of 
direct infusion of MiHA-specific T cells after isolation by pMHC-multimers is that 
numbers of donor T cells in the naïve repertoire are generally low and that their 
in vivo survival and expansion still require proper activation by endogenously 
processed and presented antigens on professional APC. Moreover, the absence 
of “help” as provided by other T cells in the DLI may significantly hamper in vivo 
survival and expansion of MiHA-specific T cells after adoptive transfer. As such, 
the efficacy of this approach may be increased by addition of a small dose of 
unselected DLI or by boosting the immune response after adoptive transfer by 
vaccination with MiHA-pulsed professional APC.
TCR gene transfer in which donor T cells are genetically engineered with a high 
affinity TCR can also be used to augment GvL after alloSCT18. By this method, 
high T-cell frequencies for a desired MiHA can be obtained within a relatively 
short culture period. The presence of high frequencies of TCR-transduced donor 
T cells favor adoptive transfer of a relatively low dose of DLI, thereby limiting the 
risk of GvHD. Alternatively, TCR gene transfer can be performed by introducing 
the high affinity TCR into virus-specific T-cells19. The advantage of virus-specific 
donor T cells is that they do not induce GvHD when infused early after alloSCT. 
Another benefit of TCR gene transfer is that high affinity TCRs capable of targeting 
endogenous MiHA as presented on leukemic cells can be selected. However, a 
disadvantage of TCR gene transfer is that it bears a risk for off-target toxicity as a 
result of mixed dimer formation leading to T cells with unknown and potentially 
unwanted specificities. The risk for off-target toxicity after TCR gene transfer to 
virus-specific T cells is significantly reduced as compared to unselected DLI due 
to expression of a more restricted repertoire of endogenous TCRs. Furthermore, 
mixed dimer formation can be reduced by introducing a disulfide bond which 
increases stability of the exogenous TCR18. Another disadvantage of TCR gene 
transfer is that a retroviral or lentiviral vector needs to be produced under GMP 
conditions and that multiple TCRs cannot easily be combined in the same cell 
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product. As such, TCR gene transfer will probably remain an approach limited to 
patients with specific MiHA mismatches and HLA restriction alleles. 
In addition to strategies that are aimed to augment GvL, approaches can be 
developed to reduce the risk of GvHD by depleting T cells for broadly expressed 
MiHA from the DLI. That such an approach can be effective is illustrated by studies 
in haplo-identical transplantations in which alloreactive T cells are depleted 
from donor lymphocytes using an anti-CD25 immunotoxin. Administration 
of this depleted lymphocyte product allows for early immune reconstitution 
without the use of immune suppressive drugs, since no severe GvHD has 
been reported20. Another approach that aims to deplete alloreactive T cells in 
vivo is administration of cyclophosphamide 48-72 hours after haplo-identical 
transplantation21. However, strategies that aim to deplete alloreactive T cells 
generally hamper an effective GvL response. Therefore, specific depletion of T 
cells for broadly expressed MiHA may be a better strategy to reduce GvHD, since 
T cells for MiHA with predominant or restricted expression to hematopoietic 
cells are unaffected and remain available in the DLI to induce a selective GvL 
response. In general, the number of broadly expressed MiHA that are targeted 
in an in vivo immune response after alloSCT is higher than the number of 
hematopoiesis-restricted MiHA. As such, depletion of donor T cells for one or a 
limited number of broadly expressed MiHA may already be sufficient to reduce 
the overall magnitude and skew T-cell reactivity towards the hematopoietic 
system. T-cell depletion for broadly-expressed MiHA has the additional benefit 
that the exact antigens that are targeted in the GvL response do not need to be 
defined. However, for this approach, a number of broadly expressed MiHA with 
balanced population frequencies in common HLA alleles need to be identified. 
Future perspectives 
To broaden applicability of alloSCT as treatment modality for hematological 
malignancies and to ensure improved quality of life, more targeted therapy for 
selective induction of GvL is required. Although application of immunotherapy 
in which MiHA are targeted is limited by HLA-restriction and MiHA status, many 
clinical approaches allow the simultaneous use of multiple MiHA, which may 
increase the efficacy of therapy and reduce the risk for antigen escape variants. 
However, to increase the number of patients in which at least one therapeutic 
MiHA can be targeted, more MiHA in common HLA alleles need to be identified. 
In this thesis, we describe new methods for efficient discovery of MiHA. 
Currently, we are composing new panels for WGAs consisting of EBV-LCLs from 
the Geuvadis project22,23 for which whole genome and transcriptome data are 
available. These panels will allow direct association between T-cell phenotype 







accelerate MiHA discovery. Furthermore, RNA-sequence data for leukemic 
samples and different healthy cell types will become increasingly available in 
the future and provide important tools for better estimation of MiHA efficacy 
and toxicity profiles. Large-scale analysis of T-cell responses after HLA-matched 
alloSCT and DLI using a toolbox of pMHC-multimers for MiHA will provide insight 
into the specificity, diversity, frequency and dynamics of MiHA-specific T cells in 
GvL and GvHD. This knowledge can then be implemented to manipulate the DLI 
in such a way that in vivo responses in selective GvL are mimicked.
This thesis is focused on discovery of MiHA as immunotherapeutic targets for T 
cells, but other types of antigens can also be targeted by cellular immunotherapy 
to treat patients with hematological malignancies. For example, non-transplanted 
patients and patients with relapsed leukemia after alloSCT can be treated by 
chimeric antigen receptor or TCR gene therapy in which non-polymorphic 
antigens are targeted that are overexpressed in leukemic cells or in specific 
hematopoietic lineages. These approaches have the advantage that they can be 
applied in the absence of alloSCT without any risk for GvHD. However, most non-
polymorphic target antigens are not exclusively expressed on leukemic cells and 
these therapies therefore carry a substantial risk for attack of healthy tissues as a 
result of on-target toxicity. Another approach that has been pioneered in patients 
with melanoma is T-cell therapy in which neoantigens are targeted. Neoantigens 
are T-cell epitopes with amino acid changes that are created by tumor-specific 
mutations. Neoantigens are ideal targets for immunotherapy, since T cells will 
eradicate tumor cells without toxicity towards healthy cells which do not carry 
the somatic mutation. However, a major drawback of neoantigens as targets for 
T-cell therapy is that the mutational profile is different for each patient and that 
therapies thus require truly personalized medicine. Moreover, it is unknown 
whether sufficient neoantigens are presented on leukemic cells with low 
mutational load for effective immunotherapy. Therefore, an attractive approach 
would be to combine neoantigens with MiHA to increase the number of patient-
specific variants that can be targeted by donor T cells. The advantage of MiHA is 
that they do not need to be restricted to tumor cells but can be hematopoiesis-
restricted, because healthy hematopoietic cells are of donor origin and will be 
spared by the donor-derived immune system. Thus, hematopoiesis-restricted 
MiHA remain important therapeutic targets to effectively treat hematological 
malignancies after alloSCT without or with a low risk for GvHD.
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Het ontdekken van minor histocompatibiliteits antigenen als 
doelwit structuren voor immuuntherapie
Allogene stamceltransplantatie
Kwaadaardige aandoeningen van de bloedvormende organen kunnen door 
middel van een allogene stamceltransplantatie (SCT) worden genezen. In 
allogene SCT wordt het bloedvormend systeem van de patiënt vernietigd en 
vervangen door een nieuw hematopoietisch systeem van een gezonde donor. 
Chemotherapie, bestraling en toediening van middelen die het immuunsysteem 
onderdrukken dienen daarbij als conditionering van de patiënt voorafgaand 
aan de transplantatie. Het doel van de conditionering is de kwaadaardige 
cellen te vernietigen en het immuunsysteem van de patiënt te onderdrukken, 
opdat het donor stamceltransplantaat niet wordt afgestoten en de donor 
hematopoiese te laten uitgroeien. Hoewel deze conditionering als doel heeft 
het aantal tumorcellen sterk te verminderen, kan de uitgroei van overlevende 
maligne cellen leiden tot het terugkeren van de tumor (recidief). Succesvolle 
behandeling met allogene SCT hangt daarom af van de complete uitroeiing 
van achtergebleven tumorcellen door het donor immuunsysteem dat met het 
transplantaat mee geïnfundeerd wordt: de zogenaamde Graft-versus-Leukemie 
(GvL) reactiviteit. Helaas gaat het gewenste anti-tumor effect vaak gepaard met 
ongewenste bijwerkingen, ook wel Graft-versus-Host ziekte (GvHD) genoemd. 
GvHD is een ernstige en mogelijk levensbedreigende complicatie van allogene 
SCT waarbij, naast de kwaadaardige cellen, ook gezonde weefsels van de patiënt 
worden aangevallen. Zowel GvL reactiviteit als GvHD worden veroorzaakt door T 
cellen van donor origine die lichaamsvreemde ofwel allo-antigenen herkennen 
op patiëntcellen. Het opwekken van effectieve GvL reactiviteit, terwijl het risico 
op (ernstige) GvHD beperkt blijft, is de grootste uitdaging voor de behandeling 
van hematologische maligniteiten met allogene SCT.
Donor lymfocyten infusie
Om het risico op GvHD te beperken kunnen donor T cellen uit het transplantaat 
verwijderd worden. Helaas wordt door deze T-cel depletie ook het gewenste 
anti-tumor effect tenietgedaan. Om een GvL effect te bewerkstelligen worden 
donor T cellen vaak op een later moment alsnog gegeven in de vorm van donor 
lymfocyten infusie (DLI). Doordat de schade ontstaan door de pre-transplantatie 
conditionering (en het bijbehorende ontstekingsmilieu) grotendeels is hersteld 
en dus minder patiënt antigenen gepresenteerd worden, is het risico op GvHD 
na DLI lager. Helaas kan ook DLI nog steeds ernstige bijwerkingen in de vorm 
van GvHD geven. Het tijdstip waarop de DLI wordt gegeven is van belang: lang 
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wachten geeft een lager risico op GvHD, maar een grotere kans op het optreden 
van een recidief in de periode tussen allogene SCT en DLI. Bij patiënten met 
een agressieve maligniteit met een hoog risico op recidief wordt daarom kort 
na allogene SCT al DLI gegeven, waardoor de kans op een sterke GvL reactie 
groot is en het risico op een recidief afneemt. Als de DLI zodanig veranderd kan 
worden dat het cel-product specifiek de maligne cellen van de patiënt herkent, 
verhoogt dit de effectiviteit en veiligheid van allogene SCT als behandelmethode 
voor hematologische maligniteiten en neemt het risico op ernstige GvHD af.
Minor histocompatibiliteits antigenen
Bij allogene SCT met een transplantaat afkomstig van een donor met een volledig 
identieke humane leukocyten antigen (HLA) typering zorgt genetische variatie – de 
zogenaamde single nucleotide polymorfismen (SNP) – voor de allo-antigenen die 
door donor T cellen herkend kunnen worden. Deze allo-antigenen zijn polymorfe 
peptiden die aan HLA kunnen binden en op patiëntcellen gepresenteerd kunnen 
worden. De patiënt varianten van polymorfe peptiden kunnen vervolgens als 
lichaamsvreemd herkend worden door het donor-afkomstige immuunsysteem. 
Deze antigenen heten ook wel minor transplantatie antigenen (MiHA). Of donor 
T cellen die MiHA herkennen alleen GvL of ook GvHD veroorzaken hangt af van 
op welke cellen van de patiënt de MiHA worden gepresenteerd. Donor T cellen 
specifiek voor een MiHA die op maligne bloedcellen van de patiënt tot expressie 
komen zorgen voor GvL reactiviteit, terwijl donor T cellen die MiHA op gezonde 
niet-hematopoietische weefsels herkennen GvHD kunnen induceren. MiHA 
die specifiek tot expressie komen op cellen van het bloedvormend systeem 
zijn relevante doelwit structuren voor immuuntherapie, omdat donor T cellen 
gericht tegen deze MiHA de kwaadaardige cellen van de patiënt zullen aanvallen 
terwijl gezonde hematopoietische cellen van donor origine gespaard blijven. De 
toepasbaarheid van MiHA in verschillende patiënten hangt af van hoe vaak de 
SNP en het HLA-restrictie molecuul in de populatie voorkomen. Om therapieën 
die MiHA als doelwit structuren gebruiken in het merendeel van de patiënten 
toe te kunnen passen, zijn daarom meer hematopoietisch-specifieke MiHA in 
verschillende HLA-allelen nodig.
MiHA kunnen geïdentificeerd worden met behulp van alloreactieve T cellen die 
uit patiënten met klinische immuunreacties na allogene SCT worden geïsoleerd 
en gekarakteriseerd op basis van hun specificiteit en mogelijke rol in GvL en GvHD. 
Om nieuwe MiHA te ontdekken wordt door middel van whole genome association 
scanning (WGAs) de T-cel herkenning van een panel van testcellen onderzocht 
op associatie met individuele SNPs. De meeste van de tot nu toe gevonden MiHA 
worden gegenereerd door SNPs die coderen voor een aminozuurverandering 






in coderende gebieden in het algemeen makkelijker te identificeren zijn met 
de huidige MiHA identificatie technieken, wordt de frequentie van MiHA die 
gecodeerd worden door andere genetische variaties dan non-synonymous SNPs 
waarschijnlijk onderschat. In dit proefschrift hebben we ons gericht op efficiënte 
karakterisering van MiHA met mogelijke therapeutische relevantie, waaronder 
MiHA die gecodeerd worden door alternatieve transcripten. 
Dit proefschrift
Om de effectiviteit en veiligheid van allogene SCT als behandelmethode voor 
hematologische maligniteiten te verhogen, moeten meer MiHA in verschillende 
HLA-restrictie allelen worden geïdentificeerd. Ondanks het feit dat het ontdekken 
van MiHA efficiënter is geworden door de implementatie van WGAs, blijven 
de antigenen voor 20-30% van de T-cel klonen onopgelost. Voor deze T-cel 
klonen zijn wel vaak associërende SNPs gevonden, maar geen SNP verschillen 
(‘disparity’) in het primaire gen transcript. Deze MiHA worden waarschijnlijk 
gecodeerd door alternatieve transcripten en moeten gekarakteriseerd 
worden met meer geavanceerde technieken dan WGAs gebaseerd op een 
panel van EBV-B-cellen waarvoor 1,1 miljoen SNPs getypeerd zijn. MiHA die 
door alternatieve transcripten gecodeerd worden, zijn hoogstwaarschijnlijk 
ondervertegenwoordigd in de huidige verzameling van bekende MiHA. Het 
ontdekken van meer van deze MiHA vormt een belangrijke bijdrage aan het 
samenstellen van een ‘toolbox’ van antigenen om T-cel responsen in GvL en 
GvHD na allogene SCT te kunnen meten en aan het uitbreiden van het repertoire 
van MiHA met therapeutische relevantie. In dit proefschrift hebben wij de 
specificiteit, diversiteit, frequentie en dynamiek van MiHA-specifieke T cellen 
bestudeerd in het kader van in vivo immuunreacties na allogene SCT en DLI. De 
in dit proefschrift beschreven studies geven inzicht in de immuun-biologie van 
GvL en GvHD na allogene SCT. Daarnaast dragen zij bij aan het identificeren van 
MiHA met therapeutische relevantie om selectieve GvL reactiviteit te induceren 
na allogene SCT zonder de complicaties van GvHD.
Met de ontwikkeling van WGAs en het daardoor verhoogde tempo van 
MiHA identificatie ontstond de behoefte aan een efficiënte en stelselmatige 
inschatting van de bijbehorende weefseldistributie, omdat die bepalend is voor 
het optreden van GvL en GvHD. De weefseldistributie kan worden gebruikt om 
de rol van een MiHA in GvL of GvHD in te schatten om zo MiHA met mogelijke 
therapeutische relevantie te kunnen onderscheiden van MiHA die breed tot 
expressie komen op niet-bloedvormende weefsels. De weefseldistributie van 
MiHA kan worden bepaald door T-cel herkenning te testen, maar dan moeten de 
celtypes positief zijn voor het MiHA- en HLA-restrictie-allel en de toegang tot niet-
hematopoietische weefsels is vaak beperkt. In hoofdstuk 2 beschrijven we een 
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microarray genexpressie database, die celtypes bevat die vaak betrokken zijn in 
GvL reactiviteit en GvHD. De database is ontworpen als platform om op efficiënte 
wijze gen expressieprofielen van nieuwe antigenen te kunnen genereren. We 
hebben in de database kwaadaardige en gezonde hematopoietische celtypes 
opgenomen alsmede niet-hematopoietische celtypes die onder normale en 
ontstekings-condities gekweekt zijn. Genexpressie is bestudeerd met Illumina 
HT12.0 microarrays waarmee messenger RNA (mRNA) voor ~39.000 genen per 
monster gemeten wordt. Op basis van kwaliteitscontroles is de oorsprong van 
de verschillende celtypes bevestigd en mogelijke verontreiniging met perifere 
bloedcellen uitgesloten. Validatie van de microarray genexpressie data is gedaan 
door middel van kwantitatieve RT-PCR (q-PCR) waarbij een sterke correlatie 
tussen genexpressie met beide technieken werd gevonden. Verder hebben we 
een specifiek profiel van ontstekings-genen vastgesteld door microarray data 
van verschillende niet-bloedvormende celtypes onder ontstekingscondities 
(na kweek met IFN-γ) onderling te vergelijken. Tenslotte hebben we de waarde 
van de microarray genexpressie database aangetoond door de effectiviteit en 
toxiciteit in te schatten van mogelijke doelwit structuren voor immuuntherapie 
van hematologische maligniteiten. We concluderen dat onze microarray 
database een relevant platform biedt om kandidaat antigenen met bloedcel-
specifieke expressie te identificeren als potentiële doelwit structuren voor de 
behandeling van hematologische maligniteiten met immuuntherapie.
In hoofdstuk 3 bestuderen we in detail LB-ARHGDIB-1R als een minor 
transplantatie antigen met mogelijke therapeutische relevantie na allogene 
SCT. Gebruikmakend van de microarray genexpressie data zoals beschreven 
in hoofdstuk 2 laten we zien dat expressie van ARHGDIB specifiek is voor 
bloedvormende cellen, met beperkte mRNA expressie in endotheel cellen als 
uitzondering. T-cel experimenten bevestigden de bloedcel-specifieke expressie, 
waarbij fibroblasten en keratinocyten uit de huid niet herkend werden, zelfs 
niet na kweken onder ontstekingscondities. Met Q-PCR kon inderdaad ARHGDIB 
genexpressie in endotheel cellen worden bevestigd, maar LB-ARHGDIB-1R 
specifieke T cellen herkenden endotheel cellen slechts in beperkte mate en 
alleen onder ontstekingscondities. Herkenning van primaire leukemiecellen was 
daarentegen sterk en T cellen die LB-ARHGDIB-1R herkennen kunnen specifieke 
celdood veroorzaken in langdurige cytotoxiciteit experimenten. Tenslotte 
hebben we de in vivo immunogeniciteit van LB-ARHGDIB-1R bestudeerd. In 8 
van de 10 bestudeerde patiënten vonden we na allogene SCT specifieke T cellen, 
waarvan in 4 patiënten de frequentie hoog genoeg was om de T cellen direct uit 
het bloed (‘ex vivo’) te kunnen meten. In een patiënt met gerecidiveerd Non-
Hodgkin’s lymfoom werden hoge T-cel frequenties gevonden na DLI, op hetzelfde 
moment als inductie van een langdurige GvL reactie zonder GvHD. Deze data 






doelwit met de potentie om selectieve GvL te induceren na allogene SCT.
Ondanks dat WGAs een efficiënte methode is, lukt het niet om het precieze 
antigen te achterhalen voor 20-30% van de T cel klonen. Associatie studies met 
een panel van EBV-B cellen waarvoor 1,1 miljoen SNPs zijn bepaald, hebben 
voor deze T-cel klonen associërende SNPs geïdentificeerd buiten de bekende 
coderende gebieden (exonen) van een gen, terwijl in de primaire gen-transcripten 
geen SNP disparity kon worden gevonden. In hoofdstuk 4 hebben we een 
afgeleide correlatie-strategie gevolgd, waarbij SNP data van het hele genoom 
uit het 1000 Genomes Project zijn gebruikt om LB-TTK-1D te identificeren als 
nieuw MiHA. SNP rs240226 werd geïdentificeerd als de genetische variatie die 
codeert voor het MiHA. Deze SNP bevindt zich in een alternatief transcript van 
het TTK gen waarin een te vroeg of ‘prematuur’ stop codon aanwezig is dat het 
transcript doelwit maakt voor snelle afbraak door een proces genaamd nonsense 
mediated decay (NMD). LB-TTK-1D is het eerste niet-artificiële antigen dat wordt 
getransleerd van een endogeen NMD transcript in de mens. Het alternatieve 
TTK transcript komt nauwelijks tot expressie volgens q-PCR experimenten en T 
cellen voor LB-TTK-1D kunnen zowel bloedvormende als niet-bloedvormende 
celtypes herkennen. Ondanks de extreem lage expressie van het alternatieve 
TTK transcript laten T cellen voor LB-TTK-1D robuuste herkenning van EBV-B 
cellen zien, terwijl de meerderheid van de primaire leukemie monsters niet 
herkend wordt. Deze data suggereren dat T-cel herkenning, naast genexpressie 
en aanwezigheid van de SNP en HLA-restrictie allel, nog afhankelijk is van andere 
factoren. Deze bevindingen zijn belangrijk voor toekomstige MiHA-identificatie 
studies en dragen bij aan het begrip hoe antigenen in effectieve immuunreacties 
ontstaan en de biologie die daaraan ten grondslag ligt.
In hoofdstuk 5 beschrijven we de implementatie van ‘whole transcriptome’ 
analyse in onze WGAs strategie en de succesvolle identificatie van LB-ITGB2-1 
als MiHA gecodeerd door een alternatief transcript. Met behulp van WGAs 
identificeerden we een associërende SNP rs760462 in het ITGB2 gen en ontdekten 
vervolgens met behulp van RNA-sequentie analyse een regio met transcriptionele 
activiteit in intron 3 direct volgend op de associërende SNP. Analyse van losse 
RNA-sequentie ‘reads’ laat zien dat SNP rs760462 een nieuwe ‘splice’-sequentie 
introduceert waarmee een alternatief transcript gegenereerd wordt dat alleen 
tot expressie komt in MiHA positieve individuen. Het immunogene antigen 
wordt ‘downstream’ van de SNP van het alternatieve transcript afgeschreven. 
Verder laten we zien dat RNA-sequentie analyse het mogelijk maakt antigenen te 
identificeren die gegeneerd worden door transcripten die ontstaan doordat een 
exon wordt overgeslagen met ACC-6 als voorbeeld. Verder brengen we in kaart 
in hoeverre LB-ITGB2-1 therapeutische waarde heeft en hebben we gevonden 
dat de weefseldistributie van het alternatieve transcript hetzelfde patroon volgt 
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als het normale ITGB2 transcript. Expressie van het normale en alternatieve 
ITGB2 transcript is hematopoiese-specifiek, zoals bevestigd door het gebrek 
aan T-cel reactiviteit tegen huidfibroblasten, zelfs onder ontstekingscondities. 
Tenslotte waren LB-ITGB2-1 specifieke T cellen in staat specifieke herkenning en 
celdood van kwaadaardige hematopoietische (voorloper) cellen te veroorzaken. 
Dit ondersteunt de therapeutische relevantie van LB-ITGB2-1 als doelwit voor 
immuuntherapie om GvL reactiviteit te induceren na allogene SCT zonder GvHD. 
Samenvattend hebben we verschillende MiHA die door diverse mechanismen 
gegenereerd worden, efficiënt geïdentificeerd en gekarakteriseerd. Microarray 
genexpressie data zijn met succes gebruikt om een inschatting te maken van 
de weefseldistributie van MiHA en whole genome en transcriptome data zijn 
geïmplementeerd in de WGAs methode om identificatie van MiHA gecodeerd 
door alternatieve transcripten mogelijk te maken. Door het combineren van 
deze strategieën, is het nu mogelijk op efficiënte wijze een grote variëteit aan 
MiHA te identificeren, hun rol in GvL reactiviteit en GvHD te evalueren en 
hematopoiese-specifieke kandidaat antigenen te selecteren met potentiële 
waarde voor immuuntherapie na allogene SCT. Door MiHA te gebruiken om 
selectief GvL reactiviteit te induceren zonder GvHD, kunnen patiënten met 
kwaadaardige aandoeningen van het bloedvormend systeem effectiever en 









“Als het makkelijk was, zou iedereen het doen” is een spreuk waar ik de afgelopen 
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